0001613780-25-000011.txt : 20250430 0001613780-25-000011.hdr.sgml : 20250430 20250430160222 ACCESSION NUMBER: 0001613780-25-000011 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250430 DATE AS OF CHANGE: 20250430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DBV Technologies S.A. CENTRAL INDEX KEY: 0001613780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36697 FILM NUMBER: 25894789 BUSINESS ADDRESS: STREET 1: 107 AVENUE DE LA REPUBLIQUE CITY: CHATILLON STATE: I0 ZIP: 92320 BUSINESS PHONE: 33(0)155427878 MAIL ADDRESS: STREET 1: 107 AVENUE DE LA REPUBLIQUE CITY: CHATILLON STATE: I0 ZIP: 92320 10-Q 1 dbvt-20250331.htm 10-Q dbvt-20250331
000161378012/312025Q1falsexbrli:sharesiso4217:USDiso4217:EURxbrli:sharesiso4217:USDxbrli:sharesiso4217:EURdbvt:studydbvt:candidatedbvt:objectiondbvt:regulatorydbvt:patchxbrli:puredbvt:employeedbvt:segment00016137802025-01-012025-03-310001613780dei:AdrMember2025-01-012025-03-310001613780us-gaap:CommonStockMember2025-01-012025-03-3100016137802025-04-3000016137802025-03-3100016137802024-12-3100016137802024-01-012024-03-3100016137802023-12-3100016137802024-03-310001613780us-gaap:CommonStockMember2023-12-310001613780us-gaap:AdditionalPaidInCapitalMember2023-12-310001613780us-gaap:TreasuryStockCommonMember2023-12-310001613780us-gaap:RetainedEarningsMember2023-12-310001613780us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001613780us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001613780us-gaap:RetainedEarningsMember2024-01-012024-03-310001613780us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001613780us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310001613780us-gaap:CommonStockMember2024-01-012024-03-310001613780us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001613780us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001613780us-gaap:CommonStockMember2024-03-310001613780us-gaap:AdditionalPaidInCapitalMember2024-03-310001613780us-gaap:TreasuryStockCommonMember2024-03-310001613780us-gaap:RetainedEarningsMember2024-03-310001613780us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001613780us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310001613780us-gaap:CommonStockMember2024-12-310001613780us-gaap:AdditionalPaidInCapitalMember2024-12-310001613780us-gaap:TreasuryStockCommonMember2024-12-310001613780us-gaap:RetainedEarningsMember2024-12-310001613780us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001613780us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310001613780us-gaap:RetainedEarningsMember2025-01-012025-03-310001613780us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001613780us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-03-310001613780us-gaap:CommonStockMember2025-01-012025-03-310001613780us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001613780us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001613780us-gaap:CommonStockMember2025-03-310001613780us-gaap:AdditionalPaidInCapitalMember2025-03-310001613780us-gaap:TreasuryStockCommonMember2025-03-310001613780us-gaap:RetainedEarningsMember2025-03-310001613780us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001613780us-gaap:AccumulatedTranslationAdjustmentMember2025-03-310001613780dbvt:PrivateInvestmentInPublicEquityMember2022-01-012022-12-310001613780us-gaap:SubsequentEventMember2025-04-072025-04-070001613780dbvt:ViaskintmClinicalProgramMember2021-03-012021-03-310001613780dbvt:ComfortToddlersSafetyStudyMemberdbvt:ViaskintmClinicalProgramMember2023-07-312023-07-310001613780dbvt:ComfortToddlersSafetyStudyMemberdbvt:ViaskintmClinicalProgramMember2024-10-222024-10-220001613780dbvt:ViaskintmClinicalProgramMemberdbvt:ComfortToddlersSafetyStudyMembersrt:MinimumMember2024-10-222024-10-220001613780dbvt:ViaskintmClinicalProgramMemberdbvt:ComfortToddlersSafetyStudyMembersrt:MaximumMember2024-10-222024-10-220001613780dbvt:ViaskintmClinicalProgramMember2021-08-020001613780dbvt:ViaskintmClinicalProgramMember2024-10-222024-10-2200016137802024-12-110001613780srt:MinimumMember2024-12-1100016137802025-03-270001613780srt:MinimumMember2025-03-270001613780dbvt:ABSAWarrantsMember2025-03-270001613780dbvt:ABSAWarrantsMemberus-gaap:SubsequentEventMember2025-04-072025-04-070001613780dbvt:ABSAWarrantsMemberus-gaap:SubsequentEventMember2025-04-070001613780dbvt:ABSAWarrantsMemberus-gaap:SubsequentEventMembersrt:MaximumMember2025-04-070001613780dbvt:PFWBSPFWMemberus-gaap:SubsequentEventMember2025-04-072025-04-070001613780dbvt:PFWBSPFWMemberus-gaap:SubsequentEventMember2025-04-070001613780dbvt:PrefundedPFWBSPFWMemberus-gaap:SubsequentEventMember2025-04-070001613780dbvt:FirstPreFundedWarrantsMemberus-gaap:SubsequentEventMember2025-04-070001613780dbvt:BSWarrantsMemberus-gaap:SubsequentEventMember2025-04-070001613780dbvt:SecondPreFundedWarrantsMemberus-gaap:SubsequentEventMember2025-04-070001613780dbvt:FirstPreFundedWarrantsMemberus-gaap:SubsequentEventMembersrt:MaximumMember2025-04-072025-04-070001613780dbvt:SecondPreFundedWarrantsMemberus-gaap:SubsequentEventMembersrt:MaximumMember2025-04-072025-04-070001613780us-gaap:RealEstateMember2025-03-310001613780dbvt:OtherAssetMember2025-03-310001613780us-gaap:RealEstateMember2024-12-310001613780dbvt:OtherAssetMember2024-12-310001613780dbvt:EmployeeRelatedLiabilitiesMember2025-03-310001613780dbvt:EmployeeRelatedLiabilitiesMember2024-12-310001613780dbvt:TaxLiabilitiesMember2025-03-310001613780dbvt:TaxLiabilitiesMember2024-12-310001613780dbvt:OtherDebtsMember2025-03-310001613780dbvt:OtherDebtsMember2024-12-310001613780dbvt:ShareCapitalMember2025-03-310001613780us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001613780us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001613780dbvt:BSAWarrantsMember2024-12-310001613780us-gaap:EmployeeStockOptionMember2024-12-310001613780us-gaap:RestrictedStockUnitsRSUMember2024-12-310001613780dbvt:BSAWarrantsMember2025-01-012025-03-310001613780dbvt:BSAWarrantsMember2025-03-310001613780us-gaap:EmployeeStockOptionMember2025-03-310001613780us-gaap:RestrictedStockUnitsRSUMember2025-03-310001613780us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001613780us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001613780us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001613780us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001613780us-gaap:EmployeeStockOptionMemberus-gaap:SellingAndMarketingExpenseMember2025-01-012025-03-310001613780us-gaap:EmployeeStockOptionMemberus-gaap:SellingAndMarketingExpenseMember2024-01-012024-03-310001613780us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SellingAndMarketingExpenseMember2025-01-012025-03-310001613780us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SellingAndMarketingExpenseMember2024-01-012024-03-310001613780us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001613780us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001613780us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001613780us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001613780us-gaap:PostemploymentRetirementBenefitsMember2024-12-310001613780dbvt:OtherContingenciesMember2024-12-310001613780us-gaap:PostemploymentRetirementBenefitsMember2025-01-012025-03-310001613780dbvt:OtherContingenciesMember2025-01-012025-03-310001613780us-gaap:PostemploymentRetirementBenefitsMember2025-03-310001613780dbvt:OtherContingenciesMember2025-03-310001613780dbvt:ExpensesByFunctionMember2025-01-012025-03-310001613780dbvt:ExpensesByFunctionMember2024-01-012024-03-310001613780dbvt:ExpensesByNatureMember2025-01-012025-03-310001613780dbvt:ExpensesByNatureMember2024-01-012024-03-310001613780dbvt:NonemployeewarrantsMember2025-01-012025-03-310001613780dbvt:NonemployeewarrantsMember2024-01-012024-03-310001613780us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001613780us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001613780us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001613780us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001613780dbvt:PrefundedWarrantsMember2025-01-012025-03-310001613780dbvt:PrefundedWarrantsMember2024-01-012024-03-310001613780us-gaap:SubsequentEventMember2025-04-152025-04-150001613780dbvt:ViaskinPeanutSegmentMember2025-01-012025-03-310001613780dbvt:ViaskinPeanutSegmentMember2024-01-012024-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 10-Q
____________________
(Mark One)
☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2025
or
☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________ to _______________
Commission file number 001-36697
DBV TECHNOLOGIES S.A.
(Exact name of registrant as specified in its charter)
____________________
FranceNot applicable
State or other jurisdiction of incorporation or organization(I.R.S. Employer Identification No.)
107 Av. de la RépubliqueN/A
92320 Châtillon
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code +33 1 55 42 78 78




____________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per shareDBVTThe Nasdaq Stock Market LLC
Ordinary shares, nominal value €0.10 per share*n/aThe Nasdaq Stock Market LLC
*Not for trading, but only in connection with the registration of the American Depositary Shares.
Securities registered pursuant to Section 12(g) of the Act: None.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
☒ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒ Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
☐ Yes ☒ No
As of April 30, 2025, the registrant had 136,948,872 ordinary shares, nominal value €0.10 per share, outstanding including treasury shares.


Table of contents
Part I
2
Item 12
3
4
5
6
Item 2
15
Item 3
20
Item 4
20
Part II
21
Item 1
21
Item 1A
21
Item 2
21
Item 3
22
Item 4
22
Item 5
22
Item 6
22
Unless the context otherwise requires, we use the terms “DBV”, “DBV Technologies,” the “Company,” “we,” “us” and “our” in this Quarterly Report on Form 10-Q, or Quarterly Report, to refer to DBV Technologies S.A. and, where appropriate, its consolidated subsidiaries. “Viaskin®”, “EPIT™” and our other registered and common law trade names, trademarks and service marks are the property of DBV Technologies S.A. or our subsidiaries. All other trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Quarterly Report may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto.


SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS
This Quarterly Report contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. Forward-looking statements include statements, other than statements of historical fact, about, among other things:
•our expectations regarding the timing or likelihood of regulatory filings and approvals, including with respect to our anticipated re-submission of a Biologics License Application (“BLA”) for Viaskin Peanut patch to the U.S. Food and Drug Administration (“FDA”);
•our expectations with respect to an actionable regulatory pathway, including an Accelerated Approval pathway, for toddlers ages 1-3 years-old for Viaskin Peanut patch;
•expectations regarding initiation of the confirmatory effectiveness study for Viaskin Peanut patch in 1 - 3 years-old;
•plans and expectations with respect to COMFORT Toddlers;
•anticipated support for the BLA re-submission for Viaskin Peanut patch to FDA;
•the timing and anticipated results of interactions with regulatory agencies;
•the design, initiation, timing, progress and results of our pre-clinical studies and clinical trials, and our research and development programs;
•the sufficiency of existing capital resources;
•the likelihood that warrants may be exercised following the disclosure of VITESSE topline results, should the results be positive;
•our business model and our other strategic plans for our business, product candidates and technology;
•our ability to manufacture clinical and commercial supplies of Viaskin Peanut and/or our other product candidates, if approved, and comply with regulatory requirements related to the manufacturing of our product candidates;
•our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize Viaskin Peanut and/or our other product candidates, if approved;
•the commercialization of our product candidates, if approved;
•our expectations regarding the potential market size and the size of the patient populations for Viaskin Peanut and/or our other product candidates, if approved, and our ability to serve such markets;
•the pricing and reimbursement of our product candidates, if approved;
•the rate and degree of market acceptance of Viaskin Peanut and/or our other product candidates, if approved, by physicians, patients, third-party payors and others in the medical community;
•our ability to advance product candidates into, and successfully complete, clinical trials;
•the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;
•estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
•the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;
•our ability to maintain and establish collaborations or obtain additional funding;
•our financial performance;
•expectations with respect to cash runway;
•developments relating to our competitors and our industry, including competing therapies; and
•other risks and uncertainties, including those listed under the caption “Risk Factors.”
Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward-looking statement. These risks, uncertainties and other factors are described in greater detail under the caption “Risk Factors” in Part I. Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on April 11, 2025. As a result of the risks and uncertainties, the results or events indicated by the forward-looking statements may not occur. Undue reliance should not be placed on any forward-looking statement. We qualify all of our forward-looking statements by these cautionary statements.
In addition, any forward-looking statement in this Quarterly Report, including statements that “we believe” and similar statements, reflect our beliefs and opinions on the relevant subject and represents our views only as of the date of this Quarterly Report and should not be relied upon as representing our views as of any subsequent date. These statements are based upon information available to us as of the date of this Quarterly Report and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, except as required by applicable law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.
1


PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
DBV Technologies S.A.
Condensed Consolidated Statements of Financial Position (unaudited)
(amounts in thousands, except share and per share data)
NoteMarch 31, 2025December 31, 2024
Assets
Current assets :
Cash and cash equivalents 3$12,962 32,456 
Other current assets 416,186 11,932 
Total current assets29,148 44,388 
Property, plant, and equipment, net10,813 11,306 
Right-of-use assets related to operating leases55,613 5,502 
Intangible assets 29 40 
Other non-current assets4,960 4,423 
Total non-current assets21,414 21,271 
Total Assets$50,562 65,658 
Liabilities and shareholders' equity
Current liabilities:
Trade payables6$34,146 22,032 
Short-term operating leases5709 654 
Current contingencies 982 122 
Other current liabilities65,447 8,328 
Total current liabilities40,384 31,136 
Long-term operating leases56,525 6,297 
Non-current contingencies 9780 838 
Total non-current liabilities7,305 7,135 
Total Liabilities$47,688 38,271 
Shareholders’ equity :
Ordinary shares, €0.10 par value; 102,858,868 and 102,847,501 shares authorized, and issued as at March 31, 2025 and December 31, 2024, respectively
$11,652 11,651 
Additional paid-in capital317,313 315,613 
Treasury stock, 230,513 and 266,868 ordinary shares as of March 31, 2025 and December 31, 2024, respectively, at cost
(1,263)(1,309)
Accumulated deficit(313,454)(286,375)
Accumulated other comprehensive income1,036 905 
Accumulated currency translation effect (12,411)(13,097)
Total Shareholders’ equity 7$2,873 27,387 
Total Liabilities and Shareholder's equity$50,562 65,658 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2


DBV Technologies S.A.
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
(amounts in thousands, except share and per share data)
NoteThree Months Ended March 31,
20252024
Operating income10$753 1,407 
Operating expenses
11
Research and development expenses(21,483)(21,403)
Sales and marketing expenses(262)(758)
General and administrative expenses(5,626)(7,804)
Total Operating expenses(27,370)(29,964)
Loss from operations(26,618)(28,558)
Financial income (expense)(461)1,261 
Loss before taxes(27,079)(27,297)
Income tax — (48)
Net loss$(27,079)(27,345)
Foreign currency translation differences, net of taxes686 (3,026)
Actuarial gains / (losses) on employee benefits, net of taxes132 (59)
Comprehensive loss$(26,261)(30,429)
Basic/diluted Net loss per share attributable to shareholders14$(0.26)(0.28)
Weighted average shares outstanding used in computing per share amounts:102,617,429 96,176,057 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3


DBV Technologies S.A.
Condensed Consolidated Statements of Cash Flows (unaudited)
(amounts in thousands)
NotesThree Months Ended March 31,
20252024
Net loss for the period$(27,079)(27,345)
Adjustments to reconcile net loss to net cash (used in) operating activities:
Depreciation, amortization and accrued contingencies952 53 
Expenses related to share-based payments
8
1,702 1,958 
Inventory write-downs4,286 1,289 
Other elements465 (8)
Changes in operating assets and liabilities:
Decrease (increase) in inventories and work in progress(4,286)(1,289)
Decrease (increase) in other current assets(3,662)(835)
(Decrease) increase in trade payables 10,943 (4,805)
(Decrease) increase in other current and non-current liabilities(3,104)(3,765)
Change in operating lease liabilities and right of use assets115 56 
Net cash flow (used in) operating activities(19,668)(34,692)
Cash flows (used in) investing activities :
Change in property, plant, and equipment(10)(1,335)
Change in non-current financial assets(366)(797)
Net cash flows (used in) investing activities (375)(2,132)
Cash flows (used) / provided by financing activities :
Treasury shares45 (62)
Net cash flows (used) / provided by financing activities45 (62)
Effect of exchange rate changes on cash and cash equivalents504 (2,957)
Net (decrease) / increase in cash and cash equivalents3(19,494)(39,842)
Net Cash and cash equivalents at the beginning of the period 32,456 141,367 
Net cash and cash equivalents at the end of the period$12,962 101,525 
The Company now presents inventory write-downs separately from the “Decrease (Increase) in inventories and work in progress” line item. Comparative information has been updated accordingly to ensure consistency.

The accompanying notes are an integral part of these condensed consolidated financial statements.
4


DBV Technologies S.A.
Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited)
(amounts in thousands, except share and per share data)
Ordinary shares
Number of SharesAmountAdditional paid-in capitalTreasury stockAccumulated deficitAccumulated other comprehensive income (loss)Accumulated currency translation effect Total Shareholders’ Equity
Balance at January 1, 202496,431,770 10,972 377,468 (1,263)(238,862)742 (8,871)140,187 
Net (loss)— — — — (27,345)— — (27,345)
Other comprehensive income (loss)— — — — — (59)(3,026)(3,084)
Issuance of ordinary shares2,599 — — — — — — — 
Treasury shares— — — (62)— — — (62)
Share-based payments— — 1,958 — — — — 1,958 
Balance at March 31, 202496,434,369 10,972 379,426 (1,325)(266,207)683 (11,897)111,654 
Ordinary shares
Number of SharesAmountAdditional paid-in capitalTreasury stockAccumulated deficitAccumulated other comprehensive income (loss)Accumulated currency translation effect Total Shareholders’ Equity
Balance at January 1, 2025102,847,501 11,651 315,613 (1,309)(286,375)905 (13,097)27,387 
Net (loss)— — — — (27,079)— — (27,079)
Other comprehensive income (loss)— — — — — 132 686 817 
Issuance of ordinary shares11,367 1 (1)— — — — — 
Treasury shares— — — 46 — — — 46 
Share-based payments — — 1,702 — — — — 1,702 
Balance at March 31, 2025102,858,868 11,652 317,313 (1,263)(313,454)1,036 (12,411)2,873 


The accompanying notes are an integral part of these condensed consolidated financial statements.
5


NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Note 1: The Company
Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies” or the “Company”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy (“EPIT”), a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Basis of Presentation
The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.
The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on April 11, 2025 (the “ Annual Report”). The condensed consolidated statement of financial position as of December 31, 2024 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2024.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2025, or any other future period.
Use of Estimates
The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates.
On an on-going basis, management evaluates its estimates, primarily those related to: (1) research tax credits, (2) assumptions used in the valuation of right of use assets—operating lease, (3) impairment of right-of-use assets related to leases and property, plant and equipment, (4) recoverability of the Company’s net deferred tax assets and related valuation allowance, (5) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, 6) estimate of contingencies and provisions, and (7) estimate of employee benefits obligations.
Going Concern
These Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The Company has incurred operating losses and negative cash flows from operations since inception. The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.
Since its inception, the Company has primarily funded its operations through equity financings, as well as public assistance and Research Tax Credit.. Prior to 2022, the Company underwent restructuring efforts, scaled down certain clinical programs, and engaged with regulatory authorities to advance Viaskin Peanut’s approval process in the United States and European Union. In 2022, the Company secured a private placement financing of $194 million and lifted a partial clinical hold from the FDA on its VITESSE Phase 3 clinical study.
On April 7, 2025, the Company received gross proceeds of $125.5 million (€116.3 million) from the issuance of the ABSA and PFW-BS-PFW, as described in Note 15. With the receipt of the aforementioned proceeds, and based on its current operations, plans, and assumptions examined by the Board of Directors (“Board”) on March 23, 2025, the Company estimates that its cash and cash equivalents are sufficient to fund its operations into June 2026.
Given the Company’s historical operating losses and reliance on external financings, the Company may still seek additional capital for future needs through a combination of public or private equity or debt financings, collaborations, licensing agreements, and other funding options. While recent financing events have improved the Company’s financial position, access to additional capital in the future remains subject to market conditions and investor interest.

Accounting Pronouncements Recently Adopted
There have been no recently issued accounting standards adopted during the period which had a material impact on the Company’s financial statements.
There are no recently issued accounting standards that are expected to have a material impact on our results of operations, financial condition, or cash flows.
6


Accounting Pronouncements issued not yet adopted
In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740 — Improvements to Income Tax Disclosures which enhances the transparency and usefulness of income tax disclosures. This amendment requires disclosure of disaggregated information about the Company’s effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. For SEC filers, this ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income Topic 220 — Expense Disaggregation Disclosures. The guidance requires disclosure of additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. For SEC filers, this ASU is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this ASU 2024-03 will have on its consolidated financial statements and related disclosures.
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption.

Note 2: Significant Events and Transactions
Clinical Programs
United States Regulatory History and Current Status
In August 2019, we announced the submission of a BLA to the FDA for Viaskin Peanut for the treatment of peanut allergy in children four to 11 years of age.
In August 2020, the Company received a Complete Response Letter (“CRL”) in which the FDA indicated it could not approve the Viaskin Peanut BLA in its then-current form. The FDA did not raise any safety concerns related to Viaskin Peanut.
In January 2021, the Company received written responses from the FDA to questions provided in the Type A meeting request that the Company submitted in October 2020 following receipt of the CRL.
In March 2021, the Company commenced CHAMP (Comparison of adHesion Among Modified Patches), a Phase 1 trial in healthy adult volunteers. . In May 2021, the Company submitted a proposed protocol to the FDA for STAMP (Safety, Tolerability, and Adhesion of Modified Patches)a 6-month safety and adhesion study which was to be conducted concurrently with DBV’s allergen uptake comparison studies (i.e., ‘EQUAL in Adults’, EQUAL). On October 14, 2021, in an Advice/Information Request letter, the FDA requested the Company conduct a stepwise, or sequential, approach to the modified Viaskin patch development program by conducting EQUAL first and submitting the data for FDA review and feedback prior to starting the STAMP study.
In December 2021, the Company decided not to pursue the sequential approach requested by the FDA and instead announced its plan to initiate a pivotal Phase 3 placebo-controlled efficacy trial for a modified Viaskin Peanut patch (mVP) in children in the intended patient population. Following written exchanges with the FDA, the FDA confirmed it was aligned with the Company’s strategy.
On September 7, 2022, the Company announced the initiation of VITESSE, a Phase 3 pivotal study of the mVP in children ages 4-7 years with peanut allergy. On September 21, 2022, the Company announced it received from FDA a partial clinical hold letter related to certain design elements of VITESSE.
On December 23, 2022, the Company announced that the FDA lifted the partial clinical hold The Company announced on September 23, 2024, that subject screening was completed in the third quarter of 2024. Topline results are anticipated in the fourth quarter of 2025.
In June 2022, the Company announced positive topline results from Part B of EPITOPE.
On April 19, 2023, the Company outlined the regulatory pathway for Viaskin Peanut in children 1 – 3 years old after the FDA confirmed in written responses to the Company’s Pre-BLA meeting request that the Company’s EPITOPE phase 3 study met the pre-specified criteria for success for the primary endpoint and did not request an additional efficacy study in this age group. The FDA required additional safety data to augment the safety data collected from EPITOPE in support of a BLA.
On July 31, 2023, the Company announced receipt of feedback from FDA on two supplemental safety studies, COMFORT Children and COMFORT Toddlers.
On November 9, 2023, the Company submitted the protocol for its COMFORT Toddlers supplemental safety study in 1 – 3 years-old to FDA. The Company received comments and queries to the protocol from the FDA on March 11, 2024. On July 30, 2024, the Company announced that it and the FDA had been engaged in ongoing dialogue since May 2023 on the COMFORT Toddlers supplemental safety study in 1 – 3 years-old with a peanut allergy.
The Company also announced on November 9, 2023, 2-year results from the ongoing phase 3 open-label extension to the EPITOPE trial, EPOPEX, of Viaskin Peanut in toddlers.
On October 22, 2024, the Company announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV had agreed to guidance provided by the FDA on a potential pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old. FDA confirmed that the Company has met Accelerated Approval qualifying criterion 1 and 2. Regarding criterion 3, FDA has provided guidance and suggestion regarding the intermediate clinical endpoint, which the Company agreed to in informal discussions with the FDA. The Company formalized the Accelerated Approval guidance provided by FDA via submission of a meeting request and confirmed the general elements of the two study components: the COMFORT Toddlers safety study, to be completed before BLA submission, and the confirmatory effectiveness study, including
7


the third Accelerated Approval criterion regarding the intermediate clinical endpoint. The Company expects that the confirmatory study will be initiated by the time of BLA submission and would run in parallel to commercialization in the United States, if Viaskin Peanut is approved.
The Company announced further that it has aligned with FDA on a wear time collection methodology in COMFORT Toddlers intended to generate sufficient data to support a BLA submission. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. The company anticipates enrolling approximately 300 – 350 subjects on active treatment into the safety study, which would bring the total Viaskin Peanut patch safety database in toddlers to approximately 600 subjects, consistent with prior FDA guidance. With this path forward, the BLA submission for Viaskin Peanut patch in 1 – 3 years-old under the Accelerated Approval program is anticipated to be supported by:
i. Positive efficacy and safety data from DBV’s previously completed EPITOPE Phase 3 Study; and
ii. Additional safety data generated in COMFORT Toddlers supplemental safety study to be initiated in the second quarter of 2025.

On December 11, 2024, the Company announced that it reached alignment with FDA on the Accelerated Approval pathway for Viaskin Peanut patch in toddlers 1 – 3 years-old and on key study design elements for the COMFORT Toddlers study, including study size and wear time collection methodology and analysis. The Company announced further that FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1-3 years-old and that the Company and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch, will include a double-blind, placebo-controlled food challenge (DBPCFC), will use the same statistical criteria for success (i.e., lower bound of the 95% CI > 15%) as used in the EPITOPE, and will need to be initiated at the time that the BLA is submitted.
The Company submitted the protocol for its COMFORT Children supplemental safety study in ages 4-through-7-years-old to the FDA on November 29, 2023. On March 24, 2025, the Company announced that in a Written Responses Only to the Company’s Type D IND meeting request the FDA agreed with the Company’s proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4-7-year-olds will be sufficient to support a BLA filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required and the Company will not conduct the study. The Company will utilize the safety data from the VITESSE participants randomized to active treatment as well as placebo-crossover participants in the VITESSE Open Label Extension (OLE). Accordingly, the Company plans to submit a BLA in the first half of 2026 and anticipates potentially accelerating the product launch by approximately one year, subject to FDA approval.
Viaskin Peanut —European Union Regulatory History and Current Status
In November 2020, we announced that our Marketing Authorization Application, or MAA, for Viaskin Peanut, submitted under the name “Abylqis®”, had been validated by the European Medicines Agency, or EMA. The validation of the MAA confirmed that the submission was sufficiently complete to begin the formal review process for Viaskin Peanut to treat peanut allergies in children ages four to 11 years. Following the MAA validation, the EMA’s Committee for Medicinal Products for Human Use, or CHMP, reviews the application and provides a recommendation to the European Commission, on whether to grant a marketing authorization.
On August 2, 2021, we announced we had received from the EMA the Day 180 list of outstanding issues, which is an established part of the prescribed EMA review process. The EMA identified one Major Objection remained at Day 180n questioning the limitations of the data, for example, the clinical relevance and effect size supported by a single pivotal study.
On December 17, 2021, we announced we had withdrawn the MAA for Viaskin Peanut, submitted under the name “Abylqis”, and formally notified the EMA of our decision.
On October 22, 2024, the Company announced it received scientific advice from EMA on an indication for ages 1 – 7 years-old in Europe regarding the components of a MAA for the Viaskin Peanut patch. Previous advice obtained from two local country regulatory health authorities indicated a potential path for a 1 – 7 year-old registration with one patch, the modified patch. The EMA recently confirmed through scientific advice that the completed EPITOPE study in 1 – 3 years-old, and a positive VITESSE study in 4 – 7 years-old, could constitute an MAA submission for a 1 – 7 years-old indication for peanut allergy patients using the modified patch, along with a new safety study in toddlers ages 1 – 3 years-old with the modified patch. Timing for the initiation of this new safety study to satisfy the important EU market is currently being planned.
The Company intends to resubmit the MAA when that data set is available.
Viaskin Peanut for Children Ages 1 – 3
In June 2020, the Company announced that in Part A of the EPITOPE phase 3 clinical study subject in both treatment arms showed consistent treatment effects after 12 months of therapy, as assessed by a double-blind placebo-controlled food challenge and biomarker results. Part A subjects were not included in Part B and the efficacy analyses from Part A were not statistically powered to demonstrate superiority of either dose versus placebo.
In June 2022, the Company announced positive topline results from Part B of EPITOPE.
On April 19, 2023, the Company outlined the regulatory pathway for Viaskin Peanut in children 1 – 3 years old after the FDA confirmed in written responses to the Company’s Pre-BLA meeting request that the Company’s EPITOPE phase 3 study met the pre-specified criteria for success for the primary endpoint and did not request any additional efficacy study in this age group. The FDA requires additional safety data to augment the safety data collected from EPITOPE in support of a BLA. This new safety study will also generate patch adhesion data and will include updated instructions for use.
On May 10, 2023, the New England Journal of Medicine (“NEJM”) published results from the EPITOPE phase 3 clinical study that demonstrated EPIT with Viaskin Peanut was statistically superior to placebo in desensitizing children to peanut exposure by increasing the peanut dose that triggers allergic symptoms. As stated in an accompanying editorial piece, these data are seen as “very good news” for toddlers with peanut allergy.
In November 2023, the Company announced the interim analyses from the first year of the open-label extension of EPITOPE, called EPOPEX, which showed improvement between months 12 and 24 of treatment with Viaskin Peanut across all efficacy parameters. These data were presented at the annual American College of Allergy, Asthma and Immunology (ACAAI) in November 2023.
On November 9, 2023, the Company submitted the protocol for its COMFORT Toddlers supplemental safety study in 1 – 3 years-old to FDA. The Company received comments and queries to the protocol from the FDA on March 11, 2024.

8


On October 22, 2024, the Company announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV agreed to guidance provided by the FDA on a potential pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old.
FDA confirmed that the Company has met Accelerated Approval qualifying criteria 1 and 2. Regarding criterion 3, FDA has provided guidance and suggestion regarding the intermediate clinical endpoint, which the Company has agreed to in informal discussions with the FDA. The Company formalized the Accelerated Approval guidance provided by FDA via submission of a meeting request and confirmed the general elements of the two study components: the COMFORT Toddlers safety study, to be completed before BLA submission, and the confirmatory effectiveness study, including the third Accelerated Approval criterion regarding the intermediate clinical endpoint. The Company expects that the confirmatory study will be initiated by the time of BLA submission and would run in parallel to commercialization in the United States, if Viaskin Peanut is approved.

The Company announced further that it has aligned with FDA on a wear time collection methodology in COMFORT Toddlers that provides a practical approach for subjects and families, is intended to generate sufficient data to support a BLA submission, and places wear time into an acceptable clinical hierarchy relative to other study endpoints. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. The company anticipates enrolling approximately 300 – 350 subjects on active treatment into the safety study, which would bring the total Viaskin Peanut patch safety database in toddlers to approximately 600 subjects, consistent with prior FDA guidance. With this path forward, the BLA submission for Viaskin Peanut patch in 1 – 3 years-old under the Accelerated Approval program is anticipated to be supported by:
i. Positive efficacy and safety data from DBV’s previously completed EPITOPE Phase 3 Study; and
ii. Additional safety data generated in COMFORT Toddlers supplemental safety study to be initiated in the second quarter of 2025.
On December 11, 2024, the Company announced that it reached alignment with FDA on the Accelerated Approval pathway for Viaskin Peanut patch in toddlers 1-3 years-old and on key study design elements for the COMFORT Toddlers study, including study size and wear time collection methodology and analysis. The Company announced further that FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1-3 years-old and that the Company and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch, will include a double-blind, placebo-controlled food challenge (DBPCFC), will use the same statistical criteria for success (i.e., lower bound of the 95% CI > 15%) as used in the EPITOPE, and will need to be initiated at the time that the BLA is submitted.
Viaskin Peanut for Children Ages 4 – 7
On September 7, 2022, the Company announced the initiation of VITESSE, a Phase 3 pivotal study of the mVP in children ages 4-7 years with peanut allergy. The Company defined initiation as the submission of the trial protocol to selected study sites for subsequent Institutional Review Board (IRB)/Ethics Committee (EC) approval.
On September 21, 2022, the Company announced it received from the FDA a partial clinical hold letter related to certain design elements of VITESSE. The Company announced on December 23, 2022 that the FDA lifted the partial clinical hold.The Company announced on September 23, 2024 that subject screening was completed in the third quarter of 2024. Topline results are anticipated in the fourth quarter of 2025.

In July 2023, the Company received Type C Meeting Written Responses from the FDA regarding key study design elements for COMFORT Children. Subsequently, in October 2023, the Company received feedback from the FDA addressing the remaining protocol design elements for COMFORT Children.
The Company submitted the protocol for its COMFORT Children supplemental safety study in 4--7-years-old to the FDA on November 29, 2023.On March 24, 2025, the Company announced that in a Written Responses Only to the Company’s Type D IND meeting request the FDA agreed with the Company’s proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4 – 7-year-olds will be sufficient to support a BLA filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required and the Company will not conduct the study. The Company will utilize the safety data from the VITESSE participants randomized to active treatment as well as placebo-crossover participants in the VITESSE Open Label Extension (OLE). Accordingly, the Company plans to submit a BLA in the first half of 2026 and anticipates potentially accelerating the product launch by approximately one year, subject to FDA approval.
Financing
On March 27, 2025, the Company announced a financing of up to $306.9 million (€284.5 million), to advance the Viaskin Peanut Patch through BLA submission and U.S. commercial launch, if approved. The financing includes gross proceeds of $125.5 million (€116.3 million) received on April 7, 2025, and up to $181.4 million (€168.2 million) in potential additional gross proceeds that may be received if all the warrants are exercised, subject to satisfaction of specified conditions. The VITESSE Phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of some of the warrants. The ABSA Warrants (defined below) will be exercisable from their respective date of issue until the earlier of (i) April 7, 2027 and (ii) 30 days following the publication by the Company of a press release announcing that the ongoing VITESSE trial of Viaskin Peanut in children 4-7 years old met the primary endpoint defined in the VITESSE study protocol, it being specified that (i) the primary measure of treatment effect will be the difference in response rates at Month 12 between active and placebo treatment groups, (ii) the primary analysis will be based on a 2-sided confidence interval (“CI”) for the difference in response rates, and (iii) the primary analysis must be positive according to the success criterion (lower bound of the 2-sided 95% CI of the difference in response rates ≥ 15%) (the “ABSA Warrant Exercise Period”). The exercise of one (1) ABSA Warrant will give the holder the right to subscribe to one point seventy-five (1.75) ABSA Warrant Shares at a price of €1.5939 per ABSA Warrant.
The financing resulted in an immediate dilution of 22.4% and a maximal dilution of up to 73.7% of existing shareholders (on a non-diluted basis) if all the warrants in the Offering are exercised in full.
The financing consists of:
•a share capital increase without preferential subscription rights reserved to categories of persons satisfying determined characteristics pursuant to the 24th resolution of the general meeting of shareholders of May 16, 2024 (the "2024 General Meeting") completed on April 7, 2025 for an amount of €38 million, consisting of the issuance of (i) 34,090,004 new shares at a par value of €0.10 (the "New Shares") each with warrants of the Company attached (the "ABSA Warrants", and together with the New Shares, the "ABSA") at a subscription price of €1.1136 per ABSA and (ii) up to 59,657,507 additional new shares, if all the ABSA Warrants attached to the New Shares are exercised (the "ABSA Warrant Shares"); and
•the issue through an offering reserved to categories of persons satisfying determined characteristics of 71,005,656 units (the “PFW-BS-PFW”) completed on April 7, 2025 for an amount of €79 million at a subscription price of €1.1136 per PFW-BS-PFW (of which €1.1036 will have been
9


prefunded on the issue date), each PFW-BS-PFW consisting of one pre-funded warrant to subscribe for one share of the Company (the "First Pre-Funded Warrants") and one warrant (the "BS Warrants") to subscribe to one second pre-funded warrants (the "Second Pre-Funded Warrants"), each of which entitles the holder to subscribe for 1.75 shares of the Company (the "Second PFW Shares"), allowing to issue up to 71,005,656 additional new shares if all the First Pre-Funded Warrants are exercised (the "First PFW Shares") and up to 124,259,898 additional new shares if all the Second Pre-Funded Warrants are exercised (the "Second PFW Shares", together with the ABSA Warrant Shares and the First Pre-Funded Warrant Shares, the "Warrant Shares", and together with the New Shares, the "Offered Shares"),
(together, the "Offering").
The net proceeds from the issue of the ABSA and the PFW-BS-PFW, together with existing cash and cash equivalents, will be mainly used by the Company in the following order of priority (i) for working capital and general corporate purposes, (ii) to finance the continued development of the Viaskin Peanut program, (iii) to finance the preparation and submission of a potential BLA and, (iv) to finance the readiness of a launch of Viaskin Peanut in the U.S., if approved.
The ordinary shares, including the ordinary shares issuable upon exercise of the warrants from the Offering, have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the ordinary shares, including the ordinary shares underlying the warrants issued as part of the Offering.
Taking into account the net proceeds of $125.5 million (€116.3 million) received on April 7, 2025 from the issuance of the ABSA and the PFW-BS-PFW and based on its current operations, plans and assumptions, the Company estimates that it has sufficient balance of cash & cash equivalents to fund its operations into June 2026.
Legal Proceedings
From time to time, the Company may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. The Company is not currently subject to any material legal proceedings.
Note 3: Cash and Cash Equivalents
The following tables summarize the cash and cash equivalents as of March 31, 2025 and December 31, 2024:
March 31, 2025December 31, 2024
Cash 12,962 32,456 
Cash equivalents— — 
Total cash and cash equivalents as reported in the statements of financial position12,962 32,456 

Note 4: Other Current Assets
Other current assets consisted of the following:
March 31, 2025December 31, 2024
Research tax credit4,917 3,980 
Other tax claims6,015 4,452 
Prepaid expenses3,875 1,541 
Other receivables1,380 1,959 
Total16,186 11,932 
Research tax credit
The variance in Research Tax Credit is presented as follows:
Amount in thousands of US dollars
Opening research tax credit receivable as of January 1, 20253,980 
+ Operating revenue 753 
- Adjustment and currency translation effect184 
Closing research tax credit receivable as of March 31, 20254,917 
Of which - Non-current portion— 
Of which - Current portion4,917 
Before currency translation effect, the balance in research tax credit as of March 31, 2025, consisted of $4.0 million research tax credit for the previous fiscal year filed with the tax authorities. The estimated research tax credit for the first three months of the 2025 fiscal year amounts to $0.8 million.
10


The other tax claims are primarily related to the VAT as well as the reimbursement of VAT that has been requested. Prepaid expenses are comprised primarily of insurance expenses, as well as legal and scientific consulting fees.




Note 5: Lease contracts
Future minimum lease payments under the Company’s operating leases’ right of use as of March 31, 2025 and December 31, 2024, are as follows:
March 31, 2025December 31, 2024
Real EstateOther assetsTotalReal EstateOther assetsTotal
Current portion1,015 76 1,091 810 26 836 
Year 21,259 56 1,315 1,222 7 1,228 
Year 31,267 7 1,274 1,230 7 1,237 
Thereafter4,990 7 4,997 5,127 9 5,136 
Total minimum lease payments8,531 146 8,677 8,388 49 8,437 
Less: Effects of discounting(1,430)(13)(1,443)(1,463)(23)(1,486)
Present value of lease liabilities7,101 133 7,234 6,925 26 6,951 
Less: current portion(643)(66)(709)(648)(6)(654)
Long-term lease liabities6,459 66 6,525 6,278 20 6,297 
Weighted average remaining lease term (years)7.340.047.490.02
Weighted average discount rate5.06 %0.09 %5.02 %0.02 %
The Company recognizes rent expense, calculated as the remaining cost of the lease allocated over the remaining lease term on a straight-line basis. Rent expense presented in the consolidated statement of operations and comprehensive loss was:
March 31,
20252024
Operating lease expense / (income)288 586 
Net termination impact49 
Net restructuring impact(1)(7)
Supplemental cash flow information related to operating leases is as follows for the period March 31, 2025 and 2024:
March 31,
20252024
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows used in operating leases96 501 

Note 6: Trade Payables and Other Liabilities
6.1 Trade Payables
Trade payables increased by $12.1 million as of March 31, 2025, compared to December 31, 2024.
No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each fiscal period presented.
6.2 Other Liabilities
The following tables summarize the other liabilities as of March 31, 2025 and December 31, 2024:
11


March 31, 2025December 31, 2024
Other current liabilitiesOther non-current liabilitiesTotalOther current liabilitiesOther non-current liabilitiesTotal
Employee related liabilities4,844 — 4,844 7,294 — 7,294 
Tax liabilities332 — 332 188 — 188 
Other debts272 — 272 846 — 846 
Total5,447 — 5,447 8,328 — 8,328 
The Employee related liabilities include short-term debt to employees including social welfare, tax agency obligations and bonus provision. The variance versus year end is due to bonus accruals.
Note 7: Shareholders’ equity
The share capital as of March 31, 2025 is set at the sum of €10,285,887 ($11,652 thousand converted at historical rates). It is divided into102,858,868 fully authorized, subscribed and paid-up ordinary shares with a par value of €0.10.

Note 8: Share-Based Payments
The Board of Directors has been authorized at the General Meeting of the Shareholders to grant restricted stock units (“RSU”), stock options plan (“SO”), and non-employee warrants (Bons de Souscription d’Actions or “BSA”).
During the three months ended March 31, 2025, the Company granted neither stock options nor restricted stock units to employees.
There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 12 to the consolidated financial statements included in the Annual Report.
Change in Number of BSA/SO/RSU:
Number of outstanding
BSASORSUs
Balance as of December 31, 2024244,69310,444,8032,813,366
Granted during the period    ———
Forfeited during the period    —(3,725)(36,350)
Exercised/released during the period    ——(20,467)
Expired during the period    ———
Balance as of March 31, 2025244,69310,441,0782,756,549
Share-based payments expense reflected in the condensed consolidated statements of operations is as follows:
Three Months Ended March 31,
20252024
Research & developmentSO(382)(513)
RSU(199)(256)
Sales & marketingSO(12)(23)
RSU(6)(9)
General & administrativeSO(997)(1,030)
RSU(105)(126)
Total share-based compensation (expense)(1,701)(1,958)
Note 9: Contingencies
The following tables summarize the contingencies as of March 31, 2025 and December 31, 2024:
March 31, 2025December 31, 2024
Current contingencies82 122 
Non-current contingencies780 838 
Total contingencies861 961 
12


The changes in contingencies are as follows:
Pension retirement obligationsOther contingenciesTotal
At January 1, 2025838 122 961 
Increases in liabilities34 21 55 
Used liabilities— (63)(63)
Reversals of unused liabilities— — — 
Net interest related to employee benefits, and unwinding of discount— — — 
Actuarial gains and losses on defined-benefit plans(132)— (132)
Currency translation effect39 1 41 
At March 31, 2025780 82 861 
Of which current — 82 82 
Of which non-current 780 — 780 
The Company does not hold any plan assets related to long-term employee benefit for any of the periods presented. There have been no significant changes in assumptions for the estimation of the retirement commitments from those disclosed in Note 13 to the consolidated financial statements included in the Annual Report.
Note 10: Operating income
The following table summarizes the operating income during the three and nine months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
Research tax credit753 1,407 
Other operating income— — 
Total753 1,407 
The decrease in Research tax credit was primarily due to the fact that a greater proportion of studies activities were carried out in North America and were therefore not eligible to the French Research tax credit.
Note 11: Operating Expenses
The Company had an average of 106 employees during the three months ended March 31, 2025, in comparison with an average of 105 employees during the three months ended March 31, 2024. The increase is mainly due to hiring to support development activities and quality activities.
The following table summarizes the allocation of personnel expenses by function during the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
Research and Development expenses4,630 5,048 
Sales & Marketing expenses155 334 
General & Administrative expenses2,996 3,236 
 Total personnel expenses7,782 8,618 
The following table summarizes the allocation of personnel expenses by nature during the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
Wages and salaries4,677 5,144 
Social security contributions 1,370 1,207 
Expenses for pension commitments34 309 
Share-based payments1,702 1,958 
 Total7,782 8,618 
The decrease in personnel expenses is primarily due to lower bonuses paid in 2025 compared to last year.
Note 12: Commitments
13


There were no significant changes in other commitments from those disclosed in Note 17 to the consolidated financial statements included in the  Annual Report.
Note 13: Relationships with Related Parties
There were no new significant related-party transactions during the period nor any changes in the nature of the transactions from those described in Note 18 to the consolidated financial statements included in the Annual Report.
Note 14: Loss Per Share
Basic loss per share is calculated by dividing the net loss attributable to the shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. As the Company was in a loss position for each of the three-month periods ended March 31, 2025 and 2024, the diluted loss per share is equal to basic loss per share because the effects of potentially dilutive shares were anti-dilutive as a result of the Company’s net loss.
The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three months period ended March 31, 2025 and 2024 indicated in number of potential shares:
Three Months Ended March 31,
20252024
Non-employee warrants 244,693 244,693 
Stock options10,492,903 7,388,016 
Restricted stock units3,087,872 2,064,035 
Prefunded warrants22,266,331 28,276,331 
Note 15: Events after the Close of the Period

On March 27, 2025, the company announced a financing of up to $306.9 million (€284.5 million), to advance Viaskin® Peanut Patch through biologics license application submission and U.S. commercial launch, if approved. The financing includes gross proceeds of $125.5 million (€116.3 million) received on April 7, 2025 and up to $181.4 million (€168.2 million) in potential additional gross proceeds that may be received if all the warrants are exercised, subject to satisfaction of specified conditions.


On April 15, 2025, the Company received the 2024 Research Tax Credit (Crédit d’Impôt Recherche) in the amount of $4.0M in cash.
Note 16: Reportable segment disclosure

Three Months Ended March 31,
20252024
Clinical studies6,802 8,173 
BLA & Regulatory1,385 1,480 
Medical Affairs & Other Medical1,958 2,664 
Research & Innovation744 190 
Manufacturing & Supply and Quality10,594 8,896 
Sales & Marketing262 758 
General & Administrative 5,626 7,804 
Total expenses27,371 29,965 
The Company operates and is managed as one operating segment driving expenses for the development of Viaskin Peanut. The Company’s R&D organization is primarily responsible for the development and registration efforts of Viaskin Peanut. The Company’s technical operations group is responsible for the development of manufacturing processes, supplying clinical drug product. The Company is also supported by corporate staff functions.
The Company’s Chief Executive Officer as the CODM manages and allocates resources to the operations of the total company by assessing the overall level of resources available and how to best allocate them to support the Company’s long-term company-wide strategic goals. In making this decision, the CODM uses consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods.
The CODM's analysis includes a comparison to budgeted results. Segment assets provided to the CODM are consistent with those reported on the Consolidated Statement of Financial Position with particular emphasis on the Company's available liquidity including cash, cash equivalents.
14


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part 1, Item 1 of this Report and with our audited financial statements and related notes thereto for the year ended December 31, 2024, included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on April 11, 2025, or the Annual Report. This discussion and other parts of this Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause such differences are discussed in the section of this Report titled “Special Note Regarding Forward-Looking Statements” and under “Item 1A. Risk Factors” in the Annual Report.
Overview
We are a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy (EPIT) our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). We have generated significant data demonstrating that Viaskin’s mechanism of action is novel and differentiated, Viaskin targets specialized antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen that accumulates in the outer layer of the skin, and then migrate to the skin-draining lymph nodes in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. We are advancing this unique technology to treat children suffering from food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. We believe Viaskin may offer convenient, self-administered, non-invasive immunotherapy to patients, if approved.
Our most advanced product candidate is Viaskin Peanut, evaluated as a potential immunotherapy for children with peanut allergy in eleven clinical trials, including four Phase 2 trials and four completed Phase 3 trials. We are advancing two separate Viaskin Peanut product candidates in parallel to support two potential Biologics License Applications (BLAs) in two distinct age groups: one in toddlers ages one through three with the original (square) patch, and one in children ages four through seven with the modified (circular) patch.
Currently, we have an ongoing Phase 3 efficacy and safety trial (VITESSE) to evaluate the modified Viaskin Peanut patch in children ages four through seven with peanut allergy. On March 7, 2023, the Company announced that the first subject was screened in the VITESSE study. The Company announced on September 23, 2024 that subject screening was completed in the third quarter of 2024. Topline results are anticipated in the fourth quarter of 2025. On March 24, 2025, the Company announced that in a Written Responses Only to the Company’s Type D IND meeting request the FDA agreed with the Company’s proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4 – 7-year-olds will be sufficient to support a BLA filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required and the Company will not conduct the study. The Company will utilize the safety data from the VITESSE subjects randomized to active treatment as well as placebo-crossover subjects in the VITESSE Open Label Extension (OLE). Accordingly, the Company plans to submit a BLA in the first half of 2026 and anticipates potentially accelerating the product launch by approximately one year, subject to FDA approval.

We also have an ongoing Phase 3 open-label extension to the EPITOPE trial (our completed Phase 3 efficacy and safety trial conducted in peanut-allergic toddlers which met its clinical endpoints), with 3-year results for active-treatment subjects in 2024, as well as a planned Phase 3 supplementary safety study, in peanut-allergic toddlers ages one through three. The Company submitted the protocol for its COMFORT Toddlers supplemental safety study in 1 – 3 years-old to the FDA on November 9, 2023. The Company received comments and queries to the protocol from the FDA on March 11, 2024.

On July 30, 2024, the Company announced that it and the FDA had been engaged in ongoing dialogue since May 2023 on the COMFORT Toddlers supplemental safety study in 1 – 3-years-old with a peanut allergy. The study protocol was submitted on November 9, 2023, with comments provided by FDA on March 11, 2024. Since March, much of the dialogue between DBV and FDA regarding the COMFORT Toddlers supplemental study had focused on patch wear-time experience, including how prescribers would advise parents and caregivers to manage day-to-day variability in patch wear time. The Company proposed an approach, informed by the EPITOPE efficacy data, that focuses on the user experience during the first 90-days of treatment. The Company submitted to the FDA draft labeling for Section 2 – Dosing and Administration, for a potential Viaskin Peanut Prescribing Information (PI), along with comprehensive supportive data and analyses. Within the first 90-days of treatment (excluding the lead-in dosing period) it is possible to identify those patients who are very likely to have a robust clinical efficacy response based on patch wear time experience (i.e., “Label-in” patients). The proposed PI recommends continuation of treatment for these patients. With the same 90-day approach, patients less likely to have a robust clinical efficacy response, identified by their patch wear-time experience, would be identified as “Label-out” patients. In these instances, the PI would recommend a shared decision-making process, between the health care provider and the parent or caregiver, to determine whether treatment should be discontinued.
On October 22, 2024, the Company announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV has agreed to guidance provided by the FDA on a potential pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old. FDA confirmed that the Company has met Accelerated Approval qualifying criterion 1 and 2 . Regarding criterion 3, FDA has provided guidance and suggestion regarding the intermediate clinical endpoint, which the Company agreed to in informal discussions with the FDA. The Company formalized the Accelerated Approval guidance provided by FDA via submission of a meeting request and confirmed the general elements of the two study components: the COMFORT Toddlers safety study, to be completed before BLA submission, and the confirmatory effectiveness study, including the third Accelerated Approval criterion regarding the intermediate clinical endpoint. The Company expects that the confirmatory study will be initiated by the time of BLA submission and would run in parallel to commercialization in the United States, if Viaskin Peanut is approved.

The Company announced further that it has aligned with FDA on a wear time collection methodology in COMFORT Toddlers that provides a practical approach for subjects and families, is intended to generate sufficient data to support a BLA submission, and places wear time into an acceptable clinical hierarchy relative to other study endpoints. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. The Company anticipates enrolling approximately 300 – 350 subjects on active treatment into the safety study, which would bring the total Viaskin Peanut patch safety database in toddlers to approximately 600 subjects, consistent with prior FDA guidance. With this path forward, the BLA submission for Viaskin Peanut patch in 1 – 3 years-old under the Accelerated Approval program is anticipated to be supported by:
15


i. Positive efficacy and safety data from DBV’s previously completed EPITOPE Phase 3 Study; and
ii. Additional safety data generated in COMFORT Toddlers supplemental safety study to be initiated in the second quarter of 2025.

On December 11, 2024, the Company announced that it reached alignment with FDA on the Accelerated Approval pathway for Viaskin Peanut patch in toddlers 1-3 years-old and on key study design elements for the COMFORT Toddlers study, including study size and wear time collection methodology and analysis. The Company announced further that FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1-3 years-old and that the Company and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch, will include a include a double-blind, placebo-controlled food challenge (DBPCFC) and will use the same statistical criteria for success (i.e., lower bound of the 95% CI > 15%) as used in the EPITOPE and will need to be initiated at the time that the BLA is submitted.

The Company announced further that it sought scientific advice from the EMA regarding the components of a MAA for the Viaskin Peanut patch. Previous advice obtained from two local country regulatory health authorities indicated a potential path for a 1 – 7 year-old registration with one patch, the modified patch. The EMA recently confirmed through scientific advice that the completed EPITOPE study in 1 – 3 years-old, and a positive VITESSE study in 4 – 7 years-old, could constitute an MAA submission for a 1 – 7 year-old indication for peanut allergy patients using the modified patch, along with a new safety study in 1 – 3 years-old with the modified patch. Timing for the initiation of this new safety study to satisfy the important EU market is currently being planned.


Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States(“U.S. GAAP”). The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the revenue, costs and expenses recognized during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no new policies or significant changes to our critical accounting policies as disclosed in the critical accounting policies described in the Annual Report. Our significant accounting policies are more fully described in Note 1 of the Notes to the Consolidated Financial Statements in Part I, Item 1 of our Annual Report.
Business Trends and Results of Operations
Comparison of the Three Months Ended March 31, 2025 and 2024
The following table summarizes our results of operations, derived from our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. dollars, for the three months ended March 31, 2025 and 2024.

Three Months Ended March 31,
20252024$ change% of change
Operating income753 1,407 (654)(46)%
Operating expenses
Research and development expenses(21,483)(21,403)(80)— %
Sales and marketing expenses(262)(758)496 (65)%
General and administrative expenses(5,626)(7,804)2,178 (28)%
Total Operating expenses(27,370)(29,964)2,594 (9)%
Financial income (expense)(461)1,261 (1,722)(137)%
Income tax 0-4848(100)%
Net loss(27,079)(27,345)267 (1)%
Basic/diluted Net loss per share attributable to shareholders(0.26)(0.28)
Operating Income
The following table summarizes our operating income during the three months ended March 31, 2025 and 2024:


16


Three Months Ended March 31,
20252024$ change% of change
Sales— — — — %
Other income753 1,407 (654)(46)%
Research tax credit753 1,407 (654)(46)%
Other operating income— — — — %
Total operating income753 1,407 (654)(46)%
Research tax credit decreased by $0.7 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024 primarily due to a greater proportion of studies activities carried out in North America and therefore not eligible to the French Research tax credit.
Operating Expenses
Research and Development Expenses
The following table summarizes our research and development expenses incurred during the three months ended March 31, 2025 and 2024:
Research and Development expensesThree Months Ended March 31,
20252024$ change% of change
External clinical-related expenses13,957 14,026 (69)— %
Employee-related costs4,050 4,278 (228)(5)%
Share-based payment expenses581 770 (189)(25)%
Depreciation, amortization and other costs2,895 2,329 566 24 %
Total Research and Development expenses21,483 21,403 80 — %
Research and Development expenses remain stable for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 in particular for external clinical-related expenses given the continuity of efforts made on VITESSE Phase 3 clinical trial.
Employee-related costs, excluding share-based payments, decreased by $0.2 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024 due to lower bonuses paid in 2025 compared to 2024.
Depreciation, amortization and other costs increased by $0.6 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024 primarily as a result of a favorable reversal on accrual by $0.8 million due to the termination of the Collaboration Agreement with NESTEC in October 2023.
Sales and Marketing Expenses
The following table summarizes our sales and marketing expenses incurred during the three months ended March 31, 2025 and 2024:
Sales & Marketing expensesThree Months Ended March 31,
20252024$ change% of change
External professional services105 192 (87)(45)%
Employee-related costs137 302 (165)(55)%
Share-based payment expenses18 32 (14)(44)%
Depreciation, amortization and other costs2 232 (230)(99)%
Total Sales & Marketing expenses262 758 (496)(65)%
Sales and marketing expenses have decreased by $0.5 million during the three months ended March 31, 2025, compared to the three months ended March 31, 2024 due operating expenses containment in the first quarter of 2025, including lower bonuses paid in 2025 compared to 2024.

General and Administrative Expenses
The following table summarizes our general and administrative expenses incurred during the three months ended March 31, 2025 and 2024:
General & Administrative expensesThree Months Ended March 31,
20252024$ change% of change
External professional services1,052 2,433 (1,380)(57)%
Employee-related costs1,893 2,080 (186)(9)%
Share-based payment expenses1,103 1,157 (54)(5)%
Depreciation, amortization and other costs1,577 2,135 (558)(26)%
Total General & Administrative expenses5,626 7,804 (2,178)(28)%
General and Administrative expenses decreased by $2.2 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024.
17



External professional services decreased by $1.4 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024 mainly due to (1) one-time costs associated with financing activities, lower lease costs following office moves in France and the U.S, and trademark and patent activities that all occurred last year, and (2) a containment of costs and expenses during the Company’s financing period ended in March 31, 2025.
Employee-related costs, excluding share-based payments, decreased by $0.186 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024 due to lower bonuses paid in 2025 compared to last year.
Depreciation, amortization and other costs decreased by $0.6 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024 as a result of a lower lease cost in France.
Financial Income (Expense)
Our financial expense was $0.5 million for the three months ended March 31, 2025, compared to a financial income of $1.3 million for the three months ended March 31, 2024. This item mainly includes the financial income on our financial assets and foreign exchange result.
Income Tax
Our income tax expense was nil for the three months ended March 31, 2025 compared to $48 thousand for the three months ended March 31, 2024.
Net Loss
Net loss was $27.1 million for the three months ended March 31, 2025, compared to $27.3 million for the three months ended March 31, 2024. Net loss per share (based on the weighted average number of shares outstanding over the period) was $0.26 and $0.28 for the three months ended March 31, 2025 and 2024, respectively.

Liquidity and Capital Resources
Financial Condition
On March 31, 2025, we had $13.0 million in cash and cash equivalents compared to $32.5 million of cash and cash equivalents on December 31, 2024.

On March 27, 2025, the Company announced the 2025 PIPE, as further described below, of up to $306.9 million (€284.5 million), to advance Viaskin® Peanut Patch through BLA submission and U.S. commercial launch, if approved. The financing included gross proceeds of $125.5 million (€116.3 million) received on April 7 2025. With the receipt of the aforementioned proceeds, and based on its current operations, plans, and assumptions examined by the Board on March 23, 2025, the Company estimates that its cash and cash equivalents are sufficient to fund its operations into June 2026.

Sources of Liquidity and Material Cash Requirements
On March 27, 2025, the Company entered into securities purchase agreements (together, the “Securities Purchase Agreements”) pursuant to which the Company agreed to issue and sell to Investors in a private placement (the “2025 PIPE”) the following securities:
•a share capital increase without preferential subscription rights reserved to categories of persons satisfying determined characteristics pursuant to the 24th resolution of the general meeting of shareholders of May 16, 2024 (the "2024 General Meeting") completed on April 7, 2025 for an amount of €38 million, consisting of the issuance of (i) 34,090,004 new shares at a par value of €0.10 (the "New Shares") each with warrants of the Company attached (the "ABSA Warrants", and together with the New Shares, the "ABSA") at a subscription price of €1.1136 per ABSA and (ii) up to 59,657,507 additional new shares, if all the ABSA Warrants attached to the New Shares are exercised (the "ABSA Warrant Shares"); and
•the issue through an offering reserved to categories of persons satisfying determined characteristics of 71,005,656 units (the “PFW-BS-PFW”) completed on April 7, 2025 for an amount of €79 million at a subscription price of €1.1136 per PFW-BS-PFW (of which €1.1036 will have been prefunded on the issue date), each PFW-BS-PFW consisting of one pre-funded warrant to subscribe for one share of the Company (the "First Pre-Funded Warrants") and one warrant (the "BS Warrants") to subscribe to one second pre-funded warrants (the "Second Pre-Funded Warrants"), each of which entitles the holder to subscribe for 1.75 shares of the Company (the "Second PFW Shares"), allowing to issue up to 71,005,656 additional new shares if all the First Pre-Funded Warrants are exercised (the "First PFW Shares") and up to 124,259,898 additional new shares if all the Second Pre-Funded Warrants are exercised (the "Second PFW Shares", together with the ABSA Warrant Shares and the First Pre-Funded Warrant Shares, the "Warrant Shares", and together with the New Shares, the "Offered Shares"). The Company has assessed the PFW-BS-PFW will be classified as a component of permanent equity
The Company received initial gross proceeds of $125.5 million (€116.3 million) on April 7, 2025, and based on our current operations, plans and assumptions, we estimate that our balance of cash and cash equivalents will be sufficient to fund our operations into June 2026. We further estimate that, following the potential issuance of all Warrant Shares in the financing, representing potential additional gross proceeds of up to $181.4 million (€168.2 million), we could extend our financial visibility into 2028 and through potential commercialization of Viaskin Peanut in the U.S, if approved.

In May 2022, we established an At-The-Market (“ATM”) program to offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $100 million of American Depositary Shares (“ADSs”), each ADS representing one-half of one ordinary share of the Company. The ATM program terminated on July 16, 2024 at the time the Company’s existing registration statement registering the ADSs to be issued under the ATM program expired.
Pursuant to the ATM program, the Company issued and completed sales of new Ordinary Shares in the form of ADSs for a total gross amount of $15.3 million on May 4, 2022, and of $7.8 million on June 14, 2023. Respectively, 6,036,238 and 2,052,450 new Ordinary Shares in the form of ADSs were issued through a capital increase without preferential subscription rights of the shareholders reserved to specific categories of persons fulfilling
18


certain characteristics (the “ATM issuance”), at a unit subscription price of $1.27 and $1.90 per ADS, each ADS giving the right to receive one-half of one ordinary share of the Company.
We have incurred net losses each year since our inception. Substantially all of our net losses resulted from costs incurred in connection with our development programs and from general and administrative expenses associated with our operations. We have not incurred any bank debt.
We may seek additional capital as we prepare for the launch of Viaskin Peanut, if approved, and continue other research and development efforts. We may seek to finance our future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of non-dilutive financings.
We cannot guarantee that we will be able to obtain the necessary financing to meet our needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets due any future pandemics, epidemics or global health crises and conflict in Ukraine or other global political or military crises. A severe or prolonged economic downturn could result in a variety of risks to us, including reduced ability to raise additional capital when needed or on acceptable terms, if at all. If we are not successful in our financing objectives, we could have to scale back our operations, notably by delaying or reducing the scope of our research and development efforts or obtain financing through arrangements with collaborators or others that may require us to relinquish rights to our product candidates that we might otherwise seek to develop or commercialize independently.
Operating Leases
Our corporate headquarters are located in Châtillon, France. Our principal offices occupy a 2,447 square meters facility, pursuant to a lease agreement dated November, 2023 and represents $6.7 million cash requirement as of March 31, 2025. The lease term ends in March, 2033.
The lease agreement for the former office occupying 4,470 square meters facility in Montrouge, France, signed on March 3, 2015, with an effective date of August 1, 2015, expired on May 31, 2024. Associated lease termination costs were reflected in the Company’s financial accounts in the Annual Report.
Our primary U.S. office is located in Warren, New Jersey. In February 2024, we entered into a sublease agreement, commencing on March 19, 2024 and effective for 70 months, for an office of 16,704 square feet in Warren, New Jersey. The Warren office represent a $1.7 million cash requirement as of March 31, 2025 which expires December 31, 2029.
We also have facilities in North America that were intended to support our U.S. operations. We lease 5,799 square feet in Basking Ridge, New Jersey, which commenced on April 1, 2022 and is effective for 38 months.The Basking Ridge office represents a $26 thousand cash requirement as of March 31, 2025 which expires April 30, 2025.
The Company transitioned to its new offices location in Warren NJ and Châtillon France in April 2024.
There have been no material changes in our operating leases from those disclosed in the Annual Report.
Purchase Obligations - Obligations Under the Terms of CRO Agreements
In preparation of the launch of our clinical trials for Viaskin Peanut, we signed agreements with several contract research organizations. As of March 31, 2025 expenses associated with the ongoing trials amounted globally to $180.0 million compared to $170.3 million as of December 31, 2024.
There have been no material changes in our purchase obligations from those disclosed in our Annual Report.
Summary Statement of Cash Flows
The table below summarizes our sources and uses of cash for the three months ended March 31, 2025 and 2024.
Three Months Ended March 31,
(Amounts in thousands of U.S. Dollars)20252024$ change% of change
 Net cash flow used in operating activities(19,668)(34,692)15,024 (43)%
 Net cash flow used in investing activities(375)(2,132)1,756 (82)%
 Net cash flow used / provided by financing activities45 (62)107 (174)%
Effect of exchange rate changes on cash and cash equivalents504 (2,957)3,461 (117)%
Net (decrease) increase in cash and cash equivalents(19,494)(39,842)20,348 (51)%
Operating Activities
Our net cash flows used in operating activities were $19.7 million and $34.7 million during the three months ended March 31, 2025 and 2024, respectively. Our net cash flows used in operating activities decreased by $15.0 million as our costs and expenses have been contained during the Company’s financing period ended in March 31, 2025.
Investing Activities
Our net cash flows used in investing activities were $0.4 million and $2.1 million during the three months ended March 31, 2025 and 2024 respectively. The variance is primarily explained by capitalized costs for the headquarters move to Châtillon.
Financing Activities
Our net cash flows from financing activities were $45 thousand for the three months ended March 31, 2025 compared to $(62) thousand for the three months ended March 31, 2024.
19


Off-Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements and do not have variable interests in variable interest entities.
Smaller Reporting Company Status
We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended. We may, and intend to, take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as we are a smaller reporting company. We may be a smaller reporting company in any year in which (i) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) (a) our annual revenue is less than $100.0 million during the most recently completed fiscal year and (b) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.


Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Based on its evaluation as of March 31, 2025, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) were effective to provide reasonable assurance that (i) the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitation on Effectiveness of Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error of fraud may occur and not be detected.
20


PART II – OTHER INFORMATION
Item 1. Legal Proceedings
See “Note 2: Significant Events and Transactions – Legal Proceedings” in the notes to the condensed consolidated financial statements included elsewhere in this Quarterly Report.
Item 1A. Risk Factors
Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and trading price of our securities. In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report. There have been no material changes in our risk factors from those disclosed in the Annual Report, aside from those disclosed below:
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
We operate in a global economy, which includes utilizing third-party suppliers in several countries outside the United States. There is inherent risk, based on the complex relationships among the U.S. and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations. The current international trade and regulatory environment is subject to significant ongoing uncertainty. The U.S. government has recently announced substantial new tariffs affecting a wide range of products and jurisdictions and has indicated an intention to continue developing new trade policies, including with respect to the pharmaceutical industry. In response, certain foreign governments have announced or implemented retaliatory tariffs and other protectionist measures. These developments have created a dynamic and unpredictable trade landscape, which may adversely impact our business, results of operations, financial condition and prospects.

We do not own or operate, and currently have no plans to establish, any manufacturing facilities for Viaskin, Viaskin Peanut and other product candidates. We currently rely, and expect to continue to rely, on third parties for the manufacture of Viaskin epicutaneous patch, Viaskin Peanut and other product candidates for clinical testing, as well as for manufacture of any products that we may commercialize, if approved. Currently, several of our suppliers are located outside of the United States, and the principal suppliers of many of our critical raw materials are located in Europe. The active pharmaceutical ingredients (APIs) for Viaskin Peanut is manufactured in France. We also rely on specialized laboratory equipment, supplies, materials, and precursor compounds, all or part of which we believe may be ultimately sourced from multiple countries outside the United States, to advance our research and development efforts.

Current or future tariffs will result in increased research and development expenses, including with respect to increased costs associated with APIs, raw materials, laboratory equipment and research materials and components. In addition, such tariffs will increase our supply chain complexity and could also potentially disrupt our existing supply chain. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to our development timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relationships and could reduce investor confidence, negatively impacting our ability to secure additional financing on favorable terms or at all. In addition, as we advance toward potential commercialization of Viaskin Peanut, tariffs and trade restrictions could hinder our ability to establish cost-effective production capabilities, negatively impacting our growth prospects.

Trade disputes, tariffs, restrictions and other political tensions between the United States and other countries may also exacerbate unfavorable macroeconomic conditions including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns. The ultimate impact of current or future tariffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively monitor these risks, any prolonged economic downturn or escalation in trade tensions could materially and adversely affect our business, ability to access the capital markets or other financing sources, results of operations, financial condition and prospects.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
During the three months ended March 31, 2025,we issued the following unregistered securities:
•On January 9, 2025, the issuance of an aggregate of 7,300 ordinary shares to U.S. employees upon settlement of RSUs;;
•On January 29, 2025, the issuance of an aggregate of 1,462 ordinary shares to U.S. employees upon settlement of RSUs;
•On March 23, 2025, the issuance of an aggregate of 2,605 ordinary shares to U.S. and non-U.S. employees upon settlement of RSUs; and
•On March     27, 2025, we entered into the Securities Purchase Agreements with Investors to which we agreed to issue and sell to the Investors (i) 34,090,004 New Shares, each with ABSA Warrants at a subscription price of €1.1136 per ABSA, and (ii) 71,005,656 First Pre-Funded Warrants at a subscription price of €1.1036 (which equals the per New Share subscription price less the exercise price of €0.01), which was completed on April 7, 2025.
None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe these transactions were exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Regulation S promulgated under
21


Section 5 of the Securities Act, as transactions by an issuer not involving any public offering or as offerings made to non-U.S. resident employees pursuant to an employee benefit plan established and administered in accordance with the law of a country other than the United States (namely, the Republic of France) and in accordance with that country’s practices and documentation. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
During the three months ended March 31,2025, none of our directors and officers (as defined in Rule16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trade arrangement” as those terms are defined in Item 408 of Regulations S-K any contracts, instructions, or written plans for the purchase or sale of the Company’s securities.






Item 6. Exhibits
Exhibit Index
22


ExhibitDescriptionIncorporated by Reference
Schedule/ FormFile NumberExhibitFile Date
3.1
Form 10-K
001-36697
3.1
April 11, 2025
4.1
Form 8-K
001-36697
Exhibit A to Form of Securities Agreement filed as Exhibit 10.1
March 31, 2025
4.2
Form 8-K
001-36697
Exhibit B to Form of Securities Agreement filed as Exhibit 10.1
March 31, 2025
4.3
Form 8-K
001-36697
Exhibit C to Form of Securities Agreement filed as Exhibit 10.1
March 31, 2025
4.4
Form 8-K
001-36697
Exhibit D to Form of Securities Agreement filed as Exhibit 10.1
March 31, 2025
10.1
Form 8-K
001-36697
10.1
March 31, 2025
10.2
Form 8-K
001-36697
10.2
March 31, 2025
31.1
31.2
32.1*
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Taxonomy Extension Labels Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101.
*Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporate language contained in such filing.











23


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DBV Technologies S.A.
(Registrant)
Date: April 30, 2025
By:/s/ Daniel Tassé
Daniel Tassé
Chief Executive Officer
(Principal Executive Officer)
Date: April 30, 2025
By:
/s/ Virginie Boucinha
Virginie Boucinha
Chief Financial Officer
(Principal Financial and Accounting Officer)
24

 EX-3.1 2 exhibit31-bylawsxdbv10xq_u.htm EX-3.1 Document

BY-LAWS
(updated by decision of the CEO on April 07, 2025)
____________________
DBV Technologies
Limited Company with share capital of € 13,694,887.20
107, avenue de la République - 92320 Châtillon, France
Nanterre Trade and Companies Register No. 441 772 522


I. - CHARACTERISTIC FEATURES OF THE COMPANY
Article 1 - Form
The Company was incorporated in the form of a French Limited Company (Société Anonyme) with a Board of Directors.
Article 2 - Name
The name of the Company is: “DBV Technologies”.
Article 3 - Registered office
The registered office is located at: 107, avenue de la République, 92320 Châtillon, France.
Article 4 - Corporate Purpose
The Company’s corporate purpose in France and in all countries is:
•the development of any innovative medical products, including any drugs, or diagnostic or treatment products;
•the study, research, development, industrial manufacturing, and marketing of said products;
•the use and development of any patents or licenses relating to these products, and generally speaking any commercial, investment or real estate, financial or other transactions that are directly or indirectly related to the corporate purpose in whole or in part, or to any other similar or related purpose, and that may promote the operation and commercial development of the Company.
Article 5 - Term
The Company’s term is ninety-nine years as from its registration in the Trade and Companies Register.
Article 6 - Share capital
The share capital has been set at €13,694,887.20.
It is divided into 136,948,872 ordinary shares with a par value of 10-euro cents (€0.10) each. All of the shares have been fully subscribed, and their full amount paid up in cash.
Article 7 - Changes to the share capital
I.     The share capital may be increased either via the issue of new shares, or by increasing the par value of the existing shares.
The new shares will be paid for in cash, or via a contribution in kind, offset against liquid and due receivables, or via the incorporation of profits, reserves, or share premiums into the share capital, either as the result of a merger or demerger, or following the exercise of a right attached to transferable securities granting entitlement to the share capital, including payment of the corresponding amounts, where applicable.
The new equity securities will be issued either at their par value, or at that amount plus a share premium.
Only the Extraordinary General Meeting of Shareholders has the power to decide on increasing the share capital, based on a report from the Board of Directors containing the disclosures required by law.
However, the Extraordinary General Meeting of Shareholders may delegate this power to the Board of Directors under the conditions determined by law. The Board of Directors has the requisite powers to perform a capital increase in one or several installments, to determine its terms and conditions, to record its completion, and to amend the By-Laws accordingly within the limits of the powers so granted by the Extraordinary General Meeting of Shareholders.
If the General Meeting of Shareholders decides to increase the share capital, it may delegate the powers required to perform the transaction to the Board of Directors.
If a delegation of power or of authority is used, the Board of Directors will draw up a supplementary report at the next Ordinary General Meeting of Shareholders.
If the capital increase is performed via the incorporation of profits, reserves, or share premiums, the Extraordinary General Meeting of Shareholders will take decisions under the quorum and majority conditions provided for Ordinary General Meetings of Shareholders. In this case, it may decide that rights amounting to fractional shares may neither be traded nor transferred, and that the corresponding equity securities must be sold. The proceeds from the sale will be allocated to the holders in proportion to their rights.
A capital increase by increasing the par value of the shares can only be decided with the shareholders’ unanimous consent, except if it results from the incorporation of profits, reserves, or share premiums into the share capital.
Shareholders will have a preferential right to subscribe to the cash shares issued in order to perform a capital increase, in proportion to the number of shares that they hold. The shares purchased as a result of exercising this right will be shares in the same class as the one for the shares giving rise to said right, together with the shares resulting from the purchase of other transferable securities than shares.
1

The shareholders may sell all or some of their subscription rights throughout the subscription period. These rights will be tradable if they are stripped from shares that are themselves tradable. Otherwise, they may be sold under the same conditions as the actual shares.
Shareholders may waive their preferential subscription right on an individual basis.
The Extraordinary General Meeting of Shareholders that decides on the capital increase may waive the preferential subscription right under the conditions and limits determined by law, and rule to that effect on the reports prepared by the Board of Directors and the Statutory Auditors under the conditions determined by the laws and regulations in effect.
If the Extraordinary General Meeting of Shareholders, or the Board of Directors in the event of a delegation of authority, has expressly decided to do so, any shares that have not been subscribed on an irrevocable basis will be allotted to shareholders who subscribed to a higher number of shares on a revocable basis than the number to which they were able to subscribe on a preferential basis, in proportion to the subscription rights that they hold, and within the limits of their request, in any event.
If, for any reason, subscriptions have not absorbed the full amount of the capital increase, the Board of Directors may use the options provided for below, or only some of them, in the order that it determines:

(i)     limiting the capital increase to the amount of the subscriptions, subject to the general condition that it amounts to at least three quarters of the                         increase decided upon, and that this option was not expressly excluded by the Extraordinary General Meeting of Shareholders at the time of issue;

(ii)    allocating the balance of the shares if the Extraordinary General Meeting of Shareholders has not decided otherwise;

(iii)    opening the subscription process to the public if the Extraordinary General Meeting of Shareholders has expressly authorized it.

If subscriptions have not absorbed the entire capital increase following the exercise of these options, or three-quarters of the increase in the case provided for under (i) above, the capital increase will not be performed.
However, the Board of Directors may automatically limit the capital increase to the amount raised in all cases where the unsubscribed shares account for less than 3% of the capital increase.
In the event of a capital increase with or without preferential subscription rights, the Extraordinary General Meeting of Shareholders may provide that the number of securities may be increased by up to 15% of the initial issue, at the same price as the one used for the initial issue within a period of thirty days following the close of the subscription period.
If the capital increase creates fractions of shares, shareholders who have an insufficient number of subscription or allotment rights must make arrangements to purchase or sell the rights required to obtain the delivery of a whole number of new shares.

II.     The Extraordinary General Meeting of Shareholders (or the Board of Directors in the event of a delegation of authority) may also authorize or decide on a capital decrease, subject to the rights of creditors, where applicable.
Decreasing the share capital below the legal limit can only be decided under the condition precedent of a capital increase intended to return the share capital to an amount that is at least equal to the minimum legal threshold, unless the Company turns itself into a company with another legal form. Otherwise, any interested party may apply to the courts to have the Company wound up. The court may not order the Company to be wound up if the amount of the share capital has been restored to the statutory minimum by the day when it rules on the substance of the case.
Article 8 - Financial year
The financial year runs from January 1 to December 31.
2

II. - ADMINISTRATION OF THE COMPANY
Article 9 - Executive Management exercise method
The executive management of the Company is the responsibility either of the Chairman of the Board of Directors or of another individual appointed by the Board of Directors bearing the title of Chief Executive Officer.
The Board of Directors chooses between the two Executive Management exercise methods based on the unanimous vote of all of its members.
Where responsibility for the Company’s Executive Management is held by the Chairman of the Board of Directors, the following provisions concerning the role of Chief Executive Officer apply.
A. The Board of Directors
Article 10 - Composition of the Board of Directors
The Company is governed by a Board of Directors that consists of between 3 and 18 directors.
The Directors are appointed by the General Meeting of Shareholders, deliberating under the quorum and majority conditions for Ordinary General Meetings of Shareholders.
The term of office for the Directors appointed during the term of the company is three (3) years. This term expires at the end of the meeting convened to approve the financial statements for the year just ended, and which is held in the year during which their term of office expires.
By way of exception and in order to allow exclusively for the implementation or maintenance of the staggered terms of office of Directors, the ordinary General Meeting of Shareholders may appoint one or more members of the Board for a term of two (2) years or one (1) year.
The Directors may be dismissed at any time and without any good reason by the General Meeting of Shareholders, deliberating under the quorum and majority conditions for Ordinary General Meetings of Shareholders.
The number of Directors aged over eighty cannot exceed one third of the Board members.
Article 11 - Board Discussions
The Board of Directors meets as often as is required by the Company’s interests at the invitation of the Chairman of the Board of Directors, at the registered office or the place specified in the notice of meeting. The invitation may be issued by any means five calendar days in advance: it may also be issued orally and immediately if all of the Directors and non-voting Board members agree.
For the purposes of calculating the quorum and majority, Directors who participate in the meeting by a means of telecommunication that enables them to be identified, in accordance with legal and regulatory provisions, are deemed to be present.
Directors may vote by correspondence at a meeting of the Board of Directors by means of a form containing the information required by the regulations in force, if this method of voting is provided for in the notice convening the meeting of the Board of Directors.
If it has not met for over two months, at least one quarter of the members of the Board of Directors may ask the Chairman to convene the Board based on a determined agenda. The Chief Executive Officer or a Director may also ask the Chairman to convene the Board of Directors based on a determined agenda. The Chairman will be bound by any such requests.
An attendance register will be kept, and minutes will be drawn up following each meeting. The Board may only validly take decisions if at least half of its members are present.
Except where the choice of the method for exercising Executive Management is concerned, decisions will be taken based on a majority vote of the Directors present or represented. The Chairman will have a casting vote in the event that the vote is split.
The Board of Directors may also take decisions by written consultation of the Directors.
The decision to resort to written consultation is taken by the Chairman, who sends each Director, by e-mail, the text of the proposed decisions as well as any documents required for information purposes.
Any Director may object to the use of written consultation for the adoption of a decision, by informing the Chairman by e-mail within two working days of the date of dispatch of the draft decisions. The Chairman is bound by any objections sent to him pursuant to this paragraph.
Directors have a period of five calendar days (ending at 11:59 p.m., Paris time, on the last day of this period) from the date on which the draft decisions are sent to cast their vote in writing. Responses are sent by e-mail to the attention of the Chairman of the Board of Directors.
The Board of Directors may only validly deliberate on a written consultation if at least half of its members have replied within the time limit indicated above.
Decisions are taken by a majority of the votes of the members who have replied, each member having one vote. The Chairman will have a casting vote in the event that the vote is split.
Decisions taken by written consultation are recorded in minutes drawn up by the Chairman.
The Directors and any individuals asked to attend the Board of Directors’ meetings are required to exercise discretion with respect to information of a confidential nature, and which is provided as such by the Chairman of the Board of Directors.

3

Article 12 - The Board’s powers
The Board of Directors determines the Company’s guidelines, and ensures their implementation. Subject to the powers specifically assigned to General Meetings of Shareholders, and within the limits of the corporate purpose, the Board will deal with any matter involving the proper operation of the Company, and settle any matters concerning it through its discussions.
The Board of Directors carries out the controls and verifications that it considers appropriate. Every Director will receive all of the information required to fulfill their assignment, and may ask for the disclosure of any documents that they consider useful.
Article 13 - The Chairman of the Board of  Directors
The Board of Directors elects a Chairman, who must be a private individual, from among its members, and determines their remuneration, in accordance with applicable law. The Chairman is appointed for a period that may not exceed the length of their term of office as a Director. They are eligible for re-election. The Board of Directors may dismiss the Chairman at any time. Any provisions to the contrary will be considered void.
No one aged 75 or over may be appointed as Chairman. If the incumbent Chairman reaches this age during a financial year, their duties will automatically end following the Ordinary General Meeting of Shareholders convened to approve the financial statements for that financial year.
The Chairman organizes and directs the work undertaken by the Board, and accounts for it at the General Meeting of Shareholders. They ensure that the Company’s bodies operate properly, and especially that the Directors are in a position to fulfill their assignment.
Article 14 - Non-Voting Board Members
The General Meeting of Shareholders may appoint one or two non-voting Board members for the Company who are private individuals, regardless of whether they are shareholders; they will be aged 65 at most on the day of their appointment.
Non-voting Board members are appointed for a period of two (2) years. Their assignment ends after the General Meeting of Shareholders that has approved the financial statements for the year just ended, and held in the year during which their term of office expires.
Non-voting Board members do not receive any remuneration. They may receive allowances determined by the Board of Directors in order to reimburse the expenses that they are required to incur as part of the normal performance of their duties. If the Board delegates a specific assignment to the non-voting Board members or to one of them, they may allocate them an allowance in proportion to the importance of the assignment entrusted to them, as well as a budget for performing said assignment. Non-voting Board members are invited to all of the Board of Directors’ meetings and to all of the General Meeting of Shareholders, and take part in the discussions in an advisory capacity. Non-voting Board members perform a general and permanent advisory and supervisory role at the Company. However, they may not interfere in the management of the Company under any circumstances, or, in general, replace its legal bodies.
B. The Executive Management
Article 15 - Chief Executive Officers and Deputy Chief Executive Officers
The executive management of the Company is the responsibility of a private individual appointed by the Board of Directors bearing the title of Chief Executive Officer, under the Company’s responsibility.
The Board of Directors may appoint one or more private individuals responsible for assisting the Chief Executive Officer, who will bear the title of Deputy Chief Executive Officer, on the recommendation of the Chief Executive Officer. The number of Deputy Chief Executive Officers cannot exceed five.
The Chief Executive Officer may be dismissed by the Board of Directors at any time. The same applies to the Deputy Chief Executive Officers, on the recommendation of the Chief Executive Officer. If the dismissal is not on justified grounds, it may result in the payment of damages and interest.
Where the Chief Executive Officer ceases, or is otherwise prevented from performing their duties, the Deputy Chief Executive Officers will retain their positions and their assignments until a new Chief Executive Officer is appointed, unless the Board decides otherwise.
The Board of Directors determines the compensation paid to the Chief Executive Officer and the Deputy Chief Executive Officers, in accordance with applicable law.
Article 16 - Powers of the Chief Executive Officer and Deputy Chief Executive Officers
The Chief Executive Officer is granted very extensive powers to act in the Company’s name in all circumstances. They exercise the powers within the limit of the corporate purpose, and subject to those that the law and these By-Laws expressly assign to General Meeting of Shareholders and to the Board of Directors.
They represent the Company in its dealings with third parties. The Company will be committed even by the Chief Executive Officer’s actions that do not relate to the corporate purpose, unless it proves that the third party was aware that the action exceeded that purpose, or could not ignore this fact in view of the circumstances. The sole publication of the By-Laws does not amount to sufficient proof.
The Board of Directors determines the scope and term of the powers granted to the Deputy Chief Executive Officers, with the Chief Executive Officer’s consent. The Deputy Chief Executive Officers have the same powers as the Chief Executive Officer where third parties are concerned.

4

III. - GENERAL MEETING OF SHAREHOLDERS
Article 17 - General Meeting of Shareholders
The duly constituted General Meeting of Shareholders represents the entire body of shareholders.
Its decisions, which are taken in accordance with the law and the By-Laws, are binding on all of the shareholders, even if they are absent, disagree, or are incapable.
There are three forms of meetings, depending on the purpose of the resolutions put forward:
•Ordinary General Meetings;
•Extraordinary General Meetings;
•Special Meetings that bring together the holders of shares in a given class.
Article 18 - Invitations
The Meetings are convened by the Board of Directors. They may also be convened by the Statutory Auditor or by a court representative, under the conditions and in accordance with the procedures provided for by law.
Meetings are convened by the liquidator(s) during the liquidation period.
The Meetings are held at the registered office or at any other location specified in the notice of meeting.
A notice of meeting is published in the Bulletin des Annonces Légales Obligatoires (French Official Gazette, or BALO) at least thirty-five days before a Meeting is held. In addition to the information relating to the Company, the notice specifies the agenda for the Meeting, and the wording of the draft resolutions that will be put forward. Requests to enter points or draft resolutions on the agenda must be addressed to the Company under the conditions provided for by the regulations in effect.
The Meetings are held at the registered office or at any other location specified in the notice of meeting.
Subject to specific legal provisions, the invitation is issued at least fifteen days before the date of the Meeting by a notice inserted in a legal gazette published in the Department where the registered office is located, as well as in the BALO.
The holders of registered shares must be convened under the conditions provided for by the regulations in force.
The notice of meeting must also specify the conditions under which shareholders may vote by post, and the places where, and terms and conditions according to which, they may obtain postal vote forms.
The notice of meeting may be sent, where applicable, with a proxy form and a postal voting form, under the conditions specified in Article 21 of these Articles of Association, or with a postal voting form only, under the conditions specified in Article 21 of these Articles of Association.
Where a Meeting has been unable to take decisions as a result of failing to achieve the quorum required, a second Meeting will be convened, subject to specific legal provisions, at least ten days in advance, in the forms provided for by the regulations in effect.
Article 19 - Agenda
The agenda for Meetings will be prepared by the person convening the meeting.
One or several shareholders, who represent at least the percentage of the share capital specified by law, and acting in accordance with the legal conditions and timeframes, have the option to request the inclusion of points or draft resolutions on the agenda for the Meeting, via registered letter with a request for acknowledgment of receipt.
The Meeting may not discuss an issue that has not been entered on the agenda, which cannot be altered at the time of the second invitation. However, it may dismiss one or several members of the Board of Directors, and replace them in all circumstances.
Article 20 - Participation of Shareholders in Meetings
Any shareholder may participate, personally or by proxy, in the meetings upon proof of identity and ownership of his or her shares, in accordance with the procedures provided for by the laws and regulations in force.
Article 21 - Postal and proxy voting
Postal voting is carried out in accordance with the terms and conditions laid down by the legal and regulatory provisions. In particular, any shareholder may send postal voting forms either in paper form or, if the Board of Directors decides to do so and publishes the decision in the notice of meeting, by electronic means, before the meetings. Proxy forms may be sent either in paper form or by electronic means before the meetings.
If the Board of Directors decides at the time of convening the meeting to allow the transmission of voting or proxy forms by electronic means, the electronic signature of these forms may result from a reliable process for identifying the shareholder, guaranteeing its link with the remote form to which its signature is attached. The vote thus expressed before the meeting by this electronic means, as well as the acknowledgement of receipt given, will be considered as non-revocable writings and opposable to all. The proxy is however revocable in the same way as those required for the appointment of the proxy. In the event of a transfer of ownership of securities occurring before midnight (Paris time) on the second business day preceding the meeting, the Company will invalidate or modify accordingly, as the case may be, the proxy or the vote cast before the meeting by this electronic means.
5

Article 22 - Attendance sheet
An attendance sheet containing the information specified by law will be kept at each Meeting.
This attendance sheet, duly initialed by the shareholders present and the proxies, and the shareholders attending via video-conference or another means of telecommunication, in accordance with the legal and regulatory requirements, and to which the powers granted to each representative are appended, together with the postal voting forms, will be certified as accurate by the Meeting Bureau.
The Meetings will be chaired by the Chairman of the Board of Directors. Otherwise, the Meeting will elect its own Chairman.
The tellers’ duties will be performed by two shareholders who are present and agree to do so, and who represent the highest number of votes, both on their own behalf and as proxies.
The Bureau formed in this way will appoint a secretary, who may be chosen from outside the shareholders.
Article 23 - Voting rights attached to shares
The voting right attached to the shares is proportional to the percentage of the total share capital that they represent. Each equity share or dividend share will grant entitlement to one vote. Fully paid-up shares for which proof can be provided that they have been registered in the name of the same shareholder for at least two years do not benefit from double voting rights.
Article 24 - Minutes
The decisions taken at the Meetings will be recorded in minutes that are drawn up in a special ledger held at the registered office, and signed by the members of the Bureau.
Copies or excerpts of the minutes of the decisions will be certified either by the Chairman of the Board of Directors or by the Meeting Secretary. They will be validly certified by the liquidator(s) in the event of liquidation proceedings.
Article 25 - Disclosure of documents
Any shareholder has the right to obtain disclosure of, and the Board of Directors is required to send or make available to them, the documents required to enable them to form an opinion in full knowledge of the facts, and to make an informed judgment on the Company’s management and operations.
The nature of these documents, and the conditions for sending them or making them available to the shareholders are determined by the regulations in effect.
Every shareholder or their representative may seek the assistance of an expert registered on one of the lists drawn up by the courts, in order to exercise their right of disclosure.
The exercise of the right of disclosure entails the right to take copies, except where records are concerned.
Article 26 - Ordinary General Meeting of Shareholders
The Ordinary General Meeting of Shareholders takes all of the decisions that exceed the powers of the Board of Directors and which do not fall within the remit of the Extraordinary General Meeting of Shareholders.
The Meeting is convened at least once a year, within a period of six months following the end of each financial year, in order to approve the financial statements for that year, subject to this period being extended by an order from the Presiding Judge of the Commercial Court ruling at the request of the Board of Directors.
The Meeting is convened on an extraordinary basis every time that this appears to be in the Company’s interests.
When convened for the first time, the Ordinary General Meeting of Shareholders may only validly deliberate if the shareholders present, represented, or who have voted by post hold at least one fifth of the shares to which voting rights are attached.
No quorum is required if the meeting is convened for a second time and the original agenda has not been amended.
The Ordinary General Meeting of Shareholders decides by a majority of the votes expressed by the shareholders present, represented or voting by mail. The expressed votes do not include those attached to shares for which the shareholder has not taken part in the vote, has abstained or has voted blank or null.
Article 27 - Extraordinary General Meeting of Shareholders
The Extraordinary General Meeting of Shareholders is authorized to amend all of the provisions of the By-Laws, and to specifically decide on turning the Company into a company with another legal form. It cannot, however increase the shareholders’ undertakings, except in the case of transactions resulting from a duly executed reverse share split.
The Board of Directors may make the necessary amendments to the By-Laws to bring them into line with legislative and regulatory provisions, subject to ratification of these amendments by the next Extraordinary General Meeting of Shareholders.
The Extraordinary General Meeting of Shareholders may only validly deliberate if the shareholders present, represented or who have voted by post hold at least one quarter of the shares with voting rights at the time of the first invitation, and one fifth of the shares with voting rights at the time of the second invitation. If the second quorum is not achieved, the second Meeting may be postponed to a date no later than two months after the date on which it was convened.
6

The Meeting passes resolutions based on a two-thirds majority vote expressed by the shareholders who are present, represented, or have voted by post, or who are attending the Meeting via video-conference or another means of telecommunication, in accordance with the legal and regulatory provisions.
As a legal exemption to the above provisions, a General Meeting of Shareholders that decides on a capital increase via the capitalization of reserves, profits, or share premiums may pass resolutions under the same quorum and majority conditions as an Ordinary General Meeting of Shareholders.
Furthermore, where the Extraordinary General Meeting of Shareholders is required to discuss the approval of a contribution in kind or the granting of a particular benefit, the shares held by the individual making the contribution or the beneficial owner will not be taken into account to calculate the majority. The individual making the contribution or the beneficial owner will not have a vote, either on their own behalf, or as a proxy.
Article 28 - Special meeting
If there are several share classes, no change may be made to the rights attached to shares in one of these classes without a due vote at an Extraordinary General Meeting of Shareholders open to all shareholders and, furthermore, without an equally compliant vote at a Special Meeting open only to the holders of shares in the class in question.
Special Meetings may only validly discuss matters if the shareholders present, represented, who have voted by post, or who are attending the Meeting via video-conference or via another means of telecommunication in accordance with the legal and regulatory provisions, hold at least one third of the shares with voting rights, where an amendment to those rights is planned, on the first invitation, and one fifth of the shares on the second invitation. Otherwise, the second Special Meeting may be postponed to a date no later than two months after the date on which it was convened.
Special Meetings pass resolutions based on a two-thirds majority of the expressed votes of the shareholders present or represented.





























7

IV. - THE COMPANY’S SECURITIES
Article 29 - Payment for the shares
At least 25% of the par value of shares subscribed in cash must be paid at the time of subscription, together with the full share premium, where applicable.
The balance must be paid in one or several installments, as called by the Board of Directors, and within a period of five years from the date on which the capital increase was finalized.
Calls for funds are made known to the shareholders via a notice published in the BALO fifteen (15) days in advance.
If the shareholder does not make the required payments on the amount of the shares to which they have subscribed at the times determined by the Board of Directors, these payments will automatically bear interest payable to the Company at the legal rate determined in Article L. 313-2 of the French Monetary and Financial Code, as from the end of the month following the date when they are due, without any requirement for a court application or letter of notice. Furthermore, shares for which the required payments have not been made at the end of a period of 30 days as from the sending of a letter of notice to the defaulting shareholder, to which no reply has been received, will no longer grant the right to attend General Meetings of Shareholders and to vote at those Meetings, and will be deducted from the quorum calculation. The right to dividends, and the preferential right to subscribe to capital increases attached to the shares will be suspended. These rights will be recovered once the capital and interest amounts due have been paid. The shareholder may then request the payment of dividends that have not expired, and exercise their preferential subscription right, if the determined timeframe for exercising that right has not expired.
The share capital must be fully paid up before any issue of new shares to be paid for in cash.
Article 30 - Form of the shares - Management of the securities accounts
The shares may be in registered or bearer form, if the legislation allows, depending on the shareholder’s choice.
Issued shares give rise to a registration in individual accounts in the name of each shareholder opened by the Company or any authorized intermediary. These accounts are held under the conditions and in accordance with the procedures provided for by the legal and regulatory provisions.
In order to identify the owners of bearer shares, the company may, under the conditions provided for by the legal and regulatory provisions in force, request, at any time, information concerning the owners of its shares and securities conferring immediate or future voting rights at its own General Meetings of Shareholders.
Article 31 - Transfer of the shares
Shares registered on an account are transferred from account to account.
Cash shares are freely tradable as from the completion of the capital increase. Shares resulting from contributions are freely tradable as from the completion of the capital increase, i.e. the date of the Meeting or of the meeting of the Board of Directors acting on a delegation of authority, which approved the contributions, in the event of a contribution in kind during the term of the company.
The transfer of ownership will result from their registration on the purchaser’s account, on the date and under the conditions determined by law and the applicable regulations, where applicable.
The shares will be freely tradable, subject to the provisions provided for by law.
Article 32 - Crossing of thresholds
Any private individual or legal entity referred to in Articles L. 233-7, L. 233-9, and L. 223-10 of the French Commercial Code who comes to directly or indirectly hold a number of shares representing a percentage of the Company’s share capital or voting rights higher than or equal to 2.5% or a multiple of that percentage, either on a stand-alone basis or in concert, must inform the Company of the total number of shares, voting rights, and securities granting access to the share capital or to voting rights immediately or in the future that they hold, via registered letter with a request for an acknowledgment of receipt sent to the registered office within a period of four trading days, prior to the market close as from the point when they crossed said percentage threshold(s).
The disclosure obligation provided for above also applies under the same conditions when each threshold mentioned above is crossed downwards.
If they have not been reported under the conditions specified above, shares or voting rights that exceed the percentage that should have been reported will be stripped of their voting rights at General Meetings of Shareholders at any Meeting that may be held until the expiry of a two-year period following the date when the notice of interest was made compliant, in accordance with Article L. 233-14 of the French Commercial Code, if a failure to report has been observed, and if one or several shareholders holding an interest of at least 2.5% have made a request recorded in the minutes of the General Meeting of Shareholders.
The above reports will apply notwithstanding the reports on the crossing of thresholds provided for by the legal or regulatory provisions in effect.
Article 33 - Rights and obligations attached to the shares
Each share entitles the holder to a share in the Company’s profits and assets, in proportion to the amount of capital that it represents.
Furthermore, each share entitles the holder to vote and be represented at General Meetings of Shareholders under legal and statutory provisions.
Shareholders will only be liable up to the amount of the par value of the shares that they hold; any calls for funds above that amount are prohibited.
Ownership of a share automatically entails adherence to the Company’s By-Laws and to the decisions of the General Meeting of Shareholders.
8

Heirs, creditors, assigns, or other representatives of a shareholder will not be entitled to request seizure of the Company’s assets or securities, or ask for them to be shared out or sold at auction, nor interfere in administrative acts relating to the Company in order to exercise their rights; they must refer to the company records and to the resolutions of the General Meeting of Shareholders.
Whenever it is necessary to hold several shares in order to exercise a given right, such as in the case of an exchange, reverse share split or allotment of shares, or an increase or decrease in the share capital, or a merger or other corporate transaction, the holders of single shares, or of a lower number of shares than required, may only exercise these rights if they personally arrange for the consolidation, and potentially the purchase or sale of the shares required.
However, in the event of the exchange of securities following a merger or demerger transaction, a capital decrease, a reverse share split or share split, and the mandatory conversion of bearer shares to registered shares, or of the distribution of securities charged to the reserves relating to a capital decrease, or the distribution or allotment of bonus shares, based solely on a decision by the Board of Directors, the Company may sell securities that the beneficiaries have requested to be delivered to them, as long as it has carried out the publication formalities provided for in the regulations at least two years beforehand.
As from the sale, the old securities or the old rights to distributions or allotments will be canceled, as and when required, and their holders will only be able to claim the cash allocation of the net proceeds of the sale of the unclaimed securities.
Article 34 - Beneficial & Bare ownership
The shares are indivisible as regards the Company.
Joint owners of shares are required to have themselves represented to the Company by just one of them, who will be considered as the sole owner, or by a single proxy; in the event of disagreement, the single proxy may be appointed by a court at the request of the first joint owner to do so.
Unless the Company has been notified of an agreement to the contrary, the beneficial owners of shares will validly represent the bare owners with the Company. Voting rights will be held by the beneficial owner at Ordinary General Meetings of Shareholders and by the bare owner at Extraordinary General Meetings of Shareholders.
Unless otherwise agreed between the parties, the preferential subscription right attached to securities belongs to the bare owner where the shares are encumbered by a usufruct interest.

9

V. - COMPANY FINANCIAL STATEMENTS
Article 35. - Preparation and approval of the company financial statements
a)The Board of Directors will draw up an inventory and the annual financial statements at the end of each financial year, and will then prepare the management report.
Where applicable, the Board of Directors will prepare and publish the consolidated financial statements, together with the report regarding the management of the Group.
b)The Ordinary General Meeting of Shareholders will approve the annual company financial statements within a period of six months following the financial year-end, after familiarizing itself with the management report and the report prepared by the Statutory Auditors; the consolidated financial statements and the report regarding the management of the Group will be presented at that Meeting, if required.
All information measures will be taken in compliance with the law and the regulations.
Article 36 - Audit of the financial statements
The financial statements will be audited by one or several incumbent, and, where applicable, alternate Statutory Auditors, under the conditions determined by Articles L. 225-218 of the French Commercial Code.
Article 37 - Allocation of the amounts available for distribution
Following the approval of the financial statements, and the recording of the existence of amounts available for distribution, the Ordinary General Meeting of Shareholders will determine the share of these amounts allotted to the shareholders in the form of a dividend; this dividend will be charged to the distributable profit for the year as a priority.
The procedures for paying the dividends or interim dividends are determined by the General Meeting of Shareholders.
Write-down differences are not available for distribution.
If required, the Meeting will allocate the non-distributed portion of the profit for the financial year available for distribution in the proportions that it determines, either to one or several reserves, which may be general or special, which remain at its disposal, or to the “retained earnings” account.
Any losses will be carried forward, unless the Meeting decides to offset them against existing reserves.
VI. - LIQUIDATION OF THE COMPANY
Article 38 - Liquidation
Once it has been wound up, the Company will be liquidated under the conditions determined by the French Commercial Code.
Unless the Ordinary General Meeting of Shareholders decides otherwise, the liquidator or liquidators will pursue any ongoing business until it is completed.
The net proceeds of the liquidation, following the settlement of the liabilities and payroll expenses, and repayment to the shareholders of the non-amortized par value of their shares, will be divided between the shareholders, taking the rights of the different share categories into account, where applicable.
Vll - MISCELLANEOUS ITEMS
Article 39 - Powers
All powers will be granted to the bearers of original copies of these By-Laws, or of copies or excerpts certified as original, in order to carry out all formalities.

10
 EX-31.1 3 exhibit311-dbv_10xqxq1x2025.htm EX-31.1 Document
Exhibit 31.1
Certification by the Chief Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Daniel Tassé, certify that:
1.I have reviewed this quarterly report on Form 10-Q of DBV Technologies S.A.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 30, 2025
/s/ Daniel Tassé
Daniel Tassé
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 4 exhibit312-dbv_10xqxq1x2025.htm EX-31.2 Document
Exhibit 31.2
Certification by the Chief Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Virginie Boucinha, certify that:
1.I have reviewed this quarterly report on Form 10-Q of DBV Technologies S.A.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 30, 2025
/s/ Virginie Boucinha
Virginie Boucinha
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 5 exhibit321-dbv_10xqxq1x2025.htm EX-32.1 Document
Exhibit 32.1
Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Daniel Tassé, Chief Executive Officer of DBV Technologies S.A. (the “Company”), and Virginie Boucinha, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:
1.The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) and Section 15(d) of the Exchange Act, and
2.The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: April 30, 2025
/s/ Daniel Tassé/s/ Virginie Boucinha
Daniel TasséVirginie Boucinha
Chief Executive OfficerChief Financial Officer
(Principal Executive Officer)(Principal Financial and Accounting Officer)
This certification accompanies the Quarterly Report, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Quarterly Report), irrespective of any general incorporation language contained in such filing.

EX-101.SCH 6 dbvt-20250331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Statements of Financial Position (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Statements of Financial Position (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Significant Events and Transactions link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Other Current Assets link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Lease contracts link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Trade Payables and Other Liabilities link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Shareholders' equity link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Operating income link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Operating Expenses link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Relationships with Related Parties link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Events after the Close of the Period link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Reportable segment disclosure link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - The Company (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - Lease contracts (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - Trade Payables and Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - Operating income (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - Operating Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - Reportable segment disclosure (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - The Company (Details) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - Significant Events and Transactions - Clinical Programs (Details) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - Significant Events and Transactions - Financing (Details) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Other Current Assets - Summary of Other Current Asset (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Other Current Assets - Summary of Research Tax Credit (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - Other Current Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Lease contracts - Summary of Operating Leases Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Lease contracts - Summary of Operating Leases Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - Lease contracts - Summary of Rent Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - Lease contracts - Summary of Supplemental Cash Flow Information Related to our Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - Trade Payables and Other Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - Trade Payables and Other Liabilities - Summary of Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - Shareholders' equity (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - Share-Based Payments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - Share-Based Payments - Summary of BSA/SO/RSU actvity (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - Share-Based Payments - Summary of Share-Based Payments Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - Contingencies - Summary of Non Current Contingencies and Current Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - Contingencies - Summary of Movement in Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - Contingencies - Summary of Movement in Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - Operating income (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Operating Expenses - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - Operating Expenses - Summary of Allocation of Personnel Expenses By Function (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Operating Expenses - Summary of Allocation of Personnel Expenses By Nature (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - Events after the Close of the Period (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - Reportable segment disclosure - Schedule of Segment Reporting Information, by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - Reportable segment disclosure - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 dbvt-20250331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 dbvt-20250331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 dbvt-20250331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Number of major objection Number Of Major Objection Number Of Major Objection Tax liabilities Tax Liabilities [Member] Tax liabilities. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Other tax claims Prepaid Taxes Adjustments to reconcile net loss to net cash (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Relationships with Related Parties Related Party Transactions Disclosure [Text Block] Summary of Supplemental cash flow information related to our operating leases Schedule Of Supplemental Cash Flow Information Related To Operating Leases [Table Text Block] Schedule of Supplemental cash flow information related to operating leases [Table Text block] Summary of Rent expenses Lease, Cost [Table Text Block] Cover [Abstract] Net (decrease) / increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Summary of Operating Leases Future Minimum Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Other current liabilities Other Liabilities, Current Prefunded warrants Prefunded warrants [Member] Prefunded warrants member Trading Symbol Trading Symbol Significant Events And Transactions of the Period Disclsure [Abstract] Significant events and transactions of the period disclsure. All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Wages and salaries Wages And Salaries Wages And Salaries Non-NEOs Non-NEOs [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Summary of Research Tax Credit Summary of Tax Credit Carryforwards [Table Text Block] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Research tax credit Research Tax Credit Income Research tax credit income. Award Timing Disclosures [Line Items] Accumulated currency translation effect Accumulated Foreign Currency Translation Adjustment Net of Tax Accumulated foreign currency translation adjustment net of tax. Other Performance Measure, Amount Other Performance Measure, Amount Summary of RSU Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Common stock, shares oustanding (in shares) Common Stock, Shares, Outstanding Lease contracts Lessee, Operating Leases [Text Block] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Long-term operating leases Long-term lease liabities Operating Lease, Liability, Noncurrent Total non-current assets Assets, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Thereafter Lessee, Operating Lease, Liability, to be Paid, Due after Year Two Lessee, Operating Lease, Liability, to be Paid, Due after Year Two Capital increases, net of transaction costs Proceeds from Issuance or Sale of Equity Other non-current assets Other Assets, Noncurrent Of which non-current Liability, Defined Benefit Plan And Loss Contingency, Noncurrent Liability, Defined Benefit Plan And Loss Contingency, Noncurrent Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Net cash flow (used in) operating activities Net Cash Provided by (Used in) Operating Activities Treasury stock Treasury Stock, Common [Member] Prepaid expenses Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Share-Based Payments [Line iteam] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Other current assets Total Other Assets, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Medical Affairs & Other Medical Medical Affairs And Other Medical Expense Medical Affairs And Other Medical Expense Adjustment to Compensation, Amount Adjustment to Compensation Amount Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Depreciation, amortization and accrued contingencies Adjustment for Depreciation Amortization And Accrued Contingencies Adjustment for depreciation, amortization and accrued contingencies. Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Trade Payables and Other Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Of which current Loss Contingency, Accrual, Current Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of patches Number Of Patches Number Of Patch Sales & marketing Selling and Marketing Expense [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Subsidiary or Equity Method Investee, Sale of Stock [Table] Subsidiary or Equity Method Investee, Sale of Stock [Table] Class of warrant or right, number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Contingencies, beginning balance Contingencies, ending balance Loss Contingency Accrual Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Expenses by Nature Expenses by Nature [Member] Expenses by nature Operating lease expense / (income) Operating Lease, Expense Operating income Other Operating Income and Expense [Text Block] Net Cash and cash equivalents at the beginning of the period Net cash and cash equivalents at the end of the period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Number of RSU outstanding, Expired during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations Current assets : Assets, Current [Abstract] Treasury stock (in shares) Treasury Stock, Common, Shares Opening research tax credit receivable as of January 1, 2025 Closing research tax credit receivable as of March 31, 2025 Research Tax Credit Receivable Research tax credit receivable. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Stock options SO Share-Based Payment Arrangement, Option [Member] Year 2 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Security Exchange Name Security Exchange Name Award Type Award Type [Axis] Number of additional safety study Number Of Additional Safety Study Number Of Additional Safety Study Social security contributions Social Security Contributions Social Security Contributions Property, plant, and equipment, net Property, Plant and Equipment, Net Currency translation effect Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual, Foreign Currency Translation Gain (Loss) Total Liabilities Liabilities Summary of breakdown of cash and cash equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Common stock shares par value (in Euro per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development expenses Research and Development expenses Research & Innovation Research and Development Expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows (used in) investing activities : Net Cash Provided by (Used in) Investing Activities [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Class of warrant or right, number of securities called by each warrant or right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Other contingencies Other Contingencies [Member] Other Contingencies Short-term operating leases Less: current portion Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Financing, maximum potential dilution percentage Financing, Maximum Potential Dilution Percentage Financing, Maximum Potential Dilution Percentage Other Current Assets [Abstract] Other Current Assets [Abstract] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash Cash Subsequent Event [Line Items] Subsequent Event [Line Items] Number of stock option outstanding, Exercised during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of local country regulatory health authorities Number Of Local Country Regulatory Health Authorities Number Of Local Country Regulatory Health Authorities Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research & development Research and Development Expense [Member] Common stock shares authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average shares outstanding used in computing per share amounts (in shares) Weighted Average Number of Shares Outstanding, Diluted Currency translation effect Foreign Currency Exchange Rate Changes Foreign Currency Exchange Rate Changes Decrease (increase) in inventories and work in progress Increase (Decrease) in Finished Goods and Work in Process Inventories MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Issuance or sale of equity, maximum potential amount Issuance Or Sale Of Equity, Potential Additional Proceeds, Maximum Amount Issuance Or Sale Of Equity, Potential Additional Proceeds, Maximum Amount Total Shareholders’ equity Beginning balance Ending balance Share capital Equity, Attributable to Parent Research Tax Credit Receivable [Roll Forward] Research Tax Credit Receivable [Roll Forward] Research Tax Credit Receivable Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Entity Address, Country Entity Address, Country Number of stock options outstanding, Granted during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] (Decrease) increase in other current and non-current liabilities Increase (Decrease) in Other Operating Liabilities Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Document Type Document Type Comfort Toddlers Safety Study Comfort Toddlers Safety Study [Member] Comfort toddlers safety study. Actuarial gains and losses on defined-benefit plans Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Pension retirement obligations Postemployment Retirement Benefits [Member] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other Income and Expenses [Abstract] Defined Benefit Plan [Table] Defined Benefit Plan [Table] Number of RSU outstanding, Released during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Estimated research tax credit for the period Estimated Research Tax Credit For The Period Estimated Research Tax Credit Ror The Period Subsequent Event [Table] Subsequent Event [Table] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounting Policies [Abstract] Accounting Policies [Abstract] Treasury shares Proceeds From (Payment For) Treasury Stock Proceeds from repayment of treasury stock Increases in liabilities Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual, Increase In Provision Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual, Increase In Provision Ratio of ABSA warrant shares to ABSA warrants Warrant Shares To Warrants, Ratio Warrant Shares To Warrants, Ratio Actuarial gains / (losses) on employee benefits, net of taxes Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Shares issued (in dollars/euro per share) Shares Issued, Price Per Share Increase in trade accounts payable Increase (Decrease) In Trade Accounts Payable, Net Of Foreign Exchange Impact Increase (Decrease) In Trade Accounts Payable, Net Of Foreign Exchange Impact Expenses by function Expenses by Function [Member] Expenses by Function Current Fiscal Year End Date Current Fiscal Year End Date Less: Effects of discounting Lessee, Operating Lease, Liability, Undiscounted Excess Amount Non-Current assets Assets, Noncurrent [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Number of warrants outstanding, Beginning Balance (in shares) Number of warrants outstanding, Ending Balance (in shares) Class of Warrant or Right, Outstanding Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Number of warrants, granted during period (in shares) Class Of Warrant Or Right Granted During Period Class Of Warrant Or Right Granted During Period Cash equivalents Cash Equivalent Term Deposits Cash equivalent term deposits. Class of warrant or right, unissued (in shares) Class of Warrant or Right, Unissued Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Name Outstanding Recovery, Individual Name Percentage of difference in response rates Percentage Of Difference In Response Rates Percentage Of Difference In Response Rates Country Region Country Region Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-current contingencies Of which non-current Liability, Defined Benefit Plan, Noncurrent Non-PEO NEO Non-PEO NEO [Member] Additional paid-in capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Programme [Axis] Programme [Axis] Programme. BLA & Regulatory BLA And Regulatory Expense BLA And Regulatory Expense Class of Stock [Line Items] Class of Stock [Line Items] Contingencies Contingencies Disclosure [Text Block] Accounting Pronouncements Recently Adopted New Accounting Pronouncements, Policy [Policy Text Block] Diluted Net loss per share attributable to shareholders (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Number of operating segments Number of Operating Segments Statement of Financial Position [Abstract] PFW-BS-PFW PFW-BS-PFW [Member] PFW-BS-PFW Expenses related to share-based payments Share-Based Payment Arrangement, Noncash Expense Entity number of employees Entity Number of Employees Sales and marketing expenses Sales & Marketing expenses Sales & Marketing Selling and Marketing Expense Income tax Income Tax Expense (Benefit) Share-Based Compensation Arrangement by Share-Based Payment Award, Warrants Instruments, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Warrants Instruments, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Warrants Instruments, Outstanding Financial income (expense) Finance Income Expenses Financial (Expenses). Current contingencies Provision For Liabilities Current Provision for liabilities current. Statement of Comprehensive Income [Abstract] Inventory write-downs Inventory Write-down BSA B S A Warrants [Member] BSA Warrants [member] Net cash flows (used in) investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Total Liabilities and Shareholder's equity Liabilities and Equity Research tax credit Research Tax Credit Research tax credit. Events after the Close of the Period Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Additional paid-in capital Additional Paid in Capital Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Commitments and Contingencies Disclosure [Abstract] Issuance or sale of equity, maximum amount Issuance Or Sale Of Equity, Maximum Amount Issuance Or Sale Of Equity, Maximum Amount Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Product and Service [Axis] Product and Service [Axis] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Trade payables Accounts Payable, Trade, Current Operating expenses Operating Expenses [Abstract] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Schedule of operating income Schedule of operating income [Table Text Block] Schedule of operating income Liabilities and shareholders' equity Liabilities and Equity [Abstract] Total contingencies Liability, Defined Benefit Plan Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date First prefunded warrants First Pre-Funded Warrants [Member] First Pre-Funded Warrants Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Related Party Transactions [Abstract] Right-of-use assets related to operating leases Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Number of stock options outstanding, Beginning Balance (in shares) Number of stock options outstanding, Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Segments [Axis] Segments [Axis] Of which current Liability, Defined Benefit Plan And Loss Contingency, Current Liability, Defined Benefit Plan And Loss Contingency, Current Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Summary of Other Current Asset Schedule of Other Current Assets [Table Text Block] Exercise Price Award Exercise Price American Depositary Share ADR [Member] Loss Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Subsequent Event Subsequent Event [Member] Shareholders’ equity : Equity, Attributable to Parent [Abstract] Net termination impact Gain (Loss) on Termination of Lease Lessee Disclosure [Abstract] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] (Decrease) increase in trade payables Increase (Decrease) in Accounts Payable, Trade All Individuals All Individuals [Member] The Company Basis of Presentation and Significant Accounting Policies [Text Block] Programme [Domain] Programme [Domain] Programme. PEO PEO [Member] Name Trading Arrangement, Individual Name Intangible assets Intangible Assets, Net (Excluding Goodwill) Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Treasury stock, 230,513 and 266,868 ordinary shares as of March 31, 2025 and December 31, 2024, respectively, at cost Treasury Stock, Common, Value Pension retirement obligations, beginning balance Pension retirement obligations, ending balance Defined Benefit Plan, Benefit Obligation Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Current contingencies Of which current Liability, Defined Benefit Plan, Current Summary of share-based payments expenses [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Total non-current liabilities Liabilities, Noncurrent Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount + Operating revenue Research Tax Credit, Operating Income Reverse tax credit operating revenue. Type Of Arrangement1 [Domain] Type Of Arrangement1 [Domain] Type Of Arrangement1 [Domain] Local Phone Number Local Phone Number Summary of Movement in Provisions Schedule of Loss Contingencies by Contingency [Table Text Block] Clinical studies Clinical Study Expense Clinical Study Expense Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total Operating expenses Total personnel expenses Operating Expenses Other Current Assets Other Current Assets [Text Block] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Non-Current liabilities Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Tax credit carryforward amount before currency translation Tax Credit Carryforward Amount Before Currency Translation Tax Credit Carryforward Amount Before Currency Translation Accounting Pronouncements issued not yet adopted New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block] New accounting pronouncements not yet adopted, policy. Type Of Arrangement1 [Axis] Type Of Arrangement1 [Axis] Type Of Arrangement1 Research tax credit, (Crédit d’Impôt Recherche) payment received Research Tax Credit, Payment Received Research tax credit payment received. Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] No Trading Symbol Flag No Trading Symbol Flag Commitments Commitments and Contingencies Disclosure [Text Block] Treasury shares Stock Issued During Period, Value, Treasury Stock Reissued Pension retirement obligations Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Common Stock Ordinary shares Common Stock [Member] Measure: Measure [Axis] Second prefunded warrants Second Pre-Funded Warrants [Member] Second Pre-Funded Warrants Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Issuance of ordinary shares (in shares) Stock issued during period (in shares) Stock Issued During Period, Shares, New Issues Total number of candidates covered by the study Total Number Of Candidates Covered By The Study Total Number Of Candidates Covered By The Study Entity Emerging Growth Company Entity Emerging Growth Company Segment Reporting [Abstract] Non-current contingencies Provision For Liabilities Noncurrent Provision for liabilities noncurrent. Entity Central Index Key Entity Central Index Key Number of warrants, expired during period (in shares) Class Of Warrant Or Right Expired During Period Class Of Warrant Or Right Expired During Period General & administrative General and Administrative Expense [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Accumulated currency translation effect Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Number of study component Number Of Study Component Number Of Study Component Subsidiary or Equity Method Investee [Line Items] Subsidiary or Equity Method Investee [Line Items] Shareholders' equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Reportable segment disclosure Segment Reporting Disclosure [Text Block] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] ABSA warrants ABSA Warrants [Member] ABSA Warrants Share-based payments APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Of which non-current Loss Contingency, Accrual, Noncurrent Other debts Other Debts [Member] Other debts. Statement [Table] Statement [Table] Operating Expenses Other Operating Expenses [Text Block] Other operating expenses. Real Estate Real Estate [Member] Current liabilities: Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Stockholders' Equity Note [Abstract] Foreign currency translation differences, net of taxes Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Statement of Cash Flows [Abstract] Share capital Share Capital [Member] Share Capital [Member] Viaskintm Clinical Program Viaskintm Clinical Program [Member] Viaskintm Clinical Program Document Information [Line Items] Document Information [Line Items] Number of warrants, exercised during period (in shares) Class Of Warrant Or Right Exercised During Period Class Of Warrant Or Right Exercised During Period Subsequent Event Type [Axis] Subsequent Event Type [Axis] Other receivables Other Receivables, Current Other receivables current. Earnings Per Share [Abstract] Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Number of additional candidates covered by the study Number Of Additional Candidates Covered By The Study Total number of additional candidates covered by the study. Of which - Non-current portion Research Tax Credit, Non current Research tax credit, non current. Class of Stock [Domain] Class of Stock [Domain] General and administrative expenses General & Administrative expenses General & Administrative General and Administrative Expense Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Present value of lease liabilities Operating Lease, Liability Financing, dilution percentage Financing, Dilution Percentage Financing, Dilution Percentage Net cash flows (used) / provided by financing activities Net Cash Provided by (Used in) Financing Activities Expenses for pension commitments Expenses For Pension Commitments Expenses For Pension Commitments Underlying Securities Award Underlying Securities Amount - Adjustment and currency translation effect Research Tax Credit, Adjustment And Currency Translation Effect Research tax credit adjustment and currency translation effect. Going Concern Going Concern [Policy Text Block] Going concern. Amendment Flag Amendment Flag Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity Registrant Name Entity Registrant Name Increases in liabilities Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Used liabilities Loss Contingency Accrual, Liabilities Used Loss Contingency Accrual, Liabilities Used Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Total Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual [Roll Forward] Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual Net restructuring impact Gain (Loss) on Restructuring Of Lease Gain (Loss) on Restructuring Of Lease Other contingencies Loss Contingency Accrual [Roll Forward] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Significant Events and Transactions Significant Events And Transactions Of The Period Disclosure [Text Block] Significant events and transactions of the period disclsure. Issuance of ordinary shares Issuance of ordinary shares Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Summary of Share-Based Payments Expenses Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Ordinary shares, €0.10 par value; 102,858,868 and 102,847,501 shares authorized, and issued as at March 31, 2025 and December 31, 2024, respectively Common Stock, Value, Issued Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Total cash and cash equivalents as reported in the statements of financial position Cash and Cash Equivalents, at Carrying Value Summary of Non-current Contingencies and Current Contingencies Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Manufacturing & Supply and Quality Manufacturing, Supply and Quality Expense Manufacturing, Supply and Quality Expense Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Defined benefit plan, benefit obligation and loss contingency accrual, beginning balance Defined benefit plan, benefit obligation and loss contingency accrual, ending balance Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash flows (used) / provided by financing activities : Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Basic Net loss per share attributable to shareholders (in dollars per share) Earnings Per Share, Basic Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Operating cash flows used in operating leases Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Number of warrants, forfeited during period (in shares) Class Of Warrant Or Right Forfeited During Period Class Of Warrant Or Right Forfeited During Period Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Loss Contingency [Abstract] Loss Contingency [Abstract] Currency translation effect Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total Assets Assets Number of RSU outstanding, Granted during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Cash and Cash Equivalents [Abstract] Change in property, plant, and equipment Payments to Acquire Property, Plant, and Equipment Other non-current liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Termination Date Trading Arrangement Termination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] BS Warrants BS Warrants [Member] BS Warrants Viaskin Peanut Segment Viaskin Peanut Segment [Member] Viaskin Peanut Segment Class of warrant or right, exercise price of warrants or rights (in euro per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Operating income Total Revenues Year 3 Lessee, Operating Lease, Liability, to be Paid, Year Two Share-Based Payments Share-Based Payment Arrangement [Text Block] Summary of Allocation of Personnel Expenses By Function Schedule of Allocation of Personnel Expenses By Function [Table Text Block] Schedule of Allocation of Personnel Expenses By Function [Table text block] Total Other Liabilities Entity Address, City or Town Entity Address, City or Town Change in non-current financial assets Payments to Acquire Non-Current Financial Assets Payments to Acquire Non-Current Financial Assets Of which - Current portion Research Tax Credit, Current Research tax credit current. Clinical program trial period Clinical Program Trial Period Clinical program trial period. Total share-based compensation (expense) Share-based payments Share-Based Payment Arrangement, Expense Net loss Net loss for the period Net (loss) Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Share-Based Payment Arrangement, Disclosure [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Number of RSU outstanding, Forfeited during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Percentage of confidence interval Percentage Of Confidence Interval Percentage Of Confidence Interval Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Private investment in Public Equity Private Investment In Public Equity [Member] Private Investment In Public Equity Entity File Number Entity File Number Document Fiscal Year Focus Document Fiscal Year Focus Entity Address, Address Line One Entity Address, Address Line One Name Forgone Recovery, Individual Name Current portion Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Increases in liabilities Loss Contingency Accrual, Provision Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Other elements Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Number of RSU outstanding, Beginning Balance (in shares) Number of RSU outstanding, Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of stock option outstanding, Expired during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Insider Trading Arrangements [Line Items] Cash and Cash Equivalents Cash and Cash Equivalents Disclosure [Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Decrease (increase) in other current assets Increase (Decrease) in Other Current Assets PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Other assets Other Asset [Member] Other Asset [Member] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated deficit Retained Earnings [Member] Change in operating lease liabilities and right of use assets Increase Decrease In Operating Lease Liability And Right Of Use Asset Increase decrease in operating lease liability and right of use asset. Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Non-employee warrants Nonemployeewarrants [Member] Non-employee warrants . Summary of Allocation of Personnel Expenses By Nature Schedule of Allocation of Personnel Expenses By Nature [Table Text Block] Schedule of Allocation of Personnel Expenses By Nature[Table text block] Weighted average shares outstanding used in computing per share amounts (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Prefunded PFW-BS-PFW Prefunded PFW-BS-PFW [Member] Prefunded PFW-BS-PFW Other operating income Other Operating Income Employee related liabilities Employee Related Liabilities [Member] Employee related liabilities. Document Information [Table] Document Information [Table] RSUs Restricted stock units Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Number of stock options outstanding, Forfeited during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Summary of Other Current Liabilities Other Current Liabilities [Table Text Block] Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 dbvt-20250331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2025
Apr. 30, 2025
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2025  
Document Transition Report false  
Entity File Number 001-36697  
Entity Registrant Name DBV TECHNOLOGIES S.A.  
Entity Incorporation, State or Country Code I0  
Entity Address, Country FR  
Entity Address, Address Line One 107 Av. de la République  
Entity Address, Postal Zip Code 92320  
Entity Address, City or Town Châtillon  
Country Region +33  
Local Phone Number 1 55 42 78 78  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   136,948,872
Entity Central Index Key 0001613780  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q1  
Amendment Flag false  
American Depositary Share    
Document Information [Line Items]    
Title of 12(b) Security American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share  
Trading Symbol DBVT  
Security Exchange Name NASDAQ  
Common Stock    
Document Information [Line Items]    
Title of 12(b) Security Ordinary shares, nominal value €0.10 per share*  
No Trading Symbol Flag true  
Security Exchange Name NASDAQ  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Financial Position (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets :    
Cash and cash equivalents $ 12,962 $ 32,456
Other current assets 16,186 11,932
Total current assets 29,148 44,388
Non-Current assets    
Property, plant, and equipment, net 10,813 11,306
Right-of-use assets related to operating leases 5,613 5,502
Intangible assets 29 40
Other non-current assets 4,960 4,423
Total non-current assets 21,414 21,271
Total Assets 50,562 65,658
Current liabilities:    
Trade payables 34,146 22,032
Short-term operating leases 709 654
Current contingencies 82 122
Other current liabilities 5,447 8,328
Total current liabilities 40,384 31,136
Non-Current liabilities    
Long-term operating leases 6,525 6,297
Non-current contingencies 780 838
Total non-current liabilities 7,305 7,135
Total Liabilities 47,688 38,271
Shareholders’ equity :    
Ordinary shares, €0.10 par value; 102,858,868 and 102,847,501 shares authorized, and issued as at March 31, 2025 and December 31, 2024, respectively 11,652 11,651
Additional paid-in capital 317,313 315,613
Treasury stock, 230,513 and 266,868 ordinary shares as of March 31, 2025 and December 31, 2024, respectively, at cost (1,263) (1,309)
Accumulated deficit (313,454) (286,375)
Accumulated other comprehensive income 1,036 905
Accumulated currency translation effect (12,411) (13,097)
Total Shareholders’ equity 2,873 27,387
Total Liabilities and Shareholder's equity $ 50,562 $ 65,658
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Financial Position (unaudited) (Parenthetical) - € / shares
Mar. 31, 2025
Dec. 31, 2024
Statement of Financial Position [Abstract]    
Common stock shares par value (in Euro per share) € 0.1 € 0.1
Common stock shares authorized (in shares) 102,858,868 102,847,501
Common stock shares issued (in shares) 102,858,868 102,847,501
Treasury stock (in shares) 230,513 266,868
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Statement of Comprehensive Income [Abstract]    
Operating income $ 753 $ 1,407
Operating expenses    
Research and development expenses (21,483) (21,403)
Sales and marketing expenses (262) (758)
General and administrative expenses (5,626) (7,804)
Total Operating expenses (27,370) (29,964)
Loss from operations (26,618) (28,558)
Financial income (expense) (461) 1,261
Loss before taxes (27,079) (27,297)
Income tax 0 (48)
Net loss (27,079) (27,345)
Foreign currency translation differences, net of taxes 686 (3,026)
Actuarial gains / (losses) on employee benefits, net of taxes 132 (59)
Comprehensive loss $ (26,261) $ (30,429)
Basic Net loss per share attributable to shareholders (in dollars per share) $ (0.26) $ (0.28)
Diluted Net loss per share attributable to shareholders (in dollars per share) $ (0.26) $ (0.28)
Weighted average shares outstanding used in computing per share amounts (in shares) 102,617,429 96,176,057
Weighted average shares outstanding used in computing per share amounts (in shares) 102,617,429 96,176,057
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Statement of Cash Flows [Abstract]    
Net loss for the period $ (27,079) $ (27,345)
Adjustments to reconcile net loss to net cash (used in) operating activities:    
Depreciation, amortization and accrued contingencies 952 53
Expenses related to share-based payments 1,702 1,958
Inventory write-downs 4,286 1,289
Other elements 465 (8)
Changes in operating assets and liabilities:    
Decrease (increase) in inventories and work in progress (4,286) (1,289)
Decrease (increase) in other current assets (3,662) (835)
(Decrease) increase in trade payables 10,943 (4,805)
(Decrease) increase in other current and non-current liabilities (3,104) (3,765)
Change in operating lease liabilities and right of use assets 115 56
Net cash flow (used in) operating activities (19,668) (34,692)
Cash flows (used in) investing activities :    
Change in property, plant, and equipment (10) (1,335)
Change in non-current financial assets (366) (797)
Net cash flows (used in) investing activities (375) (2,132)
Cash flows (used) / provided by financing activities :    
Treasury shares 45 (62)
Net cash flows (used) / provided by financing activities 45 (62)
Effect of exchange rate changes on cash and cash equivalents 504 (2,957)
Net (decrease) / increase in cash and cash equivalents (19,494) (39,842)
Net Cash and cash equivalents at the beginning of the period 32,456 141,367
Net cash and cash equivalents at the end of the period $ 12,962 $ 101,525
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Changes in Shareholders' Equity (unaudited) - USD ($)
$ in Thousands
Total
Ordinary shares
Additional paid-in capital
Treasury stock
Accumulated deficit
Accumulated other comprehensive income (loss)
Accumulated currency translation effect
Beginning balance (in shares) at Dec. 31, 2023   96,431,770          
Beginning balance at Dec. 31, 2023 $ 140,187 $ 10,972 $ 377,468 $ (1,263) $ (238,862) $ 742 $ (8,871)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net (loss) (27,345)       (27,345)    
Other comprehensive income (loss) (3,084)         (59) (3,026)
Issuance of ordinary shares (in shares)   2,599          
Issuance of ordinary shares 0            
Treasury shares (62)     (62)      
Share-based payments 1,958   1,958        
Ending balance (in shares) at Mar. 31, 2024   96,434,369          
Ending balance at Mar. 31, 2024 111,654 $ 10,972 379,426 (1,325) (266,207) 683 (11,897)
Beginning balance (in shares) at Dec. 31, 2024   102,847,501          
Beginning balance at Dec. 31, 2024 27,387 $ 11,651 315,613 (1,309) (286,375) 905 (13,097)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net (loss) (27,079)       (27,079)    
Other comprehensive income (loss) 817         132 686
Issuance of ordinary shares (in shares)   11,367          
Issuance of ordinary shares 0 $ 1 (1)        
Treasury shares 46     46      
Share-based payments 1,702   1,702        
Ending balance (in shares) at Mar. 31, 2025   102,858,868          
Ending balance at Mar. 31, 2025 $ 2,873 $ 11,652 $ 317,313 $ (1,263) $ (313,454) $ 1,036 $ (12,411)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.25.1
The Company
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
The Company
Note 1: The Company
Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies” or the “Company”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy (“EPIT”), a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Basis of Presentation
The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.
The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on April 11, 2025 (the “ Annual Report”). The condensed consolidated statement of financial position as of December 31, 2024 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2024.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2025, or any other future period.
Use of Estimates
The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates.
On an on-going basis, management evaluates its estimates, primarily those related to: (1) research tax credits, (2) assumptions used in the valuation of right of use assets—operating lease, (3) impairment of right-of-use assets related to leases and property, plant and equipment, (4) recoverability of the Company’s net deferred tax assets and related valuation allowance, (5) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, 6) estimate of contingencies and provisions, and (7) estimate of employee benefits obligations.
Going Concern
These Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The Company has incurred operating losses and negative cash flows from operations since inception. The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.
Since its inception, the Company has primarily funded its operations through equity financings, as well as public assistance and Research Tax Credit.. Prior to 2022, the Company underwent restructuring efforts, scaled down certain clinical programs, and engaged with regulatory authorities to advance Viaskin Peanut’s approval process in the United States and European Union. In 2022, the Company secured a private placement financing of $194 million and lifted a partial clinical hold from the FDA on its VITESSE Phase 3 clinical study.
On April 7, 2025, the Company received gross proceeds of $125.5 million (€116.3 million) from the issuance of the ABSA and PFW-BS-PFW, as described in Note 15. With the receipt of the aforementioned proceeds, and based on its current operations, plans, and assumptions examined by the Board of Directors (“Board”) on March 23, 2025, the Company estimates that its cash and cash equivalents are sufficient to fund its operations into June 2026.
Given the Company’s historical operating losses and reliance on external financings, the Company may still seek additional capital for future needs through a combination of public or private equity or debt financings, collaborations, licensing agreements, and other funding options. While recent financing events have improved the Company’s financial position, access to additional capital in the future remains subject to market conditions and investor interest.

Accounting Pronouncements Recently Adopted
There have been no recently issued accounting standards adopted during the period which had a material impact on the Company’s financial statements.
There are no recently issued accounting standards that are expected to have a material impact on our results of operations, financial condition, or cash flows.
Accounting Pronouncements issued not yet adopted
In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740 — Improvements to Income Tax Disclosures which enhances the transparency and usefulness of income tax disclosures. This amendment requires disclosure of disaggregated information about the Company’s effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. For SEC filers, this ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income Topic 220 — Expense Disaggregation Disclosures. The guidance requires disclosure of additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. For SEC filers, this ASU is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this ASU 2024-03 will have on its consolidated financial statements and related disclosures.
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Significant Events and Transactions
 3 Months Ended
Mar. 31, 2025
Significant Events And Transactions of the Period Disclsure [Abstract]  
Significant Events and Transactions
Note 2: Significant Events and Transactions
Clinical Programs
United States Regulatory History and Current Status
In August 2019, we announced the submission of a BLA to the FDA for Viaskin Peanut for the treatment of peanut allergy in children four to 11 years of age.
In August 2020, the Company received a Complete Response Letter (“CRL”) in which the FDA indicated it could not approve the Viaskin Peanut BLA in its then-current form. The FDA did not raise any safety concerns related to Viaskin Peanut.
In January 2021, the Company received written responses from the FDA to questions provided in the Type A meeting request that the Company submitted in October 2020 following receipt of the CRL.
In March 2021, the Company commenced CHAMP (Comparison of adHesion Among Modified Patches), a Phase 1 trial in healthy adult volunteers. . In May 2021, the Company submitted a proposed protocol to the FDA for STAMP (Safety, Tolerability, and Adhesion of Modified Patches)a 6-month safety and adhesion study which was to be conducted concurrently with DBV’s allergen uptake comparison studies (i.e., ‘EQUAL in Adults’, EQUAL). On October 14, 2021, in an Advice/Information Request letter, the FDA requested the Company conduct a stepwise, or sequential, approach to the modified Viaskin patch development program by conducting EQUAL first and submitting the data for FDA review and feedback prior to starting the STAMP study.
In December 2021, the Company decided not to pursue the sequential approach requested by the FDA and instead announced its plan to initiate a pivotal Phase 3 placebo-controlled efficacy trial for a modified Viaskin Peanut patch (mVP) in children in the intended patient population. Following written exchanges with the FDA, the FDA confirmed it was aligned with the Company’s strategy.
On September 7, 2022, the Company announced the initiation of VITESSE, a Phase 3 pivotal study of the mVP in children ages 4-7 years with peanut allergy. On September 21, 2022, the Company announced it received from FDA a partial clinical hold letter related to certain design elements of VITESSE.
On December 23, 2022, the Company announced that the FDA lifted the partial clinical hold The Company announced on September 23, 2024, that subject screening was completed in the third quarter of 2024. Topline results are anticipated in the fourth quarter of 2025.
In June 2022, the Company announced positive topline results from Part B of EPITOPE.
On April 19, 2023, the Company outlined the regulatory pathway for Viaskin Peanut in children 1 – 3 years old after the FDA confirmed in written responses to the Company’s Pre-BLA meeting request that the Company’s EPITOPE phase 3 study met the pre-specified criteria for success for the primary endpoint and did not request an additional efficacy study in this age group. The FDA required additional safety data to augment the safety data collected from EPITOPE in support of a BLA.
On July 31, 2023, the Company announced receipt of feedback from FDA on two supplemental safety studies, COMFORT Children and COMFORT Toddlers.
On November 9, 2023, the Company submitted the protocol for its COMFORT Toddlers supplemental safety study in 1 – 3 years-old to FDA. The Company received comments and queries to the protocol from the FDA on March 11, 2024. On July 30, 2024, the Company announced that it and the FDA had been engaged in ongoing dialogue since May 2023 on the COMFORT Toddlers supplemental safety study in 1 – 3 years-old with a peanut allergy.
The Company also announced on November 9, 2023, 2-year results from the ongoing phase 3 open-label extension to the EPITOPE trial, EPOPEX, of Viaskin Peanut in toddlers.
On October 22, 2024, the Company announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV had agreed to guidance provided by the FDA on a potential pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old. FDA confirmed that the Company has met Accelerated Approval qualifying criterion 1 and 2. Regarding criterion 3, FDA has provided guidance and suggestion regarding the intermediate clinical endpoint, which the Company agreed to in informal discussions with the FDA. The Company formalized the Accelerated Approval guidance provided by FDA via submission of a meeting request and confirmed the general elements of the two study components: the COMFORT Toddlers safety study, to be completed before BLA submission, and the confirmatory effectiveness study, including
the third Accelerated Approval criterion regarding the intermediate clinical endpoint. The Company expects that the confirmatory study will be initiated by the time of BLA submission and would run in parallel to commercialization in the United States, if Viaskin Peanut is approved.
The Company announced further that it has aligned with FDA on a wear time collection methodology in COMFORT Toddlers intended to generate sufficient data to support a BLA submission. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. The company anticipates enrolling approximately 300 – 350 subjects on active treatment into the safety study, which would bring the total Viaskin Peanut patch safety database in toddlers to approximately 600 subjects, consistent with prior FDA guidance. With this path forward, the BLA submission for Viaskin Peanut patch in 1 – 3 years-old under the Accelerated Approval program is anticipated to be supported by:
i. Positive efficacy and safety data from DBV’s previously completed EPITOPE Phase 3 Study; and
ii. Additional safety data generated in COMFORT Toddlers supplemental safety study to be initiated in the second quarter of 2025.

On December 11, 2024, the Company announced that it reached alignment with FDA on the Accelerated Approval pathway for Viaskin Peanut patch in toddlers 1 – 3 years-old and on key study design elements for the COMFORT Toddlers study, including study size and wear time collection methodology and analysis. The Company announced further that FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1-3 years-old and that the Company and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch, will include a double-blind, placebo-controlled food challenge (DBPCFC), will use the same statistical criteria for success (i.e., lower bound of the 95% CI > 15%) as used in the EPITOPE, and will need to be initiated at the time that the BLA is submitted.
The Company submitted the protocol for its COMFORT Children supplemental safety study in ages 4-through-7-years-old to the FDA on November 29, 2023. On March 24, 2025, the Company announced that in a Written Responses Only to the Company’s Type D IND meeting request the FDA agreed with the Company’s proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4-7-year-olds will be sufficient to support a BLA filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required and the Company will not conduct the study. The Company will utilize the safety data from the VITESSE participants randomized to active treatment as well as placebo-crossover participants in the VITESSE Open Label Extension (OLE). Accordingly, the Company plans to submit a BLA in the first half of 2026 and anticipates potentially accelerating the product launch by approximately one year, subject to FDA approval.
Viaskin Peanut —European Union Regulatory History and Current Status
In November 2020, we announced that our Marketing Authorization Application, or MAA, for Viaskin Peanut, submitted under the name “Abylqis®”, had been validated by the European Medicines Agency, or EMA. The validation of the MAA confirmed that the submission was sufficiently complete to begin the formal review process for Viaskin Peanut to treat peanut allergies in children ages four to 11 years. Following the MAA validation, the EMA’s Committee for Medicinal Products for Human Use, or CHMP, reviews the application and provides a recommendation to the European Commission, on whether to grant a marketing authorization.
On August 2, 2021, we announced we had received from the EMA the Day 180 list of outstanding issues, which is an established part of the prescribed EMA review process. The EMA identified one Major Objection remained at Day 180n questioning the limitations of the data, for example, the clinical relevance and effect size supported by a single pivotal study.
On December 17, 2021, we announced we had withdrawn the MAA for Viaskin Peanut, submitted under the name “Abylqis”, and formally notified the EMA of our decision.
On October 22, 2024, the Company announced it received scientific advice from EMA on an indication for ages 1 – 7 years-old in Europe regarding the components of a MAA for the Viaskin Peanut patch. Previous advice obtained from two local country regulatory health authorities indicated a potential path for a 1 – 7 year-old registration with one patch, the modified patch. The EMA recently confirmed through scientific advice that the completed EPITOPE study in 1 – 3 years-old, and a positive VITESSE study in 4 – 7 years-old, could constitute an MAA submission for a 1 – 7 years-old indication for peanut allergy patients using the modified patch, along with a new safety study in toddlers ages 1 – 3 years-old with the modified patch. Timing for the initiation of this new safety study to satisfy the important EU market is currently being planned.
The Company intends to resubmit the MAA when that data set is available.
Viaskin Peanut for Children Ages 1 – 3
In June 2020, the Company announced that in Part A of the EPITOPE phase 3 clinical study subject in both treatment arms showed consistent treatment effects after 12 months of therapy, as assessed by a double-blind placebo-controlled food challenge and biomarker results. Part A subjects were not included in Part B and the efficacy analyses from Part A were not statistically powered to demonstrate superiority of either dose versus placebo.
In June 2022, the Company announced positive topline results from Part B of EPITOPE.
On April 19, 2023, the Company outlined the regulatory pathway for Viaskin Peanut in children 1 – 3 years old after the FDA confirmed in written responses to the Company’s Pre-BLA meeting request that the Company’s EPITOPE phase 3 study met the pre-specified criteria for success for the primary endpoint and did not request any additional efficacy study in this age group. The FDA requires additional safety data to augment the safety data collected from EPITOPE in support of a BLA. This new safety study will also generate patch adhesion data and will include updated instructions for use.
On May 10, 2023, the New England Journal of Medicine (“NEJM”) published results from the EPITOPE phase 3 clinical study that demonstrated EPIT with Viaskin Peanut was statistically superior to placebo in desensitizing children to peanut exposure by increasing the peanut dose that triggers allergic symptoms. As stated in an accompanying editorial piece, these data are seen as “very good news” for toddlers with peanut allergy.
In November 2023, the Company announced the interim analyses from the first year of the open-label extension of EPITOPE, called EPOPEX, which showed improvement between months 12 and 24 of treatment with Viaskin Peanut across all efficacy parameters. These data were presented at the annual American College of Allergy, Asthma and Immunology (ACAAI) in November 2023.
On November 9, 2023, the Company submitted the protocol for its COMFORT Toddlers supplemental safety study in 1 – 3 years-old to FDA. The Company received comments and queries to the protocol from the FDA on March 11, 2024.
On October 22, 2024, the Company announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV agreed to guidance provided by the FDA on a potential pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old.
FDA confirmed that the Company has met Accelerated Approval qualifying criteria 1 and 2. Regarding criterion 3, FDA has provided guidance and suggestion regarding the intermediate clinical endpoint, which the Company has agreed to in informal discussions with the FDA. The Company formalized the Accelerated Approval guidance provided by FDA via submission of a meeting request and confirmed the general elements of the two study components: the COMFORT Toddlers safety study, to be completed before BLA submission, and the confirmatory effectiveness study, including the third Accelerated Approval criterion regarding the intermediate clinical endpoint. The Company expects that the confirmatory study will be initiated by the time of BLA submission and would run in parallel to commercialization in the United States, if Viaskin Peanut is approved.

The Company announced further that it has aligned with FDA on a wear time collection methodology in COMFORT Toddlers that provides a practical approach for subjects and families, is intended to generate sufficient data to support a BLA submission, and places wear time into an acceptable clinical hierarchy relative to other study endpoints. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. The company anticipates enrolling approximately 300 – 350 subjects on active treatment into the safety study, which would bring the total Viaskin Peanut patch safety database in toddlers to approximately 600 subjects, consistent with prior FDA guidance. With this path forward, the BLA submission for Viaskin Peanut patch in 1 – 3 years-old under the Accelerated Approval program is anticipated to be supported by:
i. Positive efficacy and safety data from DBV’s previously completed EPITOPE Phase 3 Study; and
ii. Additional safety data generated in COMFORT Toddlers supplemental safety study to be initiated in the second quarter of 2025.
On December 11, 2024, the Company announced that it reached alignment with FDA on the Accelerated Approval pathway for Viaskin Peanut patch in toddlers 1-3 years-old and on key study design elements for the COMFORT Toddlers study, including study size and wear time collection methodology and analysis. The Company announced further that FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1-3 years-old and that the Company and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch, will include a double-blind, placebo-controlled food challenge (DBPCFC), will use the same statistical criteria for success (i.e., lower bound of the 95% CI > 15%) as used in the EPITOPE, and will need to be initiated at the time that the BLA is submitted.
Viaskin Peanut for Children Ages 4 – 7
On September 7, 2022, the Company announced the initiation of VITESSE, a Phase 3 pivotal study of the mVP in children ages 4-7 years with peanut allergy. The Company defined initiation as the submission of the trial protocol to selected study sites for subsequent Institutional Review Board (IRB)/Ethics Committee (EC) approval.
On September 21, 2022, the Company announced it received from the FDA a partial clinical hold letter related to certain design elements of VITESSE. The Company announced on December 23, 2022 that the FDA lifted the partial clinical hold.The Company announced on September 23, 2024 that subject screening was completed in the third quarter of 2024. Topline results are anticipated in the fourth quarter of 2025.

In July 2023, the Company received Type C Meeting Written Responses from the FDA regarding key study design elements for COMFORT Children. Subsequently, in October 2023, the Company received feedback from the FDA addressing the remaining protocol design elements for COMFORT Children.
The Company submitted the protocol for its COMFORT Children supplemental safety study in 4--7-years-old to the FDA on November 29, 2023.On March 24, 2025, the Company announced that in a Written Responses Only to the Company’s Type D IND meeting request the FDA agreed with the Company’s proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4 – 7-year-olds will be sufficient to support a BLA filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required and the Company will not conduct the study. The Company will utilize the safety data from the VITESSE participants randomized to active treatment as well as placebo-crossover participants in the VITESSE Open Label Extension (OLE). Accordingly, the Company plans to submit a BLA in the first half of 2026 and anticipates potentially accelerating the product launch by approximately one year, subject to FDA approval.
Financing
On March 27, 2025, the Company announced a financing of up to $306.9 million (€284.5 million), to advance the Viaskin Peanut Patch through BLA submission and U.S. commercial launch, if approved. The financing includes gross proceeds of $125.5 million (€116.3 million) received on April 7, 2025, and up to $181.4 million (€168.2 million) in potential additional gross proceeds that may be received if all the warrants are exercised, subject to satisfaction of specified conditions. The VITESSE Phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of some of the warrants. The ABSA Warrants (defined below) will be exercisable from their respective date of issue until the earlier of (i) April 7, 2027 and (ii) 30 days following the publication by the Company of a press release announcing that the ongoing VITESSE trial of Viaskin Peanut in children 4-7 years old met the primary endpoint defined in the VITESSE study protocol, it being specified that (i) the primary measure of treatment effect will be the difference in response rates at Month 12 between active and placebo treatment groups, (ii) the primary analysis will be based on a 2-sided confidence interval (“CI”) for the difference in response rates, and (iii) the primary analysis must be positive according to the success criterion (lower bound of the 2-sided 95% CI of the difference in response rates ≥ 15%) (the “ABSA Warrant Exercise Period”). The exercise of one (1) ABSA Warrant will give the holder the right to subscribe to one point seventy-five (1.75) ABSA Warrant Shares at a price of €1.5939 per ABSA Warrant.
The financing resulted in an immediate dilution of 22.4% and a maximal dilution of up to 73.7% of existing shareholders (on a non-diluted basis) if all the warrants in the Offering are exercised in full.
The financing consists of:
•a share capital increase without preferential subscription rights reserved to categories of persons satisfying determined characteristics pursuant to the 24th resolution of the general meeting of shareholders of May 16, 2024 (the "2024 General Meeting") completed on April 7, 2025 for an amount of €38 million, consisting of the issuance of (i) 34,090,004 new shares at a par value of €0.10 (the "New Shares") each with warrants of the Company attached (the "ABSA Warrants", and together with the New Shares, the "ABSA") at a subscription price of €1.1136 per ABSA and (ii) up to 59,657,507 additional new shares, if all the ABSA Warrants attached to the New Shares are exercised (the "ABSA Warrant Shares"); and
•the issue through an offering reserved to categories of persons satisfying determined characteristics of 71,005,656 units (the “PFW-BS-PFW”) completed on April 7, 2025 for an amount of €79 million at a subscription price of €1.1136 per PFW-BS-PFW (of which €1.1036 will have been
prefunded on the issue date), each PFW-BS-PFW consisting of one pre-funded warrant to subscribe for one share of the Company (the "First Pre-Funded Warrants") and one warrant (the "BS Warrants") to subscribe to one second pre-funded warrants (the "Second Pre-Funded Warrants"), each of which entitles the holder to subscribe for 1.75 shares of the Company (the "Second PFW Shares"), allowing to issue up to 71,005,656 additional new shares if all the First Pre-Funded Warrants are exercised (the "First PFW Shares") and up to 124,259,898 additional new shares if all the Second Pre-Funded Warrants are exercised (the "Second PFW Shares", together with the ABSA Warrant Shares and the First Pre-Funded Warrant Shares, the "Warrant Shares", and together with the New Shares, the "Offered Shares"),
(together, the "Offering").
The net proceeds from the issue of the ABSA and the PFW-BS-PFW, together with existing cash and cash equivalents, will be mainly used by the Company in the following order of priority (i) for working capital and general corporate purposes, (ii) to finance the continued development of the Viaskin Peanut program, (iii) to finance the preparation and submission of a potential BLA and, (iv) to finance the readiness of a launch of Viaskin Peanut in the U.S., if approved.
The ordinary shares, including the ordinary shares issuable upon exercise of the warrants from the Offering, have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the ordinary shares, including the ordinary shares underlying the warrants issued as part of the Offering.
Taking into account the net proceeds of $125.5 million (€116.3 million) received on April 7, 2025 from the issuance of the ABSA and the PFW-BS-PFW and based on its current operations, plans and assumptions, the Company estimates that it has sufficient balance of cash & cash equivalents to fund its operations into June 2026.
Legal Proceedings
From time to time, the Company may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. The Company is not currently subject to any material legal proceedings.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Cash and Cash Equivalents
 3 Months Ended
Mar. 31, 2025
Cash and Cash Equivalents [Abstract]  
Cash and Cash Equivalents
Note 3: Cash and Cash Equivalents
The following tables summarize the cash and cash equivalents as of March 31, 2025 and December 31, 2024:
March 31, 2025December 31, 2024
Cash 12,962 32,456 
Cash equivalents— — 
Total cash and cash equivalents as reported in the statements of financial position12,962 32,456 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Other Current Assets
 3 Months Ended
Mar. 31, 2025
Other Current Assets [Abstract]  
Other Current Assets
Note 4: Other Current Assets
Other current assets consisted of the following:
March 31, 2025December 31, 2024
Research tax credit4,917 3,980 
Other tax claims6,015 4,452 
Prepaid expenses3,875 1,541 
Other receivables1,380 1,959 
Total16,186 11,932 
Research tax credit
The variance in Research Tax Credit is presented as follows:
Amount in thousands of US dollars
Opening research tax credit receivable as of January 1, 20253,980 
+ Operating revenue 753 
- Adjustment and currency translation effect184 
Closing research tax credit receivable as of March 31, 20254,917 
Of which - Non-current portion— 
Of which - Current portion4,917 
Before currency translation effect, the balance in research tax credit as of March 31, 2025, consisted of $4.0 million research tax credit for the previous fiscal year filed with the tax authorities. The estimated research tax credit for the first three months of the 2025 fiscal year amounts to $0.8 million.
The other tax claims are primarily related to the VAT as well as the reimbursement of VAT that has been requested. Prepaid expenses are comprised primarily of insurance expenses, as well as legal and scientific consulting fees.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Lease contracts
 3 Months Ended
Mar. 31, 2025
Lessee Disclosure [Abstract]  
Lease contracts
Note 5: Lease contracts
Future minimum lease payments under the Company’s operating leases’ right of use as of March 31, 2025 and December 31, 2024, are as follows:
March 31, 2025December 31, 2024
Real EstateOther assetsTotalReal EstateOther assetsTotal
Current portion1,015 76 1,091 810 26 836 
Year 21,259 56 1,315 1,222 7 1,228 
Year 31,267 7 1,274 1,230 7 1,237 
Thereafter4,990 7 4,997 5,127 9 5,136 
Total minimum lease payments8,531 146 8,677 8,388 49 8,437 
Less: Effects of discounting(1,430)(13)(1,443)(1,463)(23)(1,486)
Present value of lease liabilities7,101 133 7,234 6,925 26 6,951 
Less: current portion(643)(66)(709)(648)(6)(654)
Long-term lease liabities6,459 66 6,525 6,278 20 6,297 
Weighted average remaining lease term (years)7.340.047.490.02
Weighted average discount rate5.06 %0.09 %5.02 %0.02 %
The Company recognizes rent expense, calculated as the remaining cost of the lease allocated over the remaining lease term on a straight-line basis. Rent expense presented in the consolidated statement of operations and comprehensive loss was:
March 31,
20252024
Operating lease expense / (income)288 586 
Net termination impact49 
Net restructuring impact(1)(7)
Supplemental cash flow information related to operating leases is as follows for the period March 31, 2025 and 2024:
March 31,
20252024
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows used in operating leases96 501 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.25.1
Trade Payables and Other Liabilities
 3 Months Ended
Mar. 31, 2025
Payables and Accruals [Abstract]  
Trade Payables and Other Liabilities
Note 6: Trade Payables and Other Liabilities
6.1 Trade Payables
Trade payables increased by $12.1 million as of March 31, 2025, compared to December 31, 2024.
No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each fiscal period presented.
6.2 Other Liabilities
The following tables summarize the other liabilities as of March 31, 2025 and December 31, 2024:
March 31, 2025December 31, 2024
Other current liabilitiesOther non-current liabilitiesTotalOther current liabilitiesOther non-current liabilitiesTotal
Employee related liabilities4,844 — 4,844 7,294 — 7,294 
Tax liabilities332 — 332 188 — 188 
Other debts272 — 272 846 — 846 
Total5,447 — 5,447 8,328 — 8,328 
The Employee related liabilities include short-term debt to employees including social welfare, tax agency obligations and bonus provision. The variance versus year end is due to bonus accruals.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Shareholders' equity
 3 Months Ended
Mar. 31, 2025
Stockholders' Equity Note [Abstract]  
Shareholders' equity
Note 7: Shareholders’ equity
The share capital as of March 31, 2025 is set at the sum of €10,285,887 ($11,652 thousand converted at historical rates). It is divided into102,858,868 fully authorized, subscribed and paid-up ordinary shares with a par value of €0.10.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Share-Based Payments
 3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Share-Based Payments
Note 8: Share-Based Payments
The Board of Directors has been authorized at the General Meeting of the Shareholders to grant restricted stock units (“RSU”), stock options plan (“SO”), and non-employee warrants (Bons de Souscription d’Actions or “BSA”).
During the three months ended March 31, 2025, the Company granted neither stock options nor restricted stock units to employees.
There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 12 to the consolidated financial statements included in the Annual Report.
Change in Number of BSA/SO/RSU:
Number of outstanding
BSASORSUs
Balance as of December 31, 2024244,69310,444,8032,813,366
Granted during the period    ———
Forfeited during the period    —(3,725)(36,350)
Exercised/released during the period    ——(20,467)
Expired during the period    ———
Balance as of March 31, 2025244,69310,441,0782,756,549
Share-based payments expense reflected in the condensed consolidated statements of operations is as follows:
Three Months Ended March 31,
20252024
Research & developmentSO(382)(513)
RSU(199)(256)
Sales & marketingSO(12)(23)
RSU(6)(9)
General & administrativeSO(997)(1,030)
RSU(105)(126)
Total share-based compensation (expense)(1,701)(1,958)
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.25.1
Contingencies
 3 Months Ended
Mar. 31, 2025
Loss Contingency [Abstract]  
Contingencies
Note 9: Contingencies
The following tables summarize the contingencies as of March 31, 2025 and December 31, 2024:
March 31, 2025December 31, 2024
Current contingencies82 122 
Non-current contingencies780 838 
Total contingencies861 961 
The changes in contingencies are as follows:
Pension retirement obligationsOther contingenciesTotal
At January 1, 2025838 122 961 
Increases in liabilities34 21 55 
Used liabilities— (63)(63)
Reversals of unused liabilities— — — 
Net interest related to employee benefits, and unwinding of discount— — — 
Actuarial gains and losses on defined-benefit plans(132)— (132)
Currency translation effect39 1 41 
At March 31, 2025780 82 861 
Of which current — 82 82 
Of which non-current 780 — 780 
The Company does not hold any plan assets related to long-term employee benefit for any of the periods presented. There have been no significant changes in assumptions for the estimation of the retirement commitments from those disclosed in Note 13 to the consolidated financial statements included in the Annual Report.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Operating income
 3 Months Ended
Mar. 31, 2025
Other Income and Expenses [Abstract]  
Operating income
Note 10: Operating income
The following table summarizes the operating income during the three and nine months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
Research tax credit753 1,407 
Other operating income— — 
Total753 1,407 
The decrease in Research tax credit was primarily due to the fact that a greater proportion of studies activities were carried out in North America and were therefore not eligible to the French Research tax credit.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Operating Expenses
 3 Months Ended
Mar. 31, 2025
Operating Expenses [Abstract]  
Operating Expenses
Note 11: Operating Expenses
The Company had an average of 106 employees during the three months ended March 31, 2025, in comparison with an average of 105 employees during the three months ended March 31, 2024. The increase is mainly due to hiring to support development activities and quality activities.
The following table summarizes the allocation of personnel expenses by function during the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
Research and Development expenses4,630 5,048 
Sales & Marketing expenses155 334 
General & Administrative expenses2,996 3,236 
 Total personnel expenses7,782 8,618 
The following table summarizes the allocation of personnel expenses by nature during the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
Wages and salaries4,677 5,144 
Social security contributions 1,370 1,207 
Expenses for pension commitments34 309 
Share-based payments1,702 1,958 
 Total7,782 8,618 
The decrease in personnel expenses is primarily due to lower bonuses paid in 2025 compared to last year.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments
 3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
Commitments
Note 12: Commitments
There were no significant changes in other commitments from those disclosed in Note 17 to the consolidated financial statements included in the  Annual Report.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Relationships with Related Parties
 3 Months Ended
Mar. 31, 2025
Related Party Transactions [Abstract]  
Relationships with Related Parties
Note 13: Relationships with Related Parties
There were no new significant related-party transactions during the period nor any changes in the nature of the transactions from those described in Note 18 to the consolidated financial statements included in the Annual Report.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Loss Per Share
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Loss Per Share
Note 14: Loss Per Share
Basic loss per share is calculated by dividing the net loss attributable to the shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. As the Company was in a loss position for each of the three-month periods ended March 31, 2025 and 2024, the diluted loss per share is equal to basic loss per share because the effects of potentially dilutive shares were anti-dilutive as a result of the Company’s net loss.
The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three months period ended March 31, 2025 and 2024 indicated in number of potential shares:
Three Months Ended March 31,
20252024
Non-employee warrants 244,693 244,693 
Stock options10,492,903 7,388,016 
Restricted stock units3,087,872 2,064,035 
Prefunded warrants22,266,331 28,276,331 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Events after the Close of the Period
 3 Months Ended
Mar. 31, 2025
Subsequent Events [Abstract]  
Events after the Close of the Period
Note 15: Events after the Close of the Period

On March 27, 2025, the company announced a financing of up to $306.9 million (€284.5 million), to advance Viaskin® Peanut Patch through biologics license application submission and U.S. commercial launch, if approved. The financing includes gross proceeds of $125.5 million (€116.3 million) received on April 7, 2025 and up to $181.4 million (€168.2 million) in potential additional gross proceeds that may be received if all the warrants are exercised, subject to satisfaction of specified conditions.


On April 15, 2025, the Company received the 2024 Research Tax Credit (Crédit d’Impôt Recherche) in the amount of $4.0M in cash.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable segment disclosure
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Reportable segment disclosure
Note 16: Reportable segment disclosure

Three Months Ended March 31,
20252024
Clinical studies6,802 8,173 
BLA & Regulatory1,385 1,480 
Medical Affairs & Other Medical1,958 2,664 
Research & Innovation744 190 
Manufacturing & Supply and Quality10,594 8,896 
Sales & Marketing262 758 
General & Administrative 5,626 7,804 
Total expenses27,371 29,965 
The Company operates and is managed as one operating segment driving expenses for the development of Viaskin Peanut. The Company’s R&D organization is primarily responsible for the development and registration efforts of Viaskin Peanut. The Company’s technical operations group is responsible for the development of manufacturing processes, supplying clinical drug product. The Company is also supported by corporate staff functions.
The Company’s Chief Executive Officer as the CODM manages and allocates resources to the operations of the total company by assessing the overall level of resources available and how to best allocate them to support the Company’s long-term company-wide strategic goals. In making this decision, the CODM uses consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods.
The CODM's analysis includes a comparison to budgeted results. Segment assets provided to the CODM are consistent with those reported on the Consolidated Statement of Financial Position with particular emphasis on the Company's available liquidity including cash, cash equivalents.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Pay vs Performance Disclosure    
Net (loss) $ (27,079) $ (27,345)
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.25.1
The Company (Policies)
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.
The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on April 11, 2025 (the “ Annual Report”). The condensed consolidated statement of financial position as of December 31, 2024 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2024.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2025, or any other future period.
Use of Estimates
Use of Estimates
The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates.
On an on-going basis, management evaluates its estimates, primarily those related to: (1) research tax credits, (2) assumptions used in the valuation of right of use assets—operating lease, (3) impairment of right-of-use assets related to leases and property, plant and equipment, (4) recoverability of the Company’s net deferred tax assets and related valuation allowance, (5) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, 6) estimate of contingencies and provisions, and (7) estimate of employee benefits obligations.
Going Concern
Going Concern
These Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The Company has incurred operating losses and negative cash flows from operations since inception. The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.
Since its inception, the Company has primarily funded its operations through equity financings, as well as public assistance and Research Tax Credit.. Prior to 2022, the Company underwent restructuring efforts, scaled down certain clinical programs, and engaged with regulatory authorities to advance Viaskin Peanut’s approval process in the United States and European Union. In 2022, the Company secured a private placement financing of $194 million and lifted a partial clinical hold from the FDA on its VITESSE Phase 3 clinical study.
On April 7, 2025, the Company received gross proceeds of $125.5 million (€116.3 million) from the issuance of the ABSA and PFW-BS-PFW, as described in Note 15. With the receipt of the aforementioned proceeds, and based on its current operations, plans, and assumptions examined by the Board of Directors (“Board”) on March 23, 2025, the Company estimates that its cash and cash equivalents are sufficient to fund its operations into June 2026.
Given the Company’s historical operating losses and reliance on external financings, the Company may still seek additional capital for future needs through a combination of public or private equity or debt financings, collaborations, licensing agreements, and other funding options. While recent financing events have improved the Company’s financial position, access to additional capital in the future remains subject to market conditions and investor interest.
Accounting Pronouncements Recently Adopted
Accounting Pronouncements Recently Adopted
There have been no recently issued accounting standards adopted during the period which had a material impact on the Company’s financial statements.
There are no recently issued accounting standards that are expected to have a material impact on our results of operations, financial condition, or cash flows.
Accounting Pronouncements issued not yet adopted
Accounting Pronouncements issued not yet adopted
In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740 — Improvements to Income Tax Disclosures which enhances the transparency and usefulness of income tax disclosures. This amendment requires disclosure of disaggregated information about the Company’s effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. For SEC filers, this ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income Topic 220 — Expense Disaggregation Disclosures. The guidance requires disclosure of additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. For SEC filers, this ASU is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this ASU 2024-03 will have on its consolidated financial statements and related disclosures.
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Cash and Cash Equivalents (Tables)
 3 Months Ended
Mar. 31, 2025
Cash and Cash Equivalents [Abstract]  
Summary of breakdown of cash and cash equivalents
The following tables summarize the cash and cash equivalents as of March 31, 2025 and December 31, 2024:
March 31, 2025December 31, 2024
Cash 12,962 32,456 
Cash equivalents— — 
Total cash and cash equivalents as reported in the statements of financial position12,962 32,456 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Other Current Assets (Tables)
 3 Months Ended
Mar. 31, 2025
Other Current Assets [Abstract]  
Summary of Other Current Asset
Other current assets consisted of the following:
March 31, 2025December 31, 2024
Research tax credit4,917 3,980 
Other tax claims6,015 4,452 
Prepaid expenses3,875 1,541 
Other receivables1,380 1,959 
Total16,186 11,932 
Summary of Research Tax Credit
The variance in Research Tax Credit is presented as follows:
Amount in thousands of US dollars
Opening research tax credit receivable as of January 1, 20253,980 
+ Operating revenue 753 
- Adjustment and currency translation effect184 
Closing research tax credit receivable as of March 31, 20254,917 
Of which - Non-current portion— 
Of which - Current portion4,917 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Lease contracts (Tables)
 3 Months Ended
Mar. 31, 2025
Lessee Disclosure [Abstract]  
Summary of Operating Leases Future Minimum Payments
Future minimum lease payments under the Company’s operating leases’ right of use as of March 31, 2025 and December 31, 2024, are as follows:
March 31, 2025December 31, 2024
Real EstateOther assetsTotalReal EstateOther assetsTotal
Current portion1,015 76 1,091 810 26 836 
Year 21,259 56 1,315 1,222 7 1,228 
Year 31,267 7 1,274 1,230 7 1,237 
Thereafter4,990 7 4,997 5,127 9 5,136 
Total minimum lease payments8,531 146 8,677 8,388 49 8,437 
Less: Effects of discounting(1,430)(13)(1,443)(1,463)(23)(1,486)
Present value of lease liabilities7,101 133 7,234 6,925 26 6,951 
Less: current portion(643)(66)(709)(648)(6)(654)
Long-term lease liabities6,459 66 6,525 6,278 20 6,297 
Weighted average remaining lease term (years)7.340.047.490.02
Weighted average discount rate5.06 %0.09 %5.02 %0.02 %
Summary of Rent expenses
The Company recognizes rent expense, calculated as the remaining cost of the lease allocated over the remaining lease term on a straight-line basis. Rent expense presented in the consolidated statement of operations and comprehensive loss was:
March 31,
20252024
Operating lease expense / (income)288 586 
Net termination impact49 
Net restructuring impact(1)(7)
Summary of Supplemental cash flow information related to our operating leases
Supplemental cash flow information related to operating leases is as follows for the period March 31, 2025 and 2024:
March 31,
20252024
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows used in operating leases96 501 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Trade Payables and Other Liabilities (Tables)
 3 Months Ended
Mar. 31, 2025
Payables and Accruals [Abstract]  
Summary of Other Current Liabilities
The following tables summarize the other liabilities as of March 31, 2025 and December 31, 2024:
March 31, 2025December 31, 2024
Other current liabilitiesOther non-current liabilitiesTotalOther current liabilitiesOther non-current liabilitiesTotal
Employee related liabilities4,844 — 4,844 7,294 — 7,294 
Tax liabilities332 — 332 188 — 188 
Other debts272 — 272 846 — 846 
Total5,447 — 5,447 8,328 — 8,328 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Share-Based Payments (Tables)
 3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Summary of RSU Activity
Change in Number of BSA/SO/RSU:
Number of outstanding
BSASORSUs
Balance as of December 31, 2024244,69310,444,8032,813,366
Granted during the period    ———
Forfeited during the period    —(3,725)(36,350)
Exercised/released during the period    ——(20,467)
Expired during the period    ———
Balance as of March 31, 2025244,69310,441,0782,756,549
Summary of Share-Based Payments Expenses
Share-based payments expense reflected in the condensed consolidated statements of operations is as follows:
Three Months Ended March 31,
20252024
Research & developmentSO(382)(513)
RSU(199)(256)
Sales & marketingSO(12)(23)
RSU(6)(9)
General & administrativeSO(997)(1,030)
RSU(105)(126)
Total share-based compensation (expense)(1,701)(1,958)
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Contingencies (Tables)
 3 Months Ended
Mar. 31, 2025
Loss Contingency [Abstract]  
Summary of Non-current Contingencies and Current Contingencies
The following tables summarize the contingencies as of March 31, 2025 and December 31, 2024:
March 31, 2025December 31, 2024
Current contingencies82 122 
Non-current contingencies780 838 
Total contingencies861 961 
Summary of Movement in Provisions
The changes in contingencies are as follows:
Pension retirement obligationsOther contingenciesTotal
At January 1, 2025838 122 961 
Increases in liabilities34 21 55 
Used liabilities— (63)(63)
Reversals of unused liabilities— — — 
Net interest related to employee benefits, and unwinding of discount— — — 
Actuarial gains and losses on defined-benefit plans(132)— (132)
Currency translation effect39 1 41 
At March 31, 2025780 82 861 
Of which current — 82 82 
Of which non-current 780 — 780 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Operating income (Tables)
 3 Months Ended
Mar. 31, 2025
Other Income and Expenses [Abstract]  
Schedule of operating income
The following table summarizes the operating income during the three and nine months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
Research tax credit753 1,407 
Other operating income— — 
Total753 1,407 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.25.1
Operating Expenses (Tables)
 3 Months Ended
Mar. 31, 2025
Operating Expenses [Abstract]  
Summary of Allocation of Personnel Expenses By Function
The following table summarizes the allocation of personnel expenses by function during the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
Research and Development expenses4,630 5,048 
Sales & Marketing expenses155 334 
General & Administrative expenses2,996 3,236 
 Total personnel expenses7,782 8,618 
Summary of Allocation of Personnel Expenses By Nature
The following table summarizes the allocation of personnel expenses by nature during the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
Wages and salaries4,677 5,144 
Social security contributions 1,370 1,207 
Expenses for pension commitments34 309 
Share-based payments1,702 1,958 
 Total7,782 8,618 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Loss Per Share (Tables)
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three months period ended March 31, 2025 and 2024 indicated in number of potential shares:
Three Months Ended March 31,
20252024
Non-employee warrants 244,693 244,693 
Stock options10,492,903 7,388,016 
Restricted stock units3,087,872 2,064,035 
Prefunded warrants22,266,331 28,276,331 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable segment disclosure (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Three Months Ended March 31,
20252024
Clinical studies6,802 8,173 
BLA & Regulatory1,385 1,480 
Medical Affairs & Other Medical1,958 2,664 
Research & Innovation744 190 
Manufacturing & Supply and Quality10,594 8,896 
Sales & Marketing262 758 
General & Administrative 5,626 7,804 
Total expenses27,371 29,965 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.25.1
The Company (Details)
€ in Millions, $ in Millions
 12 Months Ended
Apr. 07, 2025
USD ($)
Apr. 07, 2025
EUR (€)
Dec. 31, 2022
USD ($)
Subsequent Event      
Subsidiary or Equity Method Investee [Line Items]      
Capital increases, net of transaction costs $ 125.5 € 116.3  
Private investment in Public Equity      
Subsidiary or Equity Method Investee [Line Items]      
Proceeds from issuance of common stock     $ 194.0
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Significant Events and Transactions - Clinical Programs (Details)
 1 Months Ended
Oct. 22, 2024
candidate
patch
regulatory
study
Jul. 31, 2023
study
Mar. 31, 2021
Mar. 27, 2025
Dec. 11, 2024
Aug. 02, 2021
objection
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Percentage of confidence interval       95.00% 95.00%  
Minimum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Percentage of difference in response rates       15.00% 15.00%  
Viaskintm Clinical Program            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Clinical program trial period     6 months      
Number of major objection | objection           1
Number of local country regulatory health authorities | regulatory 2          
Number of patches | patch 1          
Viaskintm Clinical Program | Comfort Toddlers Safety Study            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of additional safety study | study   2        
Number of study component | study 2          
Total number of candidates covered by the study 600          
Viaskintm Clinical Program | Comfort Toddlers Safety Study | Minimum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of additional candidates covered by the study 300          
Viaskintm Clinical Program | Comfort Toddlers Safety Study | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of additional candidates covered by the study 350          
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Significant Events and Transactions - Financing (Details)
€ / shares in Units, $ in Thousands, € in Millions
 3 Months Ended
Apr. 07, 2025
USD ($)
shares
Apr. 07, 2025
EUR (€)
€ / shares
shares
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Mar. 27, 2025
USD ($)
Mar. 27, 2025
EUR (€)
€ / shares
Dec. 11, 2024
Class of Stock [Line Items]              
Issuance or sale of equity, maximum amount         $ 306,900 € 284.5  
Issuance or sale of equity, maximum potential amount         $ 181,400 € 168.2  
Percentage of confidence interval         95.00% 95.00% 95.00%
Financing, dilution percentage         22.40% 22.40%  
Financing, maximum potential dilution percentage         73.70% 73.70%  
Issuance of ordinary shares | $     $ 0 $ 0      
ABSA warrants              
Class of Stock [Line Items]              
Ratio of ABSA warrant shares to ABSA warrants         1.75 1.75  
Class of warrant or right, exercise price of warrants or rights (in euro per share) | € / shares           € 1.5939  
Minimum              
Class of Stock [Line Items]              
Percentage of difference in response rates         15.00% 15.00% 15.00%
Subsequent Event              
Class of Stock [Line Items]              
Capital increases, net of transaction costs $ 125,500 € 116.3          
Subsequent Event | ABSA warrants              
Class of Stock [Line Items]              
Class of warrant or right, exercise price of warrants or rights (in euro per share) | € / shares   € 1.1136          
Issuance of ordinary shares | €   € 38.0          
Stock issued during period (in shares) 34,090,004 34,090,004          
Shares issued (in dollars/euro per share) | € / shares   € 0.10          
Subsequent Event | PFW-BS-PFW              
Class of Stock [Line Items]              
Class of warrant or right, exercise price of warrants or rights (in euro per share) | € / shares   € 1.1136          
Issuance of ordinary shares | €   € 79.0          
Stock issued during period (in shares) 71,005,656 71,005,656          
Subsequent Event | Prefunded PFW-BS-PFW              
Class of Stock [Line Items]              
Class of warrant or right, exercise price of warrants or rights (in euro per share) | € / shares   € 1.1036          
Class of warrant or right, unissued (in shares)   1          
Subsequent Event | Second prefunded warrants              
Class of Stock [Line Items]              
Ratio of ABSA warrant shares to ABSA warrants   1.75          
Class of warrant or right, number of securities called by each warrant or right (in shares)   1          
Subsequent Event | First prefunded warrants              
Class of Stock [Line Items]              
Class of warrant or right, number of securities called by each warrant or right (in shares)   1          
Subsequent Event | BS Warrants              
Class of Stock [Line Items]              
Class of warrant or right, unissued (in shares)   1          
Subsequent Event | Maximum | ABSA warrants              
Class of Stock [Line Items]              
Class of warrant or right, number of securities called by warrants or rights (in shares)   59,657,507          
Subsequent Event | Maximum | Second prefunded warrants              
Class of Stock [Line Items]              
Stock issued during period (in shares) 124,259,898 124,259,898          
Subsequent Event | Maximum | First prefunded warrants              
Class of Stock [Line Items]              
Stock issued during period (in shares) 71,005,656 71,005,656          
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Cash and Cash Equivalents (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Cash and Cash Equivalents [Abstract]    
Cash $ 12,962 $ 32,456
Cash equivalents 0 0
Total cash and cash equivalents as reported in the statements of financial position $ 12,962 $ 32,456
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Other Current Assets - Summary of Other Current Asset (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Other Current Assets [Abstract]    
Research tax credit $ 4,917 $ 3,980
Other tax claims 6,015 4,452
Prepaid expenses 3,875 1,541
Other receivables 1,380 1,959
Total $ 16,186 $ 11,932
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Other Current Assets - Summary of Research Tax Credit (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
Research Tax Credit Receivable [Roll Forward]  
Opening research tax credit receivable as of January 1, 2025 $ 3,980
+ Operating revenue 753
- Adjustment and currency translation effect 184
Closing research tax credit receivable as of March 31, 2025 4,917
Of which - Non-current portion 0
Of which - Current portion $ 4,917
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Other Current Assets - Additional Information (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2025
USD ($)
Other Current Assets [Abstract]  
Tax credit carryforward amount before currency translation $ 4.0
Estimated research tax credit for the period $ 0.8
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Lease contracts - Summary of Operating Leases Future Minimum Payments (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Lessee, Lease, Description [Line Items]    
Current portion $ 1,091 $ 836
Year 2 1,315 1,228
Year 3 1,274 1,237
Thereafter 4,997 5,136
Total minimum lease payments 8,677 8,437
Less: Effects of discounting (1,443) (1,486)
Present value of lease liabilities 7,234 6,951
Less: current portion (709) (654)
Long-term lease liabities 6,525 6,297
Real Estate    
Lessee, Lease, Description [Line Items]    
Current portion 1,015 810
Year 2 1,259 1,222
Year 3 1,267 1,230
Thereafter 4,990 5,127
Total minimum lease payments 8,531 8,388
Less: Effects of discounting (1,430) (1,463)
Present value of lease liabilities 7,101 6,925
Less: current portion (643) (648)
Long-term lease liabities $ 6,459 $ 6,278
Weighted average remaining lease term (years) 7 years 4 months 2 days 7 years 5 months 26 days
Weighted average discount rate 5.06% 5.02%
Other assets    
Lessee, Lease, Description [Line Items]    
Current portion $ 76 $ 26
Year 2 56 7
Year 3 7 7
Thereafter 7 9
Total minimum lease payments 146 49
Less: Effects of discounting (13) (23)
Present value of lease liabilities 133 26
Less: current portion (66) (6)
Long-term lease liabities $ 66 $ 20
Weighted average remaining lease term (years) 14 days 7 days
Weighted average discount rate 0.09% 0.02%
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.25.1
Lease contracts - Summary of Rent Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Lessee Disclosure [Abstract]    
Operating lease expense / (income) $ 288 $ 586
Net termination impact 49
Net restructuring impact $ (1) $ (7)
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Lease contracts - Summary of Supplemental Cash Flow Information Related to our Operating Leases (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Lessee Disclosure [Abstract]    
Operating cash flows used in operating leases $ 96 $ 501
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.25.1
Trade Payables and Other Liabilities - Additional Information (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2025
USD ($)
Payables and Accruals [Abstract]  
Increase in trade accounts payable $ 12.1
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.25.1
Trade Payables and Other Liabilities - Summary of Other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Other current liabilities $ 5,447 $ 8,328
Other non-current liabilities 0 0
Total 5,447 8,328
Employee related liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Other current liabilities 4,844 7,294
Other non-current liabilities 0 0
Total 4,844 7,294
Tax liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Other current liabilities 332 188
Other non-current liabilities 0 0
Total 332 188
Other debts    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Other current liabilities 272 846
Other non-current liabilities 0 0
Total $ 272 $ 846
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.25.1
Shareholders' equity (Details)
€ / shares in Units, $ in Thousands
Mar. 31, 2025
USD ($)
shares
Mar. 31, 2025
EUR (€)
€ / shares
shares
Dec. 31, 2024
€ / shares
Dec. 31, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Class of Stock [Line Items]            
Share capital | $ $ 2,873     $ 27,387 $ 111,654 $ 140,187
Common stock, shares oustanding (in shares) | shares 102,858,868 102,858,868        
Common stock shares par value (in Euro per share) | € / shares   € 0.1 € 0.1      
Share capital            
Class of Stock [Line Items]            
Share capital $ 11,652 € 10,285,887        
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Share-Based Payments - Additional Information (Details)
 3 Months Ended
Mar. 31, 2025
shares
Stock options  
Share-Based Payments [Line iteam]  
Number of stock options outstanding, Granted during the period (in shares) 0
RSUs  
Share-Based Payments [Line iteam]  
Number of RSU outstanding, Granted during the period (in shares) 0
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.25.1
Share-Based Payments - Summary of BSA/SO/RSU actvity (Details)
 3 Months Ended
Mar. 31, 2025
shares
BSA  
Share-Based Compensation Arrangement by Share-Based Payment Award, Warrants Instruments, Outstanding [Roll Forward]  
Number of warrants outstanding, Beginning Balance (in shares) 244,693
Number of warrants, granted during period (in shares) 0
Number of warrants, forfeited during period (in shares) 0
Number of warrants, exercised during period (in shares) 0
Number of warrants, expired during period (in shares) 0
Number of warrants outstanding, Ending Balance (in shares) 244,693
SO  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]  
Number of stock options outstanding, Beginning Balance (in shares) 10,444,803
Number of stock options outstanding, Granted during the period (in shares) 0
Number of stock options outstanding, Forfeited during the period (in shares) (3,725)
Number of stock option outstanding, Exercised during the period (in shares) 0
Number of stock option outstanding, Expired during the period (in shares) 0
Number of stock options outstanding, Ending Balance (in shares) 10,441,078
RSUs  
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]  
Number of RSU outstanding, Beginning Balance (in shares) 2,813,366
Number of RSU outstanding, Granted during the period (in shares) 0
Number of RSU outstanding, Forfeited during the period (in shares) (36,350)
Number of RSU outstanding, Released during the period (in shares) (20,467)
Number of RSU outstanding, Expired during the period (in shares) 0
Number of RSU outstanding, Ending Balance (in shares) 2,756,549
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.25.1
Share-Based Payments - Summary of Share-Based Payments Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Share-Based Payments [Line iteam]    
Total share-based compensation (expense) $ (1,701) $ (1,958)
Research & development | Stock options    
Share-Based Payments [Line iteam]    
Total share-based compensation (expense) (382) (513)
Research & development | RSUs    
Share-Based Payments [Line iteam]    
Total share-based compensation (expense) (199) (256)
Sales & marketing | Stock options    
Share-Based Payments [Line iteam]    
Total share-based compensation (expense) (12) (23)
Sales & marketing | RSUs    
Share-Based Payments [Line iteam]    
Total share-based compensation (expense) (6) (9)
General & administrative | Stock options    
Share-Based Payments [Line iteam]    
Total share-based compensation (expense) (997) (1,030)
General & administrative | RSUs    
Share-Based Payments [Line iteam]    
Total share-based compensation (expense) $ (105) $ (126)
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.25.1
Contingencies - Summary of Non Current Contingencies and Current Contingencies (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Loss Contingency [Abstract]    
Current contingencies $ 82 $ 122
Non-current contingencies 780 838
Total contingencies $ 861 $ 961
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.25.1
Contingencies - Summary of Movement in Contingencies (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Pension retirement obligations    
Actuarial gains and losses on defined-benefit plans $ (132)  
Of which current 82 $ 122
Of which non-current 780 $ 838
Other contingencies    
Used liabilities (63)  
Total    
Defined benefit plan, benefit obligation and loss contingency accrual, beginning balance 961  
Increases in liabilities 55  
Currency translation effect 41  
Defined benefit plan, benefit obligation and loss contingency accrual, ending balance 861  
Of which current 82  
Of which non-current 780  
Other contingencies    
Other contingencies    
Contingencies, beginning balance 122  
Increases in liabilities 21  
Used liabilities (63)  
Currency translation effect 1  
Contingencies, ending balance 82  
Of which current 82  
Of which non-current 0  
Pension retirement obligations    
Pension retirement obligations    
Pension retirement obligations, beginning balance 838  
Increases in liabilities 34  
Actuarial gains and losses on defined-benefit plans (132)  
Currency translation effect 39  
Pension retirement obligations, ending balance 780  
Of which current 0  
Of which non-current $ 780  
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Operating income (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Other Income and Expenses [Abstract]    
Research tax credit $ 753 $ 1,407
Other operating income 0 0
Total $ 753 $ 1,407
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.25.1
Operating Expenses - Additional Information (Details) - employee
Mar. 31, 2025
Mar. 31, 2024
Other Income and Expenses [Abstract]    
Entity number of employees 106 105
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.25.1
Operating Expenses - Summary of Allocation of Personnel Expenses By Function (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Share-Based Payments [Line iteam]    
Research and Development expenses $ 21,483 $ 21,403
Sales & Marketing expenses 262 758
General & Administrative expenses 5,626 7,804
Total personnel expenses 27,370 29,964
Expenses by function    
Share-Based Payments [Line iteam]    
Research and Development expenses 4,630 5,048
Sales & Marketing expenses 155 334
General & Administrative expenses 2,996 3,236
Total personnel expenses $ 7,782 $ 8,618
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.25.1
Operating Expenses - Summary of Allocation of Personnel Expenses By Nature (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Share-Based Payments [Line iteam]    
Share-based payments $ 1,701 $ 1,958
Total personnel expenses 27,370 29,964
Expenses by Nature    
Share-Based Payments [Line iteam]    
Wages and salaries 4,677 5,144
Social security contributions 1,370 1,207
Expenses for pension commitments 34 309
Share-based payments 1,702 1,958
Total personnel expenses $ 7,782 $ 8,618
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.25.1
Loss Per Share (Details) - shares
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Non-employee warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 244,693 244,693
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 10,492,903 7,388,016
Restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 3,087,872 2,064,035
Prefunded warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 22,266,331 28,276,331
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.25.1
Events after the Close of the Period (Details)
€ in Millions, $ in Millions
Apr. 15, 2025
USD ($)
Apr. 07, 2025
EUR (€)
Apr. 07, 2025
USD ($)
Mar. 27, 2025
EUR (€)
Mar. 27, 2025
USD ($)
Subsequent Event [Line Items]          
Issuance or sale of equity, maximum amount       € 284.5 $ 306.9
Issuance or sale of equity, maximum potential amount       € 168.2 $ 181.4
Subsequent Event          
Subsequent Event [Line Items]          
Capital increases, net of transaction costs   € 116.3 $ 125.5    
Research tax credit, (Crédit d’Impôt Recherche) payment received $ 4.0        
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable segment disclosure - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research & Innovation $ 21,483 $ 21,403
Sales & Marketing 262 758
General & Administrative 5,626 7,804
Total personnel expenses 27,370 29,964
Viaskin Peanut Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Clinical studies 6,802 8,173
BLA & Regulatory 1,385 1,480
Medical Affairs & Other Medical 1,958 2,664
Research & Innovation 744 190
Manufacturing & Supply and Quality 10,594 8,896
Sales & Marketing 262 758
General & Administrative 5,626 7,804
Total personnel expenses $ 27,371 $ 29,965
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable segment disclosure - Additional Information (Details)
 3 Months Ended
Mar. 31, 2025
segment
Segment Reporting [Abstract]  
Number of operating segments 1
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $J GEI&QTU(E0 ,T 0 9&]C4')O<',O87!P+GAM M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ) M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$, M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2B4^BQ-+.90D)@$XA8E MWA;1_%%BU.[M: !.,;^Y?-GR8V.4H>$3RE$3&0Q7PVN\UGJN&('HB@! MLCZ@4[D<$WYL[D)RBL9GVD-4^EWM$03GM^"0E%&D8 (6<2&RMC%:ZH2*0CKA MC5[P\2-U,\QHP X=>LI0E16P=IH8CT/7P 4PP0B3RU\%- MQKOZ)G3O 3LDA MVR75]WW9UW-NW*&"U\>'YWG=POI,RFL621A'^_1S80RY8-[9)- MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQ MEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1 M]E6\W*.76!4!EQC?-*HU+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++ M9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D> M/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO> M1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9= M=N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8 MT='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7 M\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I M=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;R MWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z M;I,[2$R<><41 71% B.5' 86%S+D4.Z2D 83 > MLX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[ MM'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ M#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1. M"CS<_N\-L,+$CN'MB[\!4$L#!!0 ( $J GEH ?+7:= 8 HE 8 M>&PO=V]R:W-H965T&ULM9K]3]LX&,?_%:N3IGL9-+'[QH!* MI#2=PV6A)WCE/@O[_'2=J4F_.T1$1"-"]^OO77KQ^[/GF0 MZGNR$$*3QRB,D]/60NOE^W8[\18BXLFA7(H8WLRDBKB&6S5O)TLEN)\%16&; M.DZO'?$@;@U/LFM(-!(>/E1B+,#1*D(\?A6AK\YTF]0N0L%Z$5(HQ\EK%> M).0B]H7_/+X-&=KDBJYS=491P<]<'1+FOB/4H5U+?L9X^&AIPAU;^+/LL$TA ML4R/5>B=2R^%IJO)),X[CFF _WR"5&2B193\:RNR7+)CES2]\WVRY)XX;4'W M2X1:B=;P[1NWYQS;_+Z2V#/WG8W[#J9>NK][6@J;4SS<=0Z^V"RA434M=3>6 MNOM9^I)RI84*G\BM6$JE;?9P*:U26Z&,T:B:]GH;>[W][-T(%4C?=$L"HX.U M\G"E34>L[(EH?$V?_8W/_IXM4W&86+)N65V/N-:,AXFU(M&PF@8'&X,#-%,7 ML0[T$[D,0D&NTNA>*)LQ7,-QW /6ZQWU;>;0T)KFCC;FCO8Q=ROF0:*A C6Y MXI&UC>(ZYV=?R=W%^./5]:?K#Y.+*9D>C@YM9E&9FF9=IYQHG7WL3F)/*FBB MV23RCDPU]$LB%1G+--;J"3Y]:QGL4)\X-L=X4%W+6VSA[F-YY/N@GKQ;>[3: MPY4N;ZWVT*"Z]FAIC[[(7G%!,C"XCNW5B$NZ3I^,5H< HB3DY/;M&\K8\3*] M#X,?]FD&UZM;!"48N2AY_%0$-S+1/"1_!\OJAHPK'E%&[6VY"09R2PAR<8SY MJ2V;.^BW=_(AMMK$Y<8+J%O:.]9!&$J;P!@7J.NW)"07YYKU>&2&9VL&SW8( M_,Z8U5838.269.3B0/-)>M ^;Q8RQF;4'2(NZ79)AY+^ /ZL)IN@(K?$(A=G MF:*MCE.E#!WE2!3$\VRV2>T+/%SQFW59.,:CZOHLZO MC5M]XHI5/IO@)+<$)70)D0,3/!:U^FT E M6J(2W0N5IA$/0W*6)O ZL;;:'3I5:S,\K*Z]$HOH7EAT$0DU-[WR RCH!4R8 MT9+'UGK=(5BY=L'CZAHM 8GN!4C3A8!ZQ.SA,M7VFH ?6L(/W0M^P%@$"\^I MEMYW /IL#XUV4S67(/ MW8M[QC">*I@Y)[$O'LD?PEZ/N)0#2]&>R_H#*]_AP74KL^0=NH-WBLGR,D@, M(7P37*'[)COD#@Y<>L!&'XJ@R H-^;C+D]D$&%Z@>5IN@'5K2#L4I M!8RIP.,Q.0=N30+-U5,^JEH]OA*I%,Z;X!Y6<@]S&OB=X95@IOBAH0DT8B4: M,9QD[@(="B)GQ*6_W/]*IL)+%4P_5M^X4F4K@K6[X-Z"*)$YB+.%TAM?QP@?.SKW=67TTP%]OZ)0YGKG6+(!>/WH+'U5@:Z]==K$;&%DAW 2XID-X_S@R>;IYJ#/*#O> MTBZ3YZ>$/G.S Y*04,P@U#GL0U]4^<&;_$;+979VY5YJ+:/L6JTP/(X[!@ D1H !@ !X;"]W M;W)K>%\YRP8K(\ MKZ[=B.4Y+U7&"GHC@"SSG(CM>YKQIXL)G#Q?^,X>ULIZ.3^IE&L7W\;/U#Y;QVYIY(>L6S?UBJUA>3> )2 MNB)EIK[SIX]T[U!@["4\D]4O>-K+>A.0E%+Q?*^L$>2LV/V3W_M M!2@/Z" M]@KH6 6\5\"5HSMDE5O71)'EN>!/0!AI;)'JI- 4Z"/),Y82I4]NE?[3V5(2\!7XP I2)(QDX(9+5H7_;5F0,F5:]AV8 M@1^WU^#MZW?@-6 %N%OS4I(BE>=SI1&:Y\R3/9KW.S1H ,T7(DX AE. /!0X MU*_&U:]I4JO[7?6YCDL='%0'!U7V\%!P2B%T# "1DNI(G+H99**1SI9OGD%0^_,Y=X+&>LXBVMG\9CUY161:Z#3!A)S0'^5[)%D MI@)<7N],A94ILU,\+B%:A.A\_MAVQY;"R _"6JJ#TZ]Q^J,XOZDU%7IIM%/C M@KBS$K0AAC .>Q =4G"!D1MB4$,,1B'><:77RF&(@?5PM(!^W(-H2_D^CF,W MQ+"&&(Z6]E=>S*X. @Q?LKA?R%C'W:AV-QK-R(W0Q"?4=@HV&2G4M"IT4^,; ML\E-04&5R__(K@XOAKB7((<4Q-Y F<04&QGT&K[SCM@^"EW^A]?GWE0'P"+T>BA=4C[" T!;Q R/V$2.! KM8$(? M^GVD+C$4P0&H#4W"46+:0[T*C:#QCY)YE MNG^ATDGE<)0@_W2[>REK7:<;EH3C-'DG2$K!AFR)7H;NK-C&)!4 MM\(#&$/K\;%5Y+8,1$/!;.@-CO-;MREJ%;H3IDU8@>]'?:"V5(S1T&)L: V. M\UJW-SJ$U&8GW\.QM:_98EA3\ #PX;&X.+H)ND0TE%&_..]XX6L=:>>AB/1 M.$=^YL7#\2L3V?P7!F9\Z^3()846D3M%J&%)-,Z27UO\>'!](IO_HKA/YPZA M& ^4/6I-DL=09)O-#Q04LLDPPIX558<4Q,$ VH8QT?@LN$/[^0!";"_.*(S[ MXXM##,>#30=J" [YHXOS=DT$7?,LI4*^>14C&)U5';W:#@SJHWSYQY/Z"UGK M.M^0)QHGSV\B90416R!-%.04Z C@T#_S3J"G25\ /;N7] Q #TWC()[&85R- M/-6Y'TT##^Y5 2F59F+V+TUW4Q&3LM0S!M%W%/A"1+*NW\A4]Z]I0O-[S3;/ M+UJF>BZ1&UJ]C\NVSM#;M RAWB/ZE>(6&ZJ4AK_1.']?IFGUTDJ7](:P=,8* MD) -TR7N!&L3-(81M@8GIUQGP.K";;@], XBKX M* RK7/)N_DVV^.I_9&MJDIQPZ9Q^D=T!S" *K4"XQ'"K-^O&H>D4T'BG<)DD M95[N)MZ4KEC"W"AM\I_I;/E!OTMP":(XQ-'0=MGT"6A\WFTCY;M.C.=ZW:_- MZ^Y'"EBASZD3O#WB0@_W6W"'U,(;0(T;EL?C+-]&O2.E9 N4((74U\P[7KI: MZ3IQOOZSR5Q7A@]A#[A33I?& .WCAO;Q,[R5UO-. M(NV]V'W_V)THOJD^(=QSI7A>':ZIGB^%$=#W5YRKYQ/S5:+^"K7\#U!+ P04 M " !*@)Y:>AXJ][CL^Y=J[3K9!WJ@30Y+[BM9HYI=;-F>NJO(2*JHEHH,:5 ME9 5U3B4:U062I:S5D-"TE46U54/EP"%]N9 MXSN/$S=L76HSX69I0]=P"_I;LY X<@>6@E50*R9J(F$U=@!^-$>0- #@M<"PAX06J.=,FOKBFJ:I5)LB331R&8Z-C<6C6Y8;4[Q M5DM<98C3V5S4!9X)% 1[2G!64(V#6XT-'I961*S(-:MIG3/*R4(H9M-_W-:T M+1C&GI#C!9486H)F.>4GY ,Y>C<-D^B MCGFB/1JT1V_63EM="LG^X(TWXKO94=$==[PCR/>":3R=)M-GTL6O/PBCGZ! B1( !@ !X M;"]W;W)KW4-I!D MN^T"W39(=KL/11]HB;:%2*)+4G;R]QU2BB1+E#8/:5^LBV=&Y\R0.1;6^PY)8EVRC/;=9S0 MSDE:6*N%?G?'5PM6RBPMZ!U'HLQSPI]O:,:.2PM;+R_NT^U.JA?V:K$G6_I MY=?]'84H M1#2CL50A"%P.])9FF8H$./ZI@UK--Y5C]_XE^D=-'LBLB:"W+/N6)G*WM&86 M2NB&E)F\9\=?:4TH4/%BE@G]BXZUK6.AN!22Y;4S(,C3HKJ2ISH1'0>(8W9P M:P>W[^"/.'BU@Z>)5L@TK0]$DM6"LR/BRAJBJ1N=&^T-;-)"E?%!'B18P9':JE@>*?F-" MH+.R(&62@NLYND!?'SZ@LW?GZ!U*"_1EQTH!;F)A2P"L/FO'-;B;"IP[ LY# MGUDA=P+]#""34W\;B#9LW1>V-^YDP,^$7R(/OT>NXP8&/+>O=_,/.'1^,E%_HV GB?";1/A3T5?U "NV,& 4;Q/9*D*H(ZCF=%A%@;>P#UT. M0QOL.U%C=((M:+ %DT5JL=&GO9HJQH$(A(>[_1, M3^@!&OU>#]$I]E7(H)/W"Q?[LWYYS&:.9RY0U"".)A$_D(Q6C0F$Z)%^MU21 M 47H]J :C*)@9@8Z:X#.)H'^0@L82IF&2A)HYJF:VTK&)O'.AE""T U[@ U6 MT+Y).(O3 +>U\V N2&MD1:UZ'3JKLWINA(N',/P0 M]\$.K;#;L3J%ZK90W>_G=$UAL4B1)$_FNMH5WHGD?H]'.G8^T9]R**)Z4 MIE4ME0#0",\;?+8_) TF%_Y8G5M)P].:]CNLP3-(H!&4_\J<&>T\/Q@!UVH: MGM20%2R!88%;P J3%K$;HA(8_0RN!'T6B1V!!H$D9*GZU*2=0:3D55O=RQ+*(?] 6P$$I9EA'=< MS VO^ORL"]RY',C=B-G8K&T%#T\KWH_ MZ8TM,"0'D,DMK9#"-J^40L+*1,E\J?:#0 CZZK[4PM_)0LY*M2U4A"M7(TMW M*)\8)CR.ND.PWG,-3>=@&#K!B#2XK=:ZTUK[?Y$UR.\8V:'I"%F[LZG/*=_J MLPX!, %1M>-MWE;G*3?XZE8?._3>7^.K:WVZ8+=AJD,:V,]N5=O,Z 9".I<1 MP.+5N4?U(-E>'QVLF90LU[<[2F# *P/X?\.8?'E0'VA.GU;_ E!+ P04 M" !*@)Y:M1!Q*?8% V& & 'AL+W=O[[\1<[87\KE:,:?2PS@MU/5IIO;GT/)6NV)JJ MUV+#"OAF*>2::KB5]Y[:2$8SNVB=>\3W8V]->3&:7=EGG^7L2FQUS@OV62*U M7:^I?+QEN=A?C_#H\. +OU]I\\";76WH/;MC^MOFLX0[K_:2\34K%!<%DFQY M/;K!EW,R,0NLQ1^<[=71-3)4%D)\-SL(A09?ZG( ME?V+]I6M/T+I5FFQKA8#@C4ORD_Z4 7B: 'X<2\@U0+27A#V+ BJ!8$E6B*S MM-Y036=74NR1--;@S5S8V-C5P(87)HUW6L*W'-;IV5P4&22%90BNE,AY1C7< MW&GX@&QIA<02S:E:H7>0<87.M@7=9AQLSM$8?;M[@\Y>G:-7B!?HZTIL%2TR M=>5I0&;\>VF%XK9$07I0!.BC*/1*H;> )CM=[P&CFA8YT+HE@PX_4OD:!?@" M$9]$#CSSGU\>#L )ZB@'UE_0XZ\.9RN:?]TLE):PE?]VQ:ST&;I]FOJ^5!N: MLNL1%+!BFNO4I/!L:\J&%^<(FJJDFA?W95?BFC-UZ6(7O61&7\C92:3B M.E+Q8$;?,'":6C;G(( RIW$)P('XF+ RBR)QMH?R5Z"B/ M241:N>[:1($[SY,:_600_=N'C>EY"C*R*'_4;D_,'"GJ\H[$)E5.JH M5I5B4.AFO^:<+GC>7[>5^Q !X& 3NGEGY/:E=/PF# M-NRNV3B<^GVX&RW'PV+>@[L5=-A A2C&A_NC G-2"AV9P'[8IN0RF\1]E!K9 MQX-:6;6'T^Z06V)'N"TG:=X*S! 'VC^TLZ)NBG"[T3F,HKB'2J/+>%B8/QVF MDR4,F$^,*$[D7;4=XR2.IVWP#KL@C!/20Z"19CP9;M4'\.H(O>E-JH4>N3OU MH/(_NU._D+?36#2*CXULS".#A2: !?MP$EKR@, G2?*AR'/(//;F-VV$U229NV*09$\B@ M\IX6SU/[SX6^\M]J4.W"=UD1'/24#FF$G>!GEBEOIV%II@0R/"5\-1JUA;G9COCNO'4E/NQDS3$&Q'TY:Z8 ,CP% MN+;#MF-:UHWG?>P+I"GW4F08<1F.21'U=H)D&R/ T8%)REM5#CG!N9]B!'5]C!FP>YY49CM!?D;/ITA7=4/2!BU MV[/##(!7N-F_)$_2.5D"<%@^D2 M7/JO)Q!>61Y2ES=:;.PY[T)H+=;V&PO=V]R:W-H965T&ULO9M=DYLV%(;_BL;-M-F9;HS$I]-=SW1M/G+1)I--VHM.+PC(:R88 M.2"OL_^^ A/;"*$U.V=Z$QOO.<\1TBL)WL#-GI5?JS6E''W?Y$5U.UESOGT[ MG5;)FF[BZ@W;TD+\9<7*3\H_;S^4XFAZ MI*39AA95Q@I4TM7MY'?\-B)FG=!$_)71?77V'=6G\H6QK_7!N_1V8M0MHCE- M>(V(Q<VCVA[0G;-2UA>-?^B?1MK3%"RJSC;M,FB!9NL.'S&W]N..$O YD " M:1.(G. ,))AM@BDE$'<@P6H3++F"/9!@MPFV7&'HI)TVP9$2K*%S<-L$5TX8 MJN"U"5XSNH?A:,9R&?-X?E.R/2KK:$&KOS2":++%$&9%K=U[7HJ_9B*/SQ>L M2(42:8K$MXKE61IS<7#/Q8>0**\06Z'%.BX>:(6R MVOXY*N69[2LOH%^=]V M&7]"KW=%O$LSD7B%KM'G^R5Z_>H*O:KC/ZW9KHJ+M+J9]+].L$-,057535767>L#OJ3@5,:_B'&WC++T69Y'$VTS= M&/^9@1RJ&21Q3]#IG576EP$>7XY-=6=(B>4*\C(M*_%:O3W2U$BM5%SP5.CV* ME1S%2II*UD"E._J0%456/(CE*H^+1+19#,YAG*]0S-&2)F^0B7]%Q""F2G%: M?KU/O*VV<4)O)Z)[*EH^TLG\YY^P8_RFTN$!9C>P>H]XG,\K9K.I%TUYL_GG(\MS)"Y<]G&9_JL:" MRDD/"EI P M'Q(60,)"2%@$!.OHTC[JTM8N!'^*FX?!;?'.[JW_U\0U+5N:\-H28Q4$"?,A M8<%EO1%"UHR 8!UM.$=M.%IMO'_!E=2=T^\DT_ L23':PF,5 PGS(6$!)"Q4 M]*P]D_8N9>\31[UWN4<=N%H=O*NJ77.-(&Z46/?>X_SR5*4&+7CL1N7V3H[8 M,ZD'EI 5?4A8 D+(6$1$*PC+N\H+N^EXE()RNMI0+H566C+C5U:(&$^)"R MA(60L @(UE'3[*BFF59-)S=B4$&S_A(IWR8LM$7&:@@2YE_0^@"R8 @)BX!@ M'6E@XV0$&EIQ-,[>=>T#IV@;/S7FG]*T,WJ=C&>V=&.ZT!<;*Y*+:OJ@-0-0 M6@A*BZ!H7:F<><98*Q6_2#4FW!]Q>31*+*6"M/2QUSTM3;;A+-.1+WY Z_J@ MM "4%H+2(BA:5VTGTQ?K75]);1,^,4.-.=66=W#JTD M^G'7V"32+7"@"B..0PS)*@P5@8XGF7N1LBCV9J[ZM@:?3% \U@75N.WJ8= 6 M&#W1S?Z@&L2S7-O \H!!%O9!:0$H+02E15"TKN).+C#6FGG/^^YJE5G].U_7 M[/GN;5AGKHLEH2>=/LW$MH-->:[WX\1<-V;R7%>$$<\Q7=D74P3.#%N>ZP-% MA^;ZR>?$]O]HP&-(DV\!2EN"TGQ06@!*"T%I$12M*]"3V8KU;JO>B<<*9X^X MACN3UP!09Q64YH/2@@M[) 2M&D'1NB(Y.;%8;\6^R)+'?>/4P[W- ])17(+2 M?%!: $H+%9TK+HCE7:T?Y'@#KCP^.:?XQ=;I<[Z\GCQZ_^J[LAB;CBM?>("Z MJ:"T )06@M(B*%I79B=+%>L]U9$./>Y;E+)%WX9T+E1EK2B,3BQ?H$)ZDP$H M+02E15"T[C-I)^.4Z(W3"UQUTOT/0"N&H+0(BM95 MR,DO)7J_]%)KG?2M3.P:\G^_Z(N-%LHE-7W0F@$H+02E15"TKE3.GG =979J MK'5;J2#8!UP5-JI!/-OSY <1EZ"%?5!: $H+06D1%*TKMY/'2_0>K]Y;5TNL M_P0H\5Q37J04C[EBQY:==468B5VSY[8IXE0/NJK"!,R2C?]0U3S#E+:T2%W5 MPO+3KM.S]R_J-WY$'SYD185RNA*)QAM7S*#R\!+-X8"S;?-*QA?&.=LT7]6MK^:(KY# Q2( M !@ !X;"]W;W)KP!F0A#T#S (8T_5"J(+W5E_*N]90C-\\-#7RQ5+?W0-LK@D[EUM0QXZQ:' MOG%*EKRIK@['1T=GA[749N_\)3^[=>+ ,].#Q_V'?822EUK8S7U@BGYJ_V)J/G%R>TGA=\T&KE M>Z\%63*S]C.]N2E?[1V10JI212 )$O_NU*6J*A($-?Y(,O>Z(VEC_W66?LVV MPY:9].K25A]U&9:O]I[MB5+-95N%MW;UFTKVG)*\PE:>_XI57'N,$XO6!UNG MS7A?:Q/_RR_)#[T-SXX>V#!.&\:L=SR(M7PM@SQ_Z>Q*.%H-:?2"3>7=4$X; M"LHT.'RJL2^2>[Y5&&//>-+-2K/:2 5^Y.[9W__-/H[.C%(]J> M=-J>/";]6[%X?//?;5!B]%STA(@;4UC76">#*H4V\.K16+2(E1,!RRJY\L+. MQ;63IE #\?KB@WBGBJ6QE5V0JZ;#R5#L__S3L_'XZ,77G_+CT0MAH["T*AV= M/GPBM!=2%%!6%[(Z\ &)+GRC"BVKL!8S;9NE1'(5J@VT0A1)];D%^*$U$K=8 M2K.@$-(Q@6(:6BB%L7@C0E9W+9I*!J(P@4,J MR/V@I?^LS;#O+U)Z]/2%%U$JJR1DTS@KBR590NG/*JE&%VV01MG6?Z5)=M?5 M[KB2!G#"X]720MD#NS+8Z-N9UZ66CI CG0+09%MJ MDDGKEQ+VS)0R\(1J\#DC4B)!74GP ^^%I5@H S=&#Q2JX&SY@2JKZSO?OA].A^'4RN>U@2!J03DWT0CR0-!!Y>QNPG?G?LB+@-RX M[D>BM&5<6"+N_VBE@Q%PYUL%'@!$EK9%_LR4H I.ZR#V4VMBB>00A(B-;YS% M#BV2=R@VR .2U&U9=;@?F9-C&DA*&F#(ZFTBM'1P=]P#.5EI\+TZI(^GR#F ME1BEDB#V>U2S+2R'>O@8N#L#"-$;NQKK=>P1&.JO5:'J&4@R5:(3L<('8$VD M)-SA;,T:]D+T#6?-V@"S4^% MTY$M^[F1ZQO!O 3/L#M3&+8\]5_(9.B2\LS%D(MV".[@1 7?('OO^6PH+I6# M%@8ZQ-Z1'0S8S*T-A)8MZPTM(7%]!#V$\@?IH_-;+]DV4$"ELK4.H1=$KV*: MZWKG84/QFUVAKKA!6OPCZ=@/M"P_H9?CYP/>JCU[V!J8#,A%\X&!HG5<#;8V MK)8:!0A&#W) JM6.S;/A M#?[:DE&QTQUY&P&+,) /T1RM$J#A6@6I>24.!\.H+ZCS[)W4(LQ;>&*.H$/H M6DDG%';#UJ^QK)GV"=S6)Y\3BE'9:R.]0." ML%M16"LM9[I"VK%(B.DG!-9!30()T57H?L9)KV7TEN;U" MZU@K7D%QA$ P8.MR&];#3%?TJ#OR7/8Z3\4RT7,6HH.Z%*QCJB')*(V4OK0P M11N%U;KD21V I$HC!3.J4+>\-7)6J5XG6VA7M#4L@RB_K96ZDU7+NGQ3,PGH MF(7E9HS:IB@(ZK2]+*@E6DV- +L^B71RA^+W).B@)VG0R]*'-!I0>U/'M$)[ MZ,G4BF,7['.Q/WI"*B!KP 1!?@%?*Y0?[-H?/]DRA-OF1!/QI)03C@94>D%X MCH#BW!B_P(A/J0-M*W@7++-_C,X=_M,N%TO>?&#G!YO-/?WBONA4:G3!_.L! M]=P$78(0LJF)%+5_0H84Z,]=Q/'ZH7PU*M!\K1R1/9G<2X)\],9 L*Q=Q3EF M__1[/%+;DD8$2\52.?1CD22)-7E5Q.2=BD1-::434N9HHT"&!W$(R7^_M/M':IN*KM65,&,FA-,[*S2"SX#$/N5 MD75I8:TSB;[^C%V5\YNW/NK'15)>W)'33*15 7\>B8 M(%N/>H[GG60)8SWRC*STOSM ]N))[O/SV%+31WV22Y%+)1+-B8M\/*-1!Y5H M.]^7DBMORZCI =OZ#%"C%K%B%=(OQ1RP\3&5TVJ*<6QJZ$^SZ5 M0-7'EBT8WX&H3$).]AL35_)S5PH;]#_X&/94$MWWDBD7OIAKYT,G;N>0P[-% M_."JI5P#V[RG9@#-P3R.JVA3AV(:38B-2#1CL!5=\M2&.',Q*OLUT]0ZY>\ET-<28=8O*X<@GJ/3C M;8V8T%?$.*"ZX.""6''4''XCKJ/6 4J6F#A%D=K+?+E 7ELX6:>44F8A%WF@ M<&K1 H86C9%L0:XN(@M*R/*.%4X#L[B%.]O0<5!T9Q1.7<_#(=F.Q5#NKO*-O(\7>,G$H6L2QTOB4L_&7TRXFHD7ZY::[T/,2-F.@(-YW9F,%[0\GU MZPF5,@KCAYMW5]/IE;A%H)4XWNSPH2W77*CB=/4T=UU]5<'1BN>=A4/J1/M5 MZ:-RX]/A::<>3=W'9RHQF,;4F^8^"/NOL%'/6&L3X^WN7,3=N1 MNAH?R8=Y@EY0?@%FL2L#3_AV/J?1"VI3)]^:>YF)/MV*O])E$(X[0TU L';/ MW+V&:RD3JR(!4C8ZT$[;=>R& M$9,Y1%*IG-&]1R+Y1!M8G[,AT0R>E&H6MI0HZ)YF9KL(8B=]-4"CTL(IE2:E M7AO9QN'"-JEH?EQB(F84;24;,78NB6AYF#QWNO'^=<& +ZE\XI%[CDA4D7P! ML(*M^$KH$P\'%KYTG]'C]%J+R.W4<\ %/(GAY5#TK[&=-7A=I$K^ELT!?4]* MR[=EJ%,X;%/@C4TFT[ &I&]?J!%;E\ Q3D[[[_7X:?A<2B*?//9S8]MVJH+.H#_C]O-]HU'G;1XR-RW 8UY..E+) M7R-@V5>@^&YT11(>QTRYGDPO\H[)]#U_=#F/\\HZEMPT\FX6\0VU]G*!#%ND+Q%Z=SDSVX:=\5<\_U*+18=RAT0M M/P( ILD7;;EYZ(LDQNZTA2J80-*0V5,J*1H=Q2TJQD(4:HR)S/E\UT[?,; & M:?[J[A4C'W#*8LN:)DRGPF9#AYE:# M;H07VABF)A1MMP')Z#3?C?7;2=V5J*H;5W,.)G!SP2N3ZEP DT)L/F=$+G;? M-?3G\6D+#S=4=>\Z.)\\".>3@Z/C#L[=6"$.TOUBG$V 9K4DAH9N&13/ M#O-7\6J! )Y!1A:^WH8I1HQ6QUN^!T#:8]_[".6OFU!-\T4&DCZHA75;LT6( M[>!NCX7N5HP;AGB9ZCIC(U'Z_R>@_F\ /4N%J'\_Z%DSOI3] 4E/_SRH)^#] MJ9#_G5N%AVO/IHZF#.!>Q:(!V/2(G"!TM4BDH"Q ML9-.!QGF7H'O\_)UZ_?5OETT_.V+@+8A&"8MAKN^PC[L_;2@5F[!/Z @GT/E M^"N#[FGW&XU)_&G"9GG\@0<:Y 5U0)6:8^O1\.GI7KQ6RF^";?B'"C,;@JWY MY5))C(2T )_3%P?Y#1W0_7+E_#]02P,$% @ 2H">6HG0] "!(T79ZTIWM3O,E ML202P'M_W@OY\MY4G^Q:J5I\SK/"_K"SKNORQ<&!3=8JEW9L2E7 +TM3Y;*& MC]7JP):5DBG=E&<'L\GDY""7NMAY]9*^NZY>O31-G>E"75?"-GDNJ\VYRLS] M#SO3'?_%1[U:U_C%P:N7I5RI&U7_7%Y7\.D@K)+J7!56FT)4:OG#SGSZXOP( MKZ<+?M'JWD9_"Z1D8DL;7)W#6LAG\0J70W'$X7*)2;NH)?-=Q7O[K1JT(O=2*+6ES>J:*V0A:IN*UD824Q MSKX\J&$CO/P@<8N>\Z*S!Q8]%%>FJ-=67!:I2KOW'\ !PREG_I3GLT<7O)+5 M6!Q.1V(VF1T_LMYAH/J0UCO\?7]WZ8GD[-'J#H*5!T]MOJ_ M*\O'%_W)U$K,7H@O6%QO-Z+L!3B5^TM)]T =*315/35_AS#7ZKSG$ON+'DWV26J6JU M$7!ULM99"D>!ZYL*EYQ.Q4;)BI0!7-2X<[;99$2+7IB\E,4&7%2BP,.D<"+\ M*E/ N(_*EL 9)=ZKNE:5V/W^;\]FL\G9Q?O\BM4+'VK M2-WFN8'%KTP*E@ 77\L:@J3=&X'(K]<0&\045$R# <#)UDIF]1HT/(4 (>Y, MUA2U4I4="W>4(4:VM$GD3VDL_ E_U 9#0T_);V[IK#J@PK60:7 M:5CE]?DOJ-+3TS/K; KTH"EK^0GO"^S$A37HQ:X>J_%(T"TG9Y?_\?/\/7)M MCMRR;J&1H._WQN)#*^GIT<@Q#BZ7>,>=3M3!NX(1"A[^HU.=C(QN%)CF5,JY MD5;X1!1P''XJ[\$V1@*X:_'BH@9ICMCT))HH2R#WS/164B)3 0W< LET+G4%IT-^.WGC3[AN"B&<1,NGO4-4@Y@J6JH1L#OT +%,VE6W8I;3TMN2V# ,R/!?Q0+J M;V4:.6;T/64&\H!5(0K .N#^0(GUG:DQ(I!Y'.(EB5J8?>!)78&YPIUJB6$E MV3C30?+E-H>=IV-&[^:_7.]U/+;S(1IL##$'7J=)#*;$D -:,19O@GOP;DI] M3M:R6($ZD@H["EN%@5."K'+VQ&@&,H,PB'[.7^[X&C0?H4&M5AM2V1M5UBR( M4]+965<6W:CFF.;,]9=WMYM9SD,K&33=)X-&-'A@T1BCL2^.'61BT[: M#76]L\VFCQ\.2 _^G;PY*0%PN")E27S07QL(5&QR<2"!R%)#<@":9X%W O!X M3NBA)9+.T^KLX5.\#VQQ@ 04%C*@/,[>Y%PKF&%<4YKGAY_>[VPS5S=PZ.(Q.(IF#E MP^[*+E5C+E8M1(,#K^\A2@W@J5CCINS#IV>@H@XL =_E$ND:L*-B ",XK]JW MI>M*[2.R>0H1A!L 4 .W9W=HF292U 2<" MMS!%%>!+2@,^A7Q>@$_N&.#K9)IJM%C0MN#%>%.2L[9HCV)5F:9L81C>KRL, M\>W=+@23_P=NR&9%083\#LTJ;# MA]0I@DHAS 0S!T.I[PVMSG;;GM4%\I&X^'#UYL/'6W$1?!!B>O?EK4G3C% / MG.64>7P4<7W2.I4'O9AFQ?++K2&@+A2&I6(%>D/& GC3 MH.ZGX-K,"D*UU7"_1X^')"#1R[O6(3(@ 4> T?_G-$(6/+$=6QAH5T8/8X^X,/ MC?Q=4Z:4I7HG,(@\G/_NYK4HQ,L&X#IDB "#29!R!>&#-&[5Z%2BT$+"$X$I M+$S!:6J'O+S/;0#$\"GFX)D0U^-V<\H V_SZZ:-Z=2!8,"CV<<]!;Z5;("YR MH8,'@0 &(7B#F"R740AIL#?7CQ@]I&ECT+2YJ'+ M0@%5BJH%[>E&P0>YT[ U0#Q35#$M,#"Z!<'W9$T0"$.@01G?.Y!%5G&=+H,XY@6[7.%?*O2RN1>D\5E:JAI %0(WHZRJTI %2) M1K$S$!^R=N#"MANROCJ3CA^ G$L$?&33[/C7_6PB>(-[=)]T?A?N\21@@6N3 M&H@!Y,&W!!\2'W0XI$Y)&%QPFRQQGON&S$2F8Q99K[33-I3C5!=K;;HV5T21KD[BMG[C;'XE?T/Z ]Z?G0Z]V M'+5ZJCL PX.? M'P[H3P017Z% Y8TR%'8:3D_(H%X(/1;7/F(&H$O..@*G%.GC*E")%0S3V&P3 M^2 ?VGU6>X.".>.B FPS'\;$7J730>5_&.PP,:U*/Z&2<1[J,=U3" Y4+EDC MFD=CSH.T/7I^D/L/9U?;X7M8OL@SV.*3\M3V4VP/#[89UG?GSM0AW+&+?,H% M4:T0A+0!#?\BC]<%&9WD"_&/K?8L=]GPA9FP2^I2N$ P%,1 M1%J+40XOZ<8]%X&#=VU#Q*#01KP<\Q7+7ZEI%IG:7X [ ZL>*'XMC8%5UQB# M"D@5=U^?7U^\N=AS"S76U>8DB (<<0W^A"+F8/;J2JJ9N0>N+T *J3__\^/O MQ,4[\?VJ/A/3X^_V@&!<.]B#,TJ& K1SH8(K:*W'<9$4(_"4>@^VS=ZZZO"% M25W('1_-6WQQJUY#1KU:8Y%KOY/<1:@Z)"8SEYF0=;L& )>0CQ\W;8S%O[I: MQ<=0J_A09)N'"A;4P7@MWOWT>J!FH6*-?+!^R$5_H#WPUS$!T)"A_F/K:PGY MQ4RIY3X>(@\0W99@.&BM#"%E!8:@K( U6-.7QRR=ZHXVR^0*2L M:08T%G2_PC.TM9&B6Z1WE]:A6D^LX8KW;?^ZIM:(W+?*)UMW;45F6 ;IW&.4:@]@H2FD1#P!!S "K)AHYQ>>4R2G>?2P3Q M1CCA4,8=@3TL.;?V& $H]LFK4$:FC-9UBD VH8K9DP\Z+-3D;G4'H?Q6\Z#? M^X[[)O[P+4FLM4!K\&"@P<1E.IUG#=&^;'+7$M=HNWEY=CQP5'(5E M*U-.-CC!9E_#A3K'4E\Q\K*@[5UBBXQ<*P8AD!95.+L B7C0(QGK$=?)77/? MMQ@[F@@?4!FZS1!'/OW_&O#<]-E$9*#L*&O3U!"T"T)8<*8&DT?.0 AS"P@, M$J"!75/#J@KM:IP-@0B_0+A\->^)EY4*OP>&@(E3-1LM]DK^$WCY@0R6,V\< MRN*P[4Y6A/:[EV:F05BR,_&"KI(-2'V6J'4LXY"M5^!,[D*YAO$20\U;]3#VZ6.,QB"95O*^"'KW55;M[)GZJ60W8%8049B!7HPDM8K:I-8K MQ9<6%>-&F27#Q8$9(:E![2KV5YSD%W[(PV=VO0+=:81P@5;6[EXMI2T&<8') M,^BA@N 8&RJ4D/DCF47-&L*:?(^1F- E$%17F[@XRM,,WF)J]AQ^3*5?P72P MOD\.40-K:FJ2DIM#&(2ZZ]!S'??6W:&]MB-KG2ML/2?AP %F1XB_GW@^7@5G M_9!M@=A'\7#;T9"01FY.!W/^6M<-]KX+DD@O@]_FBA=R1QUZLTFNFXV@W4N_ MRR8X-H(H7\,OP%WTP?,7U();6+HE!' 3L+Q7KVZOFB#AUI:(73!A67*PU#FZ M!IH>^]FY8/2"[1#)0E%W '!/T4\B./TB.(1(DP"1=PG@X L6-T$\R\O*.ZDS M\*UJ"ZD@"0&:SONLB/JODZ>R ^JTSKW7[/<>@[MTJ75;$UL89'*+*ZL<8OT: MDK8T+AFU%["'M:ZE.IV)G(>-*ECCM8UT.ZWUOG'A^0=Z)2K_0AN02>C=C M3V*HM$%BJ0B%NPPW#7PX#X@]J@]A?4#%?>EYNT*4S8+P2\Q9&7BG*DFJL:-RB*_&JM<40+ V216L)]@[TL 3[C6CX!' MD$ZGRQZLP1UHV'DMN]5Z?<$[L/EN[XV#)T:"GOY28=$S7VRB- MD[$U"A[WP52WUO^BDI[7>;R(5PH%C06*/ %W%V*;NX+LG%6VTJL5Q2[.6Q)A M-WE9F]Q2 0(/Q!:",QF):RK@:L PL$C")1KP W'7NAH*CN983.R ),=/<"H; ML4+7"-+WD)%UVT?/P7FJ7@K[X*Q%:('IO.<>V[2>NN3;::Z]B*J%0'T#_)_G0'5""1H<>47-N3GS;P0RK-409J%W\;9_@VSO#7&&>@9:.B7XD/ M7!%SPVPZHT^7F%!11^8ZHXE$_?7S$",_XY#@<'@@@<8*&&2H$HMWD=C7&G8! M#[[AZ6?.,X0A-K%XO6+8;],6WZ8MODU;_&FG+;8&#+Y-67R;LOBS35D\6=>, M"]7_EP\C[3_Z*%*LU:E:4CDMVEW:?FO4HTC.ZJ-'(_E1_S:2:I_\P,WNX39( MU+D\SS[O(S?6S@U$ ;'[[N/YWL$EA([NE(J<7ZCSO_ M_L3+6-P$C(U_\M.%(OR#YW).MK? M/_T=0UC?9K!Z/<1O@UC?!K&^9A#KC2X@N<$%6],Z?=RT@/_A)C@V))NPZM\/ M)R?CYP)2Z(S8 @IZ>')T-GMV-#[VW^Y1#4:F//TQ4*RC=PL(WY8?*%;\/+X9 MQ_".":<:1+?BT)[0P3R+>FXM3\&HE"+@WZ?@]X^WSCR=GHP/PYE;#VM\-R_P M!X_DR)\^FXZ/MI3:>M4NA*8?Z9M2#ZAV-_$8N-VQ(;GWK4H)A[[-V;Q6@Q_+[/3FR3==3\=4, MULL67_ECB9)?@(-G,%R$BDG@,\S/;^;B5T_5KL=Q"WSGTU[P:VY)JIIX#Z"I MVUQR,H#.@7:@82G(J,%]\&%DE6F.];MZKR/%4Q+BKH:O#R>PP,9&KP$A&\.V MF!NM<-6TT+]=4FD)43T.-4D;AI#X9N?]_9.+GM,,/0T:H!G0Z9$:^; PT8GSI='3>AY:6 UZ<:OJOPC2>X MLV\GBXJK_S6_O@F[1+YOY)QPJ(DM3+0!!2 [8B'$Q_&Y:]@;BSHIEP5G^U9S MK@?)8NJ. G@.L_7PEIQWH;GID^S'3C[RJO#0,7*<[8-CA&Z)]%[?HPF?Y+4% MW]V!1,^?W25\?F[N,:8"(<\FQRXOW,7+_7A:9#H0EIS1\5NG//5L9,$B<48- MF\#3O8[A,9=7VKTB"!&\*TA5^&HR%\-XL) JDSAW15IH%;[0:;._Q'MWI^/3 MX][*-VM9L6:@O=#HV%)X%SD^?G[X'-U$YYZ^&V=D$KJT.O=E\U1GC7<\L]GX MZ#LW@95+#(-9YW?VU:>'X]/O:![D,V;J:!9X/B88W _I5V&*?;H5_9 $Z>\- M>F!G>!]0=%0$C3TR_KILLJQ/BZLU8@QZP7(\.<-Y1SR%2&2I:WH%$/6T%>%, M@^BO4J0?%#R<)$IN#J%\T ?1&\$X[\.WB!AJ&]*KJBJ+_1TW4$4/A&/_-2?G MD<"^8*! -8M++_413)Z)'4]JO%5+M:TC(S[,QXFHX>/^8@#!SB9<.(R/-+: M'?KS'^Y6ETCM[$4Y7C_*%$[!H(MN@^WH?!U9;YO/='IXTII/B&:LZ\?/1R?' MIZ/CR6F,-UH.C&*M[H;A0(A3@_:,/2W?)C3PBTO%7L6]7%2 >!*UR9G.'Z6^ M<,/I% 1]#)2? A "!-[S.LWO^Z?W^S#?R$Z_!O:=]IBW=\EI'9W<#1+U^)H M+YO 9>2'UQ)\*3TW@';?4%W35:B9A8AU %"30D:+=BV!?'2E]MT"3F>[KAPI MQ.O8_?2TF67[AO(4G I[PPL%A=YS]>W@$MT=YS?Q-4.APU7UMT_GI+5SPQ<, M[NKH#@Q$KUAGRG8B5Y](#$S>\ ?)]#L"&[T"XV"L!X/&XTJ.(JV.#5I6;%@/ M\F_0DMS5T2FB1&,Z.QK-P*J?/7_V]+X/LW!PXVWZ1P.^:C"R^]>0/$!HU[GU MO,07.T6*LMAY#L+9]7?%5U!$X9A;J+I-JT+5@,7H5"!X3?S0&E*?\H 5$FG7 M/*V ?V"9 V('5LY& :9BC0VR[\:V#?AV%-G5(+U6 7[DQ*3T@ZH8K5!=\76T MO"$# MS3QUR G:7A$<*FPK?\!?AL',Y0OI4"AV[@'/&[Y1SE_=X(=QA''@%W M5P([Q>& \$1-?YZCS6LQ;9?82-G5=UO+X(M_M6_:2%^X&'XQ"UR.^?Y =D^@ M&Z%Y"&*=28S>SXP%,&ML %)W<' 'RP7]\%HT8B^,U2KRQ/SL :E@VZT%HVG< M$PWSA'@[?7YXR"/5.?6C6+\QG^>5..2A/Z\@)\Y"]M8=HE*?<42@ \;PD1_? M^.H^"$$3C"Q;#E?\_!/2#.3F')4"?9U;7:6.BK_=$EQW9FBI,T45PL%M@]%& M[* Q,/>&O.BYJL#&MBAMP8+"S.+ODRT)(MOXGUM@CC:>4I$O>C+*2Q8(E9^X M.D0E0GIBA:[H>(ROKQ%UG8X'I(_X'1ZE]WDN8A?_,E93NA*+';FJ(B4ZL"S+ MUW;K=3@XEI,FQ3,V46UX(3-_'G)EW\N\/-OR:B1ZS%WQ*.T1F'%^8OYD+-ZK M%0_C(>> LW;HA<0'T8NF&/WG%]4W5[.K_N^DM5* MPSDRM81;)Q#:=S@/\A]J4])KJQ>FKDU.?Z[!^:@*+X#?EP8\EON &X3WF+_Z M'U!+ P04 " !*@)Y:Q8JWHG4" #[!0 & 'AL+W=O(_TM5D8MXM[EI)+5)9K!0:K670YF,R'/CX$ M?..XL3LV^$R66C_ZS>=R%B5>$ HLR#,PMSSC%0KAB9R,IXXSZJ_TP%U[R_XQ MY.YR63*+5UI\YR75L^@\@A(KMA9TIS>?L,MGY/D*+6SXPJ:-S/MM'FJ$2@O7O5RM@-A2H.UZF/]&('=<;,'!P!TPLZ K<(4LZKZ2(?(:"Y1+ M-%OOO)AG$*6G@Q'X]:U>^'QT7DZ2"_Z]4$3$X<%&FRT(2R! MJY"-)48HPZG37G'%5,$=2:,M#Y/DM81]18YW&E*B686Q8Z'0:T5M;_;>?K)= MM@W]-[P=B^Y55EQ9$%@Y:')Z-HK M*.FW9!N0GLO-;EA$_$7^ , #() 9 >&PO=V]R M:W-H965T,RF$^][%;/ MIZJU@DN\U6#:IF'Z:8E"[6=!$AP$=WQ36R>(YM,MV^ ]VD_;6TV[Z(A2\@:E MX4J"QFH6+)+),G?Z7N$SQ[TY68.+9*W4%[?YHYP%L2.$ @OK$!C][7"%0C@@ MHO&UQPR.+IWAZ?J _IN/G6)9,X,K)?[BI:UGP3B $BO6"GNG]K]C'\_0X15* M&/\+^TXW2P,H6F-5TQL3@X;+[I\]]GDX,1C'/S!(>X/4\^X<>9;OF&7SJ59[ MT$Z;T-S"A^JMB1R7KBCW5M,I)SL[_VAKU+!JM49I86$,6C.-+"&[\ZCH498= M2OH#E S>*VEK [_*$LMO[2-B=*25'F@MTXN [YD>0):$D,;I\ )>=@PS\WC9 M_P@3_EZLC=74%_^N$A:+;9BR6H"H@!:B4H&O+Y68"5)*B/M8$ MWF&!S9H@>DD.=Y0&KV/9(Q0:2VXA#V^2:\C"FW'<>_2'@O'&P"B,DR&IY,,4 M;C5N&2\!'^FY,6C(9GP]A"0R M1;@>9G %B_)?>@L:7RI9]F4KGH#:5QK!_ .'545/'23C'%9"F9_F\J*P7S1!H<>(EPZ!MMS<2A+N=( MGV,:?MNNK_-!3"^D$-VX^!Z#B'A75. =IQI"Q4U!G?-$FK06!+/GMO8ZSHRU M5&K-+4QOTP^O:=.F6\J U;!ZW@P/K#O MO*F7UX5IQYT8:"Z>B(+P5,C687]>/+@D[6F\N7\GTLB;=:L-^K8A#D['ULQ" M31IK1)>FKRVZ! Z^OX#.7:$:\FC(S;-C N+2M-J7ZZ =GCH7N*$(79^:@I-O M7O'"UXHFI>O*"BFCYU[)Z&2.-:@W?EJ[5XFRU(VTH_3X0;#HYN"S>O' ]#$!W$[K;6+7U4W&M+,U8OZSIHP:U4Z#S2M'KV6^<@^-GTOP_ M4$L#!!0 ( $J GEKA>(AJK00 &D* 9 >&PO=V]R:W-H965TA+T'0KAF$?&(FV MB4JB1E)QLE^_YRC921LGVP>;I'CWW'/'NR-/MMI\MQLI'=W656-/1QOGVN/9 MS!8;60L[U:ULL+/2IA8.2[.>V=9(47JENII%09#-:J&:T?+$?[LTRQ/=N4HU M\M*0[>I:F+MS6>GMZ2@<[3Y\4>N-XP^SY4DKUO)*NM_:2X/5;(]2JEHV5NF& MC%R=CL["X_.$Y;W [TIN[8,YL2?76G_GQ:_EZ2A@0K*2A6,$@>%&7LBJ8B#0 M^'O '.U-LN+#^0[]O?<=OEP+*R]T]4V5;G,ZFH^HE"O15>Z+WOXB!W]2QBMT M9?T_;7O9:#&BHK-.UX,R&-2JZ4=Q.\3A@<(\>$(A&A0BS[LWY%F^%4XL3XS> MDF%IH/'$N^JU04XU?"A7SF!70<\M/TBX1(5NG$& [,G, 92W9L4 <-X#1$\ MQ/01RAM+[YI2EC_JST!FSRC:,3J/G@7\*,R4XG!"41"ES^#%>P]CCQ<_Z:&U M4M);98M*V\Y(^O/LVGIW_SKD;H^6'$;C&CFVK2CDZ0A%8*6YD:/EJQ=A%KQY MAFNRYYH\A_Y_3N-9@,/T/FDG*3VFG]#I?>H.>QV.$]# M;B/I0M>M:.Y>O9A'8?[&$CJ"$4XUZU[%#AMDN )(KZ@#CK \PV$6F_UIDFA* M>BL+65\#>OB:3$@8+[_2%7J$/?Y9ZY$&?9&BHG?6"3CV&10-U*T$Z:_:8><_ MMB\Z8^ BM=KXSA!.@C"E/./)(J1Y&%"4T3S.Z \I#$7X'J4+2ED@AB26442Y M'^>]3,R++.\_Y@G_QT&_BG/Z"@I2K!R())/%@C=XS"F=A%%."QYAK6?WQ'', M)VD<4IB V"3+<_S'\SDE"TP2F. L/Z9WJY7DDT7D2^2[[AI_3$C>F2DP:AN1%5)QFF9U$I<:TJY92TE$_" $3B&+,H3BB;+'!& M"!@F:3@0*7X*\5'F368P<90'"YXF<_[G7YJ,Z8-NUJ\1H/JA16\OFR0(?L;X M*0QEB.\<6< 31/";;[NR)'&#I%Q+7!1\%>V3DSSFT1T.R8XIGX)P, T2S! Z MS*+'"+O(D>'\2:=!1B]9=($A98V7O>)+/M==<-^@>,O>?R%O>FE1,J M1%5TE? 6K*^G>XJ%MKY@^&M/5Z $"B^L;X;R.^@17VC$78S)O^8VP)>3LE,D M_[UU:OOS!)QJ/!BJW^I*E=Z$KQ!.+^8P5#7V?9D6\,O(#5^_-R"GK:6M>%R; MOAP__]@0]M9G=*0: ,DQ14C6=)[1)[PSV '5>%ND$+W"<1[S#M@ZTQ5H2PPV M[!V%G#1CNNK:MO)T426%L!M:H5W L?YITK\2^D [_:A)D;(/>@S&/KB04KH\ MU*?8L\/N7K#M5JC2HXB:DP7X35%UY7VD:YA%>]V%]W$AW4=M[XSEUND1'M%? M9)2B[@Y=,K,'UW\MS=H_GB9]N\!:4A@6PO]*X;(8%&]B_+I?_ E!+ P04 M" !*@)Y:/I]3OY4# "K" &0 'AL+W=OK53^JNI$2WL&R'-.JJM;9=Q;(H:&V;&JD5) M,Y72#;/DZFUL6HVL]*!&Q,ED,HL;QF6T6?FQ>[U9J@^F:ANG#'0JU M6T?3Z#CPF6]KZP;BS:IE6_R"]M?V7I,7#RPE;U :KB1HK-;1[71YE[EX'_ ; MQYTYL<%EDBOUU3D_E^MHX@2AP,(Z!D9_C_@6A7!$)..OGC,:EG3 4_O(_J// MG7+)F<&W2OS.2UNOHT4$)5:L$_:SVOV$?3XWCJ]0POA?V(78=!Y!T1FKFAY, M"AHNPS_;]_MP EA,G@$D/2#QNL-"7N4[9MEFI=4.M(LF-F?X5#V:Q''I#N6+ MU33+"69=<)?S ]!C2Z0B227)SA2\=TDX]7_H,WUG" MMT6A.R8,_'&;&ZNI4/Z\E')@S"XSNLNS-"TK7-&; M#7JS:^S_^9BNLWY4%F&VA'_##K/Q]-O X+9'E\N"W@6#)>0'^&&:$*#A0OC+ M9T!50*=8U,,QCJ!039XTC,417@E06_ E1 .$:'XBZ,2"4W)( 0DFB M1S@@T] S(.T)98",$JA(%!-."U?ED0O+,6U1*4'/G\O"!J'A$>1_ MHV=7'B1.0)4]%I[9(]72;,2"5?79I]4);R_'_H]TTK MU &17G#!:)?.0K+1(LO@Y8M%,DW>]-Y\E+Q^&@O> ]N?X=(T&2*RV/5$1,%F2@-C3M:]85*Z=J[] M&W"L?^3&EUZC^*2!-*BWODT: M\%I=YQ"PS?)YM_ %!+ P04 " !*@)Y:MRL%^*T" "T!0 M&0 'AL+W=O+H<>O_&X;O$G3M8@U>R,N;>;Z[R>1#YA%!A1IX@ M^+7%"U3*@SB-ASTSZ*[T@8?K9_JG1CMK60F'%T;]D#D5\R -(,>UJ!7=FMUG MW.L9>5YFE&N>L&M]!Y, LMJ1*??!G$$I=?L6C_OO*N$!8+HW*T[BW@0RWI:182 MD[T]S/:494M)7J$,X-IH*AQ(-.YJ#A#5Z322:[[V1>-C+ABR&$G^IOF&FKA(9S@/N M"(=VB\'B]"0>1V='_#%7EV+K>2?QZ0FDP<);UTE/;2 M<0KK6JDG$#7CK/R->8^O7KG,RI4',KX2,O]05V!L+C4/EE:+XT:B @2;+6R% MJO$@W:@?1_V72A0>=%*)=M/,"\<*:DUM4W6GW4@Z;SOQKWL[S_CK;:1VH'#- MH5%_,@K MC.BW9"IFKY<&>(N;Y8%CU6TWH'M:\.EVV_\!=V@7OP!4$L#!!0 M ( $J GEISOD[&B00 !(* 9 >&PO=V]R:W-H965T?PS(WD[*#TH\D +'LJ.E"1^U$0#/R""^DM9F[N7B]FJK*YD'"OF:F*@NOG%>3J M,/="[SCQ(':9I0E_,2OY#M9@OY7W&K_\$TLJ"I!&*,DT;.?>,IRL>F3O#'X7 M<#!G8T:>;)1ZI(_?TKD7D"#((;'$P/&UAVO(CX_LOSC? MT9<--W"M\C]$:K.Y-_)8"EM>Y?9!'7Z%QI\^\24J-^[)#K5M+_984AFKB@:, M"@HAZS=_:N)P!A@%[P"B!A YW?5"3N4-MWPQT^K -%DC&PV3+;7F<@=N_.=R8ZS& M$OGK+>=K[M[;W-0V$U/R!.8>]H4!O0=O[-9W+V9JE8DE&5&B:D6W"/ M-*0Q43(5-3M%HP#,D4O@GN<5=TX?LW+G+##.AFVU*G 2TY@*D^2*Z@")77F$ M$8DA!'(;E8N4D]BMD%PF K-M+$[4)2-DDE=I#2;$4LH*+1Z@5-IVV;73[)BK M8H/A0"D8:']]YZ.,R=DLGA-(BZZ@2VA!8IW0%[ ;H:*4S\B695%KT)WU="&?II\2A M6%[7GS D::MR/.'-!&N8.N?\0/A!*V7P ;=*-WW%BW**';O'&T+I=F,L@E8\ MBC#4_3!N4T&P5C@>XW?4'[39FN?8#S4,;Q*/]1Y$H) PT1&"IBT$'3>K&L!3 M/$4%;?9T'7"H\1C3T<*8Q<%QL8#R'$;(\%59*OVS ";8\AB>NL=:310=P3 ( MW7O<'[7?VOK]LW.Z +USMQ&#A)6T]9%]FCU=>);U.?]B7M^6,*([@;'/88O0 MH#OL>TS7-Y#ZPZK2G?H;9?$.X8897MI DP'^WRKL^>:#%CA= Q?_ E!+ P04 M " !*@)Y:5<,XECFU=893W3HI%%X;L&U=3QN^Q$_HOC37AF9QSU*(&I456H'!:,^J/],#M\8;]3?"= M?,FXQ0LMOXG"5;-H'$&!)6^EN]&KM[CV9^3Y/DM/!RR-2A[W4X3'V_U_%4?A^<5?:(9Q-X $W M?*X02BVI(&D-',\D+79E*?X@.-K.'P"X!5T"W4U>]9<#7!7P"G.L,S2;U>%D MU^H?"[AHC4'E=HX8,T@8@RNMGN=[#5Z,!S!.Q_!9.RYWP:<)G-'/.Y97G-8M M"+7KA$'O2.>XGPBQ^[VB/BZ40\H 1YY)[@CH-&#=2'V'"!DJ+(6SS\+]M8I2H/!9 M0,<4PN:ZI3 <(E_DCKP6%((EM7L;&"05&.FA.%(OI)0LGJ]/@$9RLGF2I.SI MO8-AUF4 %2,5HK(R!!RP+*E30WH&"0P3'^2=3 H)P,)=?RQA50G:W*3*AM_O ML_MMM95-'KXQ\^-]%1MO-=(:S3(\%Q9"5+J>VJ_V+]*B:\3WYMUS1N*7/D82 M2X(.3EZ,(C#=$]%-G&Y"6\ZTHR8?AA6]JFB\ >V7FFIW/?$']._T_"]02P,$ M% @ 2H">6GZ2OE;8 @ <@8 !D !X;"]W;W)K&ULC5513]LP$/XKIR#QA)HT;0&5ME++0..!#0';'J8]N,DEL4CLS+Z2 MLE^_LQ.RCI5J+\W9ON^[[^[LZZS1YLD6B 3;JE1V'A1$]30,;5)@)>Q UZCX M)-.F$L1+DX>V-BA2#ZK*,(ZBT[ 24@6+F=^[,XN9WE I%=X9L)NJ$N9EA:5N MYL$P>-VXEWE!;B-]U\Q"Z?B>-+=&G]+S2M[^@L@&1C25<=F!54 M4K5?L>WJL ,XC]X!Q!T@]KK;0%[E!T%B,3.Z >.\F$L)&9U9V'2,:Q:AO@=AA'<:D6%A2N58OHW/F0UO:3X M5=(J/DAX*\P 1L,3B*-X1A<'-(][S>-#[/_5EL,, MGS0A#*,IO*6"QP(ATR4_1[=)8EUB]R;E+RX*5POT6TRZ,=Z9SZ@PV-91<4BH MVN:C:SYPZY*B[YUW8F,\Y9@.M'M1WOHZ/[CG0OIM$EM(#*:2X&PR@N').#J# MMI'_:#L^.H^'\47_?=0DRAV8RS=%9N/'RYB]01IAH3;2U:!\X6PY3>VSS?AV ML"$(!.1,0:R@-KK6Q@\5G8&E32JY;GZ^2')F@P8A$<9(SI,GH8OZB1$%+"LT M,A&^,M[+I80\6Q&4)L!2YM+UHXM^;5"QT#V*!_LN6;@S!SA0[J>=A41O%+4C MH=_M!^JRG2-_W-MIS-W)I;)08L;0:' V"<"T$ZY=D*[]5%EKXAGES8+_%- X M!S[/-%_ ;N$"]'\SB]]02P,$% @ 2H">6JG8N@>< P TP@ !D !X M;"]W;W)K&ULM5;;CMLV$/V5@0KD2;6NOJQC&]C= MI)>'-(MUFCP4>:"EL44L12HDM5[WZSND9*V3.D92I"\2+S-'9PXY,UKLE7XP M%:*%IUI(LPPJ:YMY%)FBPIJ9D6I0TLY6Z9I9FNI=9!J-K/1.M8C2.)Y$->,R M6"W\VIU>+51K!9=XI\&T=[-R1A<)!NE'MSD]W(9Q(X0"BRL0V#T M>L1;%,(!$8U//68P?-(YGHZ/Z+_XV"F6#3-XJ\0'7MIJ&.?L.]LLSB HC56U;TS,:BY[-[LJ=?AQ&'V-8>T=T@][^Y#GN4K M9MEJH=4>M+,F-#?PH7IO(L>E.Y2UU;3+R<^NWC:HF>5R!Z^?Z* -FD5D"=?M M1D6/<=-AI%_!R."-DK8R\%J66'[N'Q&?@51Z)'637@1\P_0(LB2$-$['%_"R M(H6 F,4N.1K'8(:@M)/ &L M&Z$.2+9EJYVO)1=;:42HNX-&=]! QU14PSF%P"44#EAS0_FVY[;Z%_CXOX'G M(T^;RX(*CZ&! 5=PQ(% R%M!Q3LL1=6E:92VE)F/5'$:JA^V2WUN.7V4R1(^ MM4QP>SA9[N"W2E"-\CAL([ O5/QOT6S-<2BH6$I2@E"L"CLIL#;%O9 M59OO4WNB&&""'9"3J)IO6L><= RS:4S/-)X^9QNU36CZ'D;)47/KSLD Z9W%5["NF,:? M75LIH6&';B\)IW%*SZOQK)?X2SU+/":"/"<7I4>CN5/X.4-(?Z0&IF3K+!K& M2^?L0^^2EA@X,V8L'.ARCUZSK Z=.SKKE$]FW?M MGN3?<5)-X)9&PO=V]R:W-H965T M:Z7=.JJ(FF4XQ=8U$4/:A6<9HD%W$MI(ZR5>_;VVQE6E)2X]Z":^M: MV#];5*9;1]/HR7$KCQ5Y1YRM&G'$.Z1OS=ZR%8\LA:Q1.VDT6"S7T6:ZW,Y] M?!_P76+G3O;@E1R,N??&YV(=);X@5)B39Q"\/. .E?)$7,;O@3,:4WK@Z?Z) M_6.OG;4A#R> J^0%0#H TK[ND*BO\EJ0R%;6=&!]-+/Y32^U1W-Q4ON? M63R7C*-N9NI;$72:WBHD)O3O.!_ V@-,7P#.X,9HJ!Q]T@<7_^)@+&:M) MGZK9IF<);X2=P&SZ#M(D79SAFXWJ9CW?['5U('0!.RY7ZB/J7**#:^ER95QK M$7YN#HXL7Y%?SW4A))D_G\2/S=(U(L=UQ'/AT#Y@E+U],[U(WI^1,!\ES,^Q MO_:#SH._&$*8IDLX;<37"EEQYS_:@)-'+4N9"TV05X*;XT!J,,11D)_ 2FMJ MH,HXA"(T#@L?&7)< AD^189H9Y0L!/%Q*;7@7@L%CM@1B*3.55L$L$=LM&XY MXA8;8VGR7,OBD_M=HSWV4^PX5:LI7/71.SX4FS ?_\+#*\,W["BU X4E0Y/) MY2("&R8W&&2:?EH.AGCV^FW%CQU:'\#GI6&]@^$3C,]G]A=02P,$% @ M2H">6K-4G\"& @ QP4 !D !X;"]W;W)K&UL MG511;],P$/XKIR#Q!$V;=&,J;:1V@.!AJ.H&/" >W.226'/L8%_6[=]S=K+0 M25N1>(E]Y_N^^\[.W?)@[*VK$0GN&Z7=*JJ)VD4+S=S'AX#O$@_N: ^^DKTQ MM][X4JRBJ1>$"G/R#(*7.[Q$I3P1R_@]<$9C2@\\WC^R?PJU>+S?*A2\<^MB4@_/.D6D&,"MHI.Y7<3_=OX\K>^?A6M%CJN(&\2AO<,H>_UJ=CY]?T+T?!0]/\7^GR]UFO.K(819 MNH!_D\--C1;AX#_:@.9^<[+2LI2YT,3]&:+?MN%*Z?A*B\Y*70'5""U::0K& M6Q#Z ?):Z(JII0ZG6E#'[*8,UA..TIJ&O<8AMYS+K=RS,H;U!5P F8#).=8H M603AI=1"YU(H<,0.GB3D4^6J*WJP1ZRU[CABAZVQ-'GNF>*CYFK05F&$.$[5 M:>K[;/2.4VK=-^??\'[$\7]<2:Y&83=602V'QN]0:8-K;HWQ(T?MC5/ M6K0^@,]+P_4.AD\PSN[L#U!+ P04 " !*@)Y:&=*%6J0# [" &0 M 'AL+W=O+L.D9?+%[F')XY)(=>MU(] MZP+1P$LI*KWQ"F/J51#HM,"2Z8FLL:*97*J2&>JJ0Z!KA2QSH%($41C.@Y+Q MRMNNW=A>;=>R,8)7N%>@F[)DZK1#(=N--_6&@4=^*(P="+;KFAWP"ZGJ]W,QKN ;QQ;?=8&FTDBY;/M_)YMO- *0H&IL0R, M/D=\0"$L$-X>V']UN5,N"=/X(,7?/#/%QEMZD&'.&F$>9?L; M]OG<6KY4"NU^H>UBX]"#M-%&ECV8%)2\ZK[LI??A#+!\#Q#U@,CI[A9R*G]A MAFW72K:@;#2QV89+U:%)'*_LICP91;.<<&;[A]0:]JC@J6 *UX$A3CL3I#U^ MU^&C=_ Q?)&5*31\KC+,WN(#TC(*B@9!N^@JX1>F)A!/?8C"Z/8*7SPF&#N^ M^!V^STQ5O#J<)0G_W"?:*#H/_U[*MZ.;7::S=V2E:Y;BQJ-+H%$=T=M^_#"= MAY^NB)V-8F?7V/_';ES%7U;W51J$Z6P%;]EAQS1/0=C!F@:U&^0:4B;21C"# M&20GR/B19V0@F *AHBKA ,P8Q9/&L$0@&.DF'4$A189*@\S=V(,L:U:=+)'M MMNZ2$#$[HJ([#U53)K0V14M%JU!9Z&B(H#':L,HMG35J4$!*N[+!/ZDV5P*JK76,6ZA?;T=L&^-MAGP(Q,D MR#K*3*< 7U+16%]R)4L'&TZ%M968!DO&$_&:]473H>S*1.?Z==-I)S.>N@-( M>_IZ1$;?>K-6E*VE/J] /W(ZOJ^RNL&R%O)$T2U3BMELH]G,G]_%X_?)R/09 M9&U3U# -_=E=Y-^%,2S\>+GTP^D<'I$*!T^M,NVBFXH34^R'RX6_7$00^>%\ MYH?Q+>SI=6FU;)CP.G? 3F! TGBUL/5/=4=1TC:_<\)-+08^.:!;WNJ&P MS>>2;.\[=H'Q_\+V/U!+ P04 " !*@)Y:\!8/:( # !]!P &0 'AL M+W=OP'L M;8KDPW:?]\A)6N-Q%X4?9'(X:R'-*JBL;:ZBR.05ULR$JD%)*Z72-;,TU?O(-!I9X8-J$27C\32J&9?! M>NEM6[U>JM8*+G&KP;1US?33#0IU7 5Q\&RXX_O*.D.T7C9LC_=HOS9;3;-H M0"EXC=)P)4%CN0JNXZN;S/E[AV\#+\3/Z[UX[:=DQ@QLE_N2%K5;!/( "2]8*>Z>.'['7 M,W%XN1+&?^'8^::S /+66%7WP<2@YK+[L\?^'%X$S,=O!"1]0.)Y=QMYEK\Q MR]9+K8Z@G3>AN8&7ZJ.)'):O(&:PJV2MC+P01;X0WQ$# >:R3/-F^0LX"W3(:3Q M"))Q,CF#EPZR4X^7OH%WW^X,?F])._0G\-?USEA-1?+W:W([M.QU-'=QKDS# M#I>G.&:#5RS<^C_.T7G4?]0%B&>7,%_@8?/$B@%>07) MK,O!R*_FJFZ8? (FI6IEC@4P*+ED,N=R[R#:!JR"=^EX&OY*Y2N$NXGO+R_F MZ31;)/,LG#Q;?QDY3U8<*!CA&V?F@4LZPUFV(!),MA:VS!(#6VG5[BO8<274 MGN<&!,^I2R"PIJ$A\[?=M+N:&]\ZF"S@:W@?.K8UZIPS 8(1W6H$O'116AVP M".$+*3JQYS(7;8$&]EH9 ^24(Q;&J7H7)Y,3\T%/'$_#=-!#+2M'ZC@%D,MU MH[F _NP\H_YDXGD<9C\C3>=AL,3[/"T MN5,HA,_6D6G-?*XU CZZHS!8C-Q9_4--TO$Q='JF9%W')*6FP9R7G'!R);M] M3>BJH1,43UY6PZ:OAF%O9Z3E#.[H4OCR^<(>8:.1D.#]1E]>)&FZ<)."A"?Q M;/&I;LB890M+,?0 40QZ_0Z*U51DUB<@"\>WSIPS4X6OW;'H14NDI.]]XS>D M@A"Z[CA8A[?ENFNI)_?N8:+"WW-)988EA8[#V20 W37[;F)5XQOL3EEJUWY8 MT?N(VCG0>JDH>?W$;3"\N.M_ 5!+ P04 " !*@)Y: R! V@0% #S"@ M&0 'AL+W=OW8FK&=I,E,W;AVFCYT^@"12Q%C$& 4++[]3T+4HS<<=SVA22 W;-GK\39 MSKI[7Q(%\5!IX\\'90CUZ7#HLY(JZ8]M308GA765#%BZS=#7CF0>E2H]3$>C M^;"2R@Q69W'OQJW.;!.T,G3CA&^J2KK'2])V=SX8#_8;MVI3!MX8KLYJN:$[ M"K_5-PZK88^2JXJ,5]8(1\7YX&)\>CEE^2CP5='.'WP+]F1M[3TO/N7G@Q$3 M(DU98 2)UY:N2&L& HUO'>:@-\F*A]][] _1=_BREIZNK/Y=Y:$\'RP'(J=" M-CKG[IGM]E^B+@ MM73'8C).1#I*9R_@37I_)Q%O\@.\N\[)UF]E-N*/B[4/#M7QYW/NMFC3Y]&X M8TY]+3,Z'Z E/+DM#59'K\;ST=L7N$Y[KM.7T/]_;EZ&^\4&$N/YJ7@15WPI M'=&3- HD(2O[+/!C*JX KS*IA0]-KLB+>;(M'(4TN?FVD5@$D1LGL9 J:RY.Y MN).:]K;AXSW%@DCGJ5C \D]DR(%'>WZ1H_L45PJ/$3%+YNE<+.#S5'RQ 6+T M@$'I@90IC8N-L4S./?[,.(]63'-?.9N01E02_%$XT;V;[LLQ=$T7R)GM*AVU)[6U4 M GW$?_TH,NNP0')0S[(H1-&8^-OPS[MR52HJQ/L'RII8#I^+0F6H7622>5]] M?G?=9;=-MM3:9C'U<-,V#L1%L%'V(!9PD7="K*>LHPMRDKWT[%Y4V')9:J$Y M.*SS'5)NI=*QL=EHB7$#(VORH2? "!7O=MZW=/_AG;9F\R:0J_8DWN"GQ)'A M &U4)C86$3Q&&\+)^Y87HII3IOAGG7R/0<-%F\$WJU4N.=:%,M)D"@XJT]XI MN)+V":\;I(%UX!9MI6[:?D"(HJS)*-F[PON]YR@!"G%+0<;$G#!W=$UK($BW MH= FH];2&);E!7 IDS[J,HNB"3P%85'9?)]]N/*:=:5^]' 4-G23<[S; #GE MV01"W>2P0MPF'M<"J.__-YS"P,UFMXI':I?\&"3I*,8(C<6B.Q5*'"(,@.DJ ME.%CH@XB>1?PVK?&ASZL-]:KZ'+$ ;F@,HQ@)ZBJ2\GT>["8V]>'9:/5MT;E M/"A;'V-+25\F\2D(I\@*;/KCYWYPPX.+2$6(.%^WN :$]H[2;_;W^@NVHO, M=_'V.HAYO%'H"4T%5$?'B]E N/:*U2Z"K>.U9FT#+DGQL\2ME!P+X+RP^-]U M"S;0WW-7?P-02P,$% @ 2H">6MB3(/9% @ G 4 !D !X;"]W;W)K M&ULK511;],P$/XK5IC0)K$Z3=(62A)I[4#P,%2M M#)[=Y-I8<^Q@.\WV[[&=-'136B'$2^,[W_?=?5??Q8V0CZH T.BI9%PE7J%U M-<=890641(U$!=S<;(4LB3:FW&%522"Y Y4,![X_Q26AW$MCYUO)-!:U9I3# M2B)5ER61SPM@HDF\L7=PW--=H:T#IW%%=K &_5"MI+%PSY+3$KBB@B,)V\2[ M&<^7D8UW 3\H-.KHC*R2C1"/UOB:)YYO"P(&F;8,Q'SVL 3&+)$IXU?'Z?4I M+?#X?&#_[+0;+1NB8"G83YKK(O'>>RB'+:F9OA?-%^CT3"Q?)IAROZAI8R<3 M#V6UTJ+LP*:"DO+V2YZZ/AP!QJ< 00<(7@.B$X"P X1.:%N9DW5+-$EC*1HD M;;1ALP?7&XI9_#X_.E!/V?0P=7_@O?1QJ5TL7#=/9V9VK MBF20>&8X%<@]>.G;-^.I_W%(ZW\B>Z$\ZI5'Y]C3;V;57!J=ZFI(9HN=.JS= M*/OT.ICYLP\QWA\+& P+HTD?UI:&CQYZ"7+GYE^A3-1F[,@]C1[E"#+:&TA_-S.#*=A>TAA:5&Z>-T&8XW;$PZQ.D M#3#W6R'TP; )^H6<_@902P,$% @ 2H">6A.MA^M$ @ B@8 !D !X M;"]W;W)K&ULG95=;YLP%$#_BL6D/;6%0#ZV#)"2 M;M/RT"E*N^W9P1>P:FQFF]#^^]F&L&Q*J)278)M[C\]UY$O<"OFL2@"-7BK& M5>*56M=+WU=9"156=Z(&;M[D0E98FZDL?%5+P,0E5

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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 123 240 1 false 41 0 false 13 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.dbv-technologies.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Statements of Financial Position (unaudited) Sheet http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited Condensed Consolidated Statements of Financial Position (unaudited) Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Statements of Financial Position (unaudited) (Parenthetical) Sheet http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunauditedParenthetical Condensed Consolidated Statements of Financial Position (unaudited) (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Sheet http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (unaudited) Sheet http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (unaudited) Statements 6 false false R7.htm 9952156 - Disclosure - The Company Sheet http://www.dbv-technologies.com/role/TheCompany The Company Notes 7 false false R8.htm 9952157 - Disclosure - Significant Events and Transactions Sheet http://www.dbv-technologies.com/role/SignificantEventsandTransactions Significant Events and Transactions Notes 8 false false R9.htm 9952158 - Disclosure - Cash and Cash Equivalents Sheet http://www.dbv-technologies.com/role/CashandCashEquivalents Cash and Cash Equivalents Notes 9 false false R10.htm 9952159 - Disclosure - Other Current Assets Sheet http://www.dbv-technologies.com/role/OtherCurrentAssets Other Current Assets Notes 10 false false R11.htm 9952160 - Disclosure - Lease contracts Sheet http://www.dbv-technologies.com/role/Leasecontracts Lease contracts Notes 11 false false R12.htm 9952161 - Disclosure - Trade Payables and Other Liabilities Sheet http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilities Trade Payables and Other Liabilities Notes 12 false false R13.htm 9952162 - Disclosure - Shareholders' equity Sheet http://www.dbv-technologies.com/role/Shareholdersequity Shareholders' equity Notes 13 false false R14.htm 9952163 - Disclosure - Share-Based Payments Sheet http://www.dbv-technologies.com/role/ShareBasedPayments Share-Based Payments Notes 14 false false R15.htm 9952164 - Disclosure - Contingencies Sheet http://www.dbv-technologies.com/role/Contingencies Contingencies Notes 15 false false R16.htm 9952165 - Disclosure - Operating income Sheet http://www.dbv-technologies.com/role/Operatingincome Operating income Notes 16 false false R17.htm 9952166 - Disclosure - Operating Expenses Sheet http://www.dbv-technologies.com/role/OperatingExpenses Operating Expenses Notes 17 false false R18.htm 9952167 - Disclosure - Commitments Sheet http://www.dbv-technologies.com/role/Commitments Commitments Notes 18 false false R19.htm 9952168 - Disclosure - Relationships with Related Parties Sheet http://www.dbv-technologies.com/role/RelationshipswithRelatedParties Relationships with Related Parties Notes 19 false false R20.htm 9952169 - Disclosure - Loss Per Share Sheet http://www.dbv-technologies.com/role/LossPerShare Loss Per Share Notes 20 false false R21.htm 9952170 - Disclosure - Events after the Close of the Period Sheet http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriod Events after the Close of the Period Notes 21 false false R22.htm 9952171 - Disclosure - Reportable segment disclosure Sheet http://www.dbv-technologies.com/role/Reportablesegmentdisclosure Reportable segment disclosure Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9955511 - Disclosure - The Company (Policies) Sheet http://www.dbv-technologies.com/role/TheCompanyPolicies The Company (Policies) Policies 25 false false R26.htm 9955512 - Disclosure - Cash and Cash Equivalents (Tables) Sheet http://www.dbv-technologies.com/role/CashandCashEquivalentsTables Cash and Cash Equivalents (Tables) Tables http://www.dbv-technologies.com/role/CashandCashEquivalents 26 false false R27.htm 9955513 - Disclosure - Other Current Assets (Tables) Sheet http://www.dbv-technologies.com/role/OtherCurrentAssetsTables Other Current Assets (Tables) Tables http://www.dbv-technologies.com/role/OtherCurrentAssets 27 false false R28.htm 9955514 - Disclosure - Lease contracts (Tables) Sheet http://www.dbv-technologies.com/role/LeasecontractsTables Lease contracts (Tables) Tables http://www.dbv-technologies.com/role/Leasecontracts 28 false false R29.htm 9955515 - Disclosure - Trade Payables and Other Liabilities (Tables) Sheet http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesTables Trade Payables and Other Liabilities (Tables) Tables http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilities 29 false false R30.htm 9955516 - Disclosure - Share-Based Payments (Tables) Sheet http://www.dbv-technologies.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.dbv-technologies.com/role/ShareBasedPayments 30 false false R31.htm 9955517 - Disclosure - Contingencies (Tables) Sheet http://www.dbv-technologies.com/role/ContingenciesTables Contingencies (Tables) Tables http://www.dbv-technologies.com/role/Contingencies 31 false false R32.htm 9955518 - Disclosure - Operating income (Tables) Sheet http://www.dbv-technologies.com/role/OperatingincomeTables Operating income (Tables) Tables http://www.dbv-technologies.com/role/Operatingincome 32 false false R33.htm 9955519 - Disclosure - Operating Expenses (Tables) Sheet http://www.dbv-technologies.com/role/OperatingExpensesTables Operating Expenses (Tables) Tables http://www.dbv-technologies.com/role/OperatingExpenses 33 false false R34.htm 9955520 - Disclosure - Loss Per Share (Tables) Sheet http://www.dbv-technologies.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.dbv-technologies.com/role/LossPerShare 34 false false R35.htm 9955521 - Disclosure - Reportable segment disclosure (Tables) Sheet http://www.dbv-technologies.com/role/ReportablesegmentdisclosureTables Reportable segment disclosure (Tables) Tables http://www.dbv-technologies.com/role/Reportablesegmentdisclosure 35 false false R36.htm 9955522 - Disclosure - The Company (Details) Sheet http://www.dbv-technologies.com/role/TheCompanyDetails The Company (Details) Details http://www.dbv-technologies.com/role/TheCompanyPolicies 36 false false R37.htm 9955523 - Disclosure - Significant Events and Transactions - Clinical Programs (Details) Sheet http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails Significant Events and Transactions - Clinical Programs (Details) Details 37 false false R38.htm 9955524 - Disclosure - Significant Events and Transactions - Financing (Details) Sheet http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails Significant Events and Transactions - Financing (Details) Details 38 false false R39.htm 9955525 - Disclosure - Cash and Cash Equivalents (Details) Sheet http://www.dbv-technologies.com/role/CashandCashEquivalentsDetails Cash and Cash Equivalents (Details) Details http://www.dbv-technologies.com/role/CashandCashEquivalentsTables 39 false false R40.htm 9955526 - Disclosure - Other Current Assets - Summary of Other Current Asset (Details) Sheet http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails Other Current Assets - Summary of Other Current Asset (Details) Details 40 false false R41.htm 9955527 - Disclosure - Other Current Assets - Summary of Research Tax Credit (Details) Sheet http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails Other Current Assets - Summary of Research Tax Credit (Details) Details 41 false false R42.htm 9955528 - Disclosure - Other Current Assets - Additional Information (Details) Sheet http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetails Other Current Assets - Additional Information (Details) Details 42 false false R43.htm 9955529 - Disclosure - Lease contracts - Summary of Operating Leases Future Minimum Payments (Details) Sheet http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails Lease contracts - Summary of Operating Leases Future Minimum Payments (Details) Details 43 false false R44.htm 9955530 - Disclosure - Lease contracts - Summary of Rent Expenses (Details) Sheet http://www.dbv-technologies.com/role/LeasecontractsSummaryofRentExpensesDetails Lease contracts - Summary of Rent Expenses (Details) Details 44 false false R45.htm 9955531 - Disclosure - Lease contracts - Summary of Supplemental Cash Flow Information Related to our Operating Leases (Details) Sheet http://www.dbv-technologies.com/role/LeasecontractsSummaryofSupplementalCashFlowInformationRelatedtoourOperatingLeasesDetails Lease contracts - Summary of Supplemental Cash Flow Information Related to our Operating Leases (Details) Details 45 false false R46.htm 9955532 - Disclosure - Trade Payables and Other Liabilities - Additional Information (Details) Sheet http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesAdditionalInformationDetails Trade Payables and Other Liabilities - Additional Information (Details) Details 46 false false R47.htm 9955533 - Disclosure - Trade Payables and Other Liabilities - Summary of Other Current Liabilities (Details) Sheet http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails Trade Payables and Other Liabilities - Summary of Other Current Liabilities (Details) Details 47 false false R48.htm 9955534 - Disclosure - Shareholders' equity (Details) Sheet http://www.dbv-technologies.com/role/ShareholdersequityDetails Shareholders' equity (Details) Details http://www.dbv-technologies.com/role/Shareholdersequity 48 false false R49.htm 9955535 - Disclosure - Share-Based Payments - Additional Information (Details) Sheet http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetails Share-Based Payments - Additional Information (Details) Details 49 false false R50.htm 9955536 - Disclosure - Share-Based Payments - Summary of BSA/SO/RSU actvity (Details) Sheet http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails Share-Based Payments - Summary of BSA/SO/RSU actvity (Details) Details 50 false false R51.htm 9955537 - Disclosure - Share-Based Payments - Summary of Share-Based Payments Expenses (Details) Sheet http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails Share-Based Payments - Summary of Share-Based Payments Expenses (Details) Details 51 false false R52.htm 9955538 - Disclosure - Contingencies - Summary of Non Current Contingencies and Current Contingencies (Details) Sheet http://www.dbv-technologies.com/role/ContingenciesSummaryofNonCurrentContingenciesandCurrentContingenciesDetails Contingencies - Summary of Non Current Contingencies and Current Contingencies (Details) Details 52 false false R53.htm 9955539 - Disclosure - Contingencies - Summary of Movement in Contingencies (Details) Sheet http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails Contingencies - Summary of Movement in Contingencies (Details) Details 53 false false R54.htm 9955540 - Disclosure - Operating income (Details) Sheet http://www.dbv-technologies.com/role/OperatingincomeDetails Operating income (Details) Details http://www.dbv-technologies.com/role/OperatingincomeTables 54 false false R55.htm 9955541 - Disclosure - Operating Expenses - Additional Information (Details) Sheet http://www.dbv-technologies.com/role/OperatingExpensesAdditionalInformationDetails Operating Expenses - Additional Information (Details) Details 55 false false R56.htm 9955542 - Disclosure - Operating Expenses - Summary of Allocation of Personnel Expenses By Function (Details) Sheet http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails Operating Expenses - Summary of Allocation of Personnel Expenses By Function (Details) Details 56 false false R57.htm 9955543 - Disclosure - Operating Expenses - Summary of Allocation of Personnel Expenses By Nature (Details) Sheet http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails Operating Expenses - Summary of Allocation of Personnel Expenses By Nature (Details) Details 57 false false R58.htm 9955544 - Disclosure - Loss Per Share (Details) Sheet http://www.dbv-technologies.com/role/LossPerShareDetails Loss Per Share (Details) Details http://www.dbv-technologies.com/role/LossPerShareTables 58 false false R59.htm 9955545 - Disclosure - Events after the Close of the Period (Details) Sheet http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails Events after the Close of the Period (Details) Details http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriod 59 false false R60.htm 9955546 - Disclosure - Reportable segment disclosure - Schedule of Segment Reporting Information, by Segment (Details) Sheet http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails Reportable segment disclosure - Schedule of Segment Reporting Information, by Segment (Details) Details 60 false false R61.htm 9955547 - Disclosure - Reportable segment disclosure - Additional Information (Details) Sheet http://www.dbv-technologies.com/role/ReportablesegmentdisclosureAdditionalInformationDetails Reportable segment disclosure - Additional Information (Details) Details 61 false false All Reports Book All Reports dbvt-20250331.htm dbvt-20250331.xsd dbvt-20250331_cal.xml dbvt-20250331_def.xml dbvt-20250331_lab.xml dbvt-20250331_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dbvt-20250331.htm": { "nsprefix": "dbvt", "nsuri": "http://www.dbv-technologies.com/20250331", "dts": { "inline": { "local": [ "dbvt-20250331.htm" ] }, "schema": { "local": [ "dbvt-20250331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "dbvt-20250331_cal.xml" ] }, "definitionLink": { "local": [ "dbvt-20250331_def.xml" ] }, "labelLink": { "local": [ "dbvt-20250331_lab.xml" ] }, "presentationLink": { "local": [ "dbvt-20250331_pre.xml" ] } }, "keyStandard": 176, "keyCustom": 64, "axisStandard": 15, "axisCustom": 2, "memberStandard": 17, "memberCustom": 21, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 123, "entityCount": 1, "segmentCount": 41, "elementCount": 480, "unitCount": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 410, "http://xbrl.sec.gov/dei/2024": 33, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.dbv-technologies.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited", "longName": "9952151 - Statement - Condensed Consolidated Statements of Financial Position (unaudited)", "shortName": "Condensed Consolidated Statements of Financial Position (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R3": { "role": "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunauditedParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Statements of Financial Position (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Financial Position (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R4": { "role": "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "dbvt:ScheduleOfOperatingIncomeTableTextBlock", "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R5": { "role": "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "longName": "9952154 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dbvt:AdjustmentForDepreciationAmortizationAndAccruedContingencies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R6": { "role": "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited", "longName": "9952155 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.dbv-technologies.com/role/TheCompany", "longName": "9952156 - Disclosure - The Company", "shortName": "The Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.dbv-technologies.com/role/SignificantEventsandTransactions", "longName": "9952157 - Disclosure - Significant Events and Transactions", "shortName": "Significant Events and Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "dbvt:SignificantEventsAndTransactionsOfThePeriodDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dbvt:SignificantEventsAndTransactionsOfThePeriodDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.dbv-technologies.com/role/CashandCashEquivalents", "longName": "9952158 - Disclosure - Cash and Cash Equivalents", "shortName": "Cash and Cash Equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.dbv-technologies.com/role/OtherCurrentAssets", "longName": "9952159 - Disclosure - Other Current Assets", "shortName": "Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.dbv-technologies.com/role/Leasecontracts", "longName": "9952160 - Disclosure - Lease contracts", "shortName": "Lease contracts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilities", "longName": "9952161 - Disclosure - Trade Payables and Other Liabilities", "shortName": "Trade Payables and Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.dbv-technologies.com/role/Shareholdersequity", "longName": "9952162 - Disclosure - Shareholders' equity", "shortName": "Shareholders' equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.dbv-technologies.com/role/ShareBasedPayments", "longName": "9952163 - Disclosure - Share-Based Payments", "shortName": "Share-Based Payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.dbv-technologies.com/role/Contingencies", "longName": "9952164 - Disclosure - Contingencies", "shortName": "Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LossContingencyDisclosures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LossContingencyDisclosures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.dbv-technologies.com/role/Operatingincome", "longName": "9952165 - Disclosure - Operating income", "shortName": "Operating income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.dbv-technologies.com/role/OperatingExpenses", "longName": "9952166 - Disclosure - Operating Expenses", "shortName": "Operating Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "dbvt:OtherOperatingExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dbvt:OtherOperatingExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.dbv-technologies.com/role/Commitments", "longName": "9952167 - Disclosure - Commitments", "shortName": "Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.dbv-technologies.com/role/RelationshipswithRelatedParties", "longName": "9952168 - Disclosure - Relationships with Related Parties", "shortName": "Relationships with Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.dbv-technologies.com/role/LossPerShare", "longName": "9952169 - Disclosure - Loss Per Share", "shortName": "Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriod", "longName": "9952170 - Disclosure - Events after the Close of the Period", "shortName": "Events after the Close of the Period", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.dbv-technologies.com/role/Reportablesegmentdisclosure", "longName": "9952171 - Disclosure - Reportable segment disclosure", "shortName": "Reportable segment disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.dbv-technologies.com/role/TheCompanyPolicies", "longName": "9955511 - Disclosure - The Company (Policies)", "shortName": "The Company (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.dbv-technologies.com/role/CashandCashEquivalentsTables", "longName": "9955512 - Disclosure - Cash and Cash Equivalents (Tables)", "shortName": "Cash and Cash Equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.dbv-technologies.com/role/OtherCurrentAssetsTables", "longName": "9955513 - Disclosure - Other Current Assets (Tables)", "shortName": "Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.dbv-technologies.com/role/LeasecontractsTables", "longName": "9955514 - Disclosure - Lease contracts (Tables)", "shortName": "Lease contracts (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesTables", "longName": "9955515 - Disclosure - Trade Payables and Other Liabilities (Tables)", "shortName": "Trade Payables and Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.dbv-technologies.com/role/ShareBasedPaymentsTables", "longName": "9955516 - Disclosure - Share-Based Payments (Tables)", "shortName": "Share-Based Payments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.dbv-technologies.com/role/ContingenciesTables", "longName": "9955517 - Disclosure - Contingencies (Tables)", "shortName": "Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LossContingencyDisclosures", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LossContingencyDisclosures", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.dbv-technologies.com/role/OperatingincomeTables", "longName": "9955518 - Disclosure - Operating income (Tables)", "shortName": "Operating income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "dbvt:ScheduleOfOperatingIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dbvt:ScheduleOfOperatingIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.dbv-technologies.com/role/OperatingExpensesTables", "longName": "9955519 - Disclosure - Operating Expenses (Tables)", "shortName": "Operating Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "dbvt:ScheduleOfAllocationOfPersonnelExpensesByFunctionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "dbvt:OtherOperatingExpensesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dbvt:ScheduleOfAllocationOfPersonnelExpensesByFunctionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "dbvt:OtherOperatingExpensesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.dbv-technologies.com/role/LossPerShareTables", "longName": "9955520 - Disclosure - Loss Per Share (Tables)", "shortName": "Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureTables", "longName": "9955521 - Disclosure - Reportable segment disclosure (Tables)", "shortName": "Reportable segment disclosure (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.dbv-technologies.com/role/TheCompanyDetails", "longName": "9955522 - Disclosure - The Company (Details)", "shortName": "The Company (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-46", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "dbvt:GoingConcernPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R37": { "role": "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails", "longName": "9955523 - Disclosure - Significant Events and Transactions - Clinical Programs (Details)", "shortName": "Significant Events and Transactions - Clinical Programs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-57", "name": "dbvt:PercentageOfConfidenceInterval", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-48", "name": "dbvt:ClinicalProgramTrialPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "dbvt:SignificantEventsAndTransactionsOfThePeriodDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R38": { "role": "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails", "longName": "9955524 - Disclosure - Significant Events and Transactions - Financing (Details)", "shortName": "Significant Events and Transactions - Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-57", "name": "dbvt:IssuanceOrSaleOfEquityMaximumAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-59", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R39": { "role": "http://www.dbv-technologies.com/role/CashandCashEquivalentsDetails", "longName": "9955525 - Disclosure - Cash and Cash Equivalents (Details)", "shortName": "Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails", "longName": "9955526 - Disclosure - Other Current Assets - Summary of Other Current Asset (Details)", "shortName": "Other Current Assets - Summary of Other Current Asset (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-5", "name": "dbvt:ResearchTaxCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "dbvt:ResearchTaxCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails", "longName": "9955527 - Disclosure - Other Current Assets - Summary of Research Tax Credit (Details)", "shortName": "Other Current Assets - Summary of Research Tax Credit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-6", "name": "dbvt:ResearchTaxCreditReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "dbvt:ResearchTaxCreditReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetails", "longName": "9955528 - Disclosure - Other Current Assets - Additional Information (Details)", "shortName": "Other Current Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-5", "name": "dbvt:TaxCreditCarryforwardAmountBeforeCurrencyTranslation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "dbvt:TaxCreditCarryforwardAmountBeforeCurrencyTranslation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails", "longName": "9955529 - Disclosure - Lease contracts - Summary of Operating Leases Future Minimum Payments (Details)", "shortName": "Lease contracts - Summary of Operating Leases Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.dbv-technologies.com/role/LeasecontractsSummaryofRentExpensesDetails", "longName": "9955530 - Disclosure - Lease contracts - Summary of Rent Expenses (Details)", "shortName": "Lease contracts - Summary of Rent Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.dbv-technologies.com/role/LeasecontractsSummaryofSupplementalCashFlowInformationRelatedtoourOperatingLeasesDetails", "longName": "9955531 - Disclosure - Lease contracts - Summary of Supplemental Cash Flow Information Related to our Operating Leases (Details)", "shortName": "Lease contracts - Summary of Supplemental Cash Flow Information Related to our Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "dbvt:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "dbvt:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesAdditionalInformationDetails", "longName": "9955532 - Disclosure - Trade Payables and Other Liabilities - Additional Information (Details)", "shortName": "Trade Payables and Other Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "dbvt:IncreaseDecreaseInTradeAccountsPayableNetOfForeignExchangeImpact", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dbvt:IncreaseDecreaseInTradeAccountsPayableNetOfForeignExchangeImpact", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails", "longName": "9955533 - Disclosure - Trade Payables and Other Liabilities - Summary of Other Current Liabilities (Details)", "shortName": "Trade Payables and Other Liabilities - Summary of Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherLiabilitiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R48": { "role": "http://www.dbv-technologies.com/role/ShareholdersequityDetails", "longName": "9955534 - Disclosure - Shareholders' equity (Details)", "shortName": "Shareholders' equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-81", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R49": { "role": "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetails", "longName": "9955535 - Disclosure - Share-Based Payments - Additional Information (Details)", "shortName": "Share-Based Payments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-82", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails", "longName": "9955536 - Disclosure - Share-Based Payments - Summary of BSA/SO/RSU actvity (Details)", "shortName": "Share-Based Payments - Summary of BSA/SO/RSU actvity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-84", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-84", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails", "longName": "9955537 - Disclosure - Share-Based Payments - Summary of Share-Based Payments Expenses (Details)", "shortName": "Share-Based Payments - Summary of Share-Based Payments Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-91", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R52": { "role": "http://www.dbv-technologies.com/role/ContingenciesSummaryofNonCurrentContingenciesandCurrentContingenciesDetails", "longName": "9955538 - Disclosure - Contingencies - Summary of Non Current Contingencies and Current Contingencies (Details)", "shortName": "Contingencies - Summary of Non Current Contingencies and Current Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "us-gaap:LossContingencyDisclosures", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "us-gaap:LossContingencyDisclosures", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R53": { "role": "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails", "longName": "9955539 - Disclosure - Contingencies - Summary of Movement in Contingencies (Details)", "shortName": "Contingencies - Summary of Movement in Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.dbv-technologies.com/role/OperatingincomeDetails", "longName": "9955540 - Disclosure - Operating income (Details)", "shortName": "Operating income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "dbvt:ResearchTaxCreditIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "dbvt:ScheduleOfOperatingIncomeTableTextBlock", "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dbvt:ResearchTaxCreditIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "dbvt:ScheduleOfOperatingIncomeTableTextBlock", "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.dbv-technologies.com/role/OperatingExpensesAdditionalInformationDetails", "longName": "9955541 - Disclosure - Operating Expenses - Additional Information (Details)", "shortName": "Operating Expenses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-5", "name": "dei:EntityNumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "dbvt:OtherOperatingExpensesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "dei:EntityNumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "dbvt:OtherOperatingExpensesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails", "longName": "9955542 - Disclosure - Operating Expenses - Summary of Allocation of Personnel Expenses By Function (Details)", "shortName": "Operating Expenses - Summary of Allocation of Personnel Expenses By Function (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-109", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "dbvt:ScheduleOfAllocationOfPersonnelExpensesByFunctionTableTextBlock", "dbvt:OtherOperatingExpensesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R57": { "role": "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails", "longName": "9955543 - Disclosure - Operating Expenses - Summary of Allocation of Personnel Expenses By Nature (Details)", "shortName": "Operating Expenses - Summary of Allocation of Personnel Expenses By Nature (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-111", "name": "dbvt:WagesAndSalaries", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "dbvt:ScheduleOfAllocationOfPersonnelExpensesByNatureTableTextBlock", "dbvt:OtherOperatingExpensesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R58": { "role": "http://www.dbv-technologies.com/role/LossPerShareDetails", "longName": "9955544 - Disclosure - Loss Per Share (Details)", "shortName": "Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-113", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-113", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails", "longName": "9955545 - Disclosure - Events after the Close of the Period (Details)", "shortName": "Events after the Close of the Period (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-57", "name": "dbvt:IssuanceOrSaleOfEquityMaximumAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-121", "name": "dbvt:ResearchTaxCreditPaymentReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R60": { "role": "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails", "longName": "9955546 - Disclosure - Reportable segment disclosure - Schedule of Segment Reporting Information, by Segment (Details)", "shortName": "Reportable segment disclosure - Schedule of Segment Reporting Information, by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "dbvt:ClinicalStudyExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "unique": true } }, "R61": { "role": "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureAdditionalInformationDetails", "longName": "9955547 - Disclosure - Reportable segment disclosure - Additional Information (Details)", "shortName": "Reportable segment disclosure - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "dbvt-20250331.htm", "first": true, "unique": true } } }, "tag": { "dbvt_ABSAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ABSAWarrantsMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ABSA warrants", "label": "ABSA Warrants [Member]", "documentation": "ABSA Warrants" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Trade Payables and Other Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r45", "r47", "r50", "r763" ] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade payables", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12", "r45" ] }, "dbvt_AccumulatedForeignCurrencyTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "AccumulatedForeignCurrencyTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated currency translation effect", "label": "Accumulated Foreign Currency Translation Adjustment Net of Tax", "documentation": "Accumulated foreign currency translation adjustment net of tax." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r13", "r14", "r62", "r111", "r444", "r481", "r482" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r8", "r14", "r382", "r385", "r422", "r477", "r478", "r727", "r728", "r729", "r733", "r734", "r735", "r736" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated currency translation effect", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r2", "r8", "r14", "r60", "r61", "r122", "r123", "r402", "r403", "r404", "r405", "r406", "r727" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r674" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r55", "r619", "r817" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r493", "r733", "r734", "r735", "r736", "r765", "r818" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r687" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r687" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r687" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r687" ] }, "dbvt_AdjustmentForDepreciationAmortizationAndAccruedContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "AdjustmentForDepreciationAmortizationAndAccruedContingencies", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation, amortization and accrued contingencies", "label": "Adjustment for Depreciation Amortization And Accrued Contingencies", "documentation": "Adjustment for depreciation, amortization and accrued contingencies." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r41", "r42", "r328" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net loss to net cash (used in) operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdrMember", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "American Depositary Share", "label": "ADR [Member]", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": [ "r640" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r720" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r646", "r656", "r666", "r698" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r649", "r659", "r669", "r701" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r721" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r687" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r694" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r650", "r660", "r670", "r694", "r702", "r706", "r714" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r712" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total share-based compensation (expense)", "terseLabel": "Share-based payments", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r357", "r361" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r155" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r17" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r83", "r91", "r107", "r131", "r159", "r167", "r185", "r189", "r197", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r377", "r379", "r399", "r440", "r528", "r591", "r592", "r619", "r636", "r758", "r759", "r772" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r103", "r114", "r131", "r197", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r377", "r379", "r399", "r619", "r758", "r759", "r772" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets :", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r131", "r197", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r377", "r379", "r399", "r758", "r759", "r772" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Current assets", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r709" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r710" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r705" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r705" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r705" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r705" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r705" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r705" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r708" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r707" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r706" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r706" ] }, "dbvt_BLAAndRegulatoryExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "BLAAndRegulatoryExpense", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BLA & Regulatory", "label": "BLA And Regulatory Expense", "documentation": "BLA And Regulatory Expense" } } }, "auth_ref": [] }, "dbvt_BSAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "BSAWarrantsMember", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA", "label": "B S A Warrants [Member]", "documentation": "BSA Warrants [member]" } } }, "auth_ref": [] }, "dbvt_BSWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "BSWarrantsMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BS Warrants", "label": "BS Warrants [Member]", "documentation": "BS Warrants" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r217", "r784", "r785" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r43", "r44", "r217", "r784", "r785" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/TheCompany" ], "lang": { "en-us": { "role": { "terseLabel": "The Company", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r71" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CashandCashEquivalentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r93", "r442", "r504", "r523", "r619", "r636", "r726" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.dbv-technologies.com/role/CashandCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/CashandCashEquivalentsDetails", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents as reported in the statements of financial position", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r16", "r105", "r581" ] }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/CashandCashEquivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify." } } }, "auth_ref": [ "r105", "r442" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Net Cash and cash equivalents at the beginning of the period", "periodEndLabel": "Net cash and cash equivalents at the end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r16", "r68", "r129" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) / increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r68" ] }, "dbvt_CashEquivalentTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "CashEquivalentTermDeposits", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CashandCashEquivalentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalent Term Deposits", "documentation": "Cash equivalent term deposits." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r685" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r682" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r680" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage", "http://www.dbv-technologies.com/role/TheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r99", "r108", "r109", "r110", "r131", "r149", "r150", "r152", "r154", "r161", "r162", "r197", "r234", "r236", "r237", "r238", "r241", "r242", "r244", "r245", "r248", "r251", "r258", "r399", "r485", "r486", "r487", "r488", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r505", "r515", "r537", "r558", "r570", "r571", "r572", "r573", "r574", "r724", "r731", "r737" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersequityDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r108", "r109", "r110", "r161", "r244", "r245", "r246", "r248", "r251", "r256", "r258", "r485", "r486", "r487", "r488", "r600", "r724", "r731" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r39" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in euro per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r259" ] }, "dbvt_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of warrants, exercised during period (in shares)", "label": "Class Of Warrant Or Right Exercised During Period", "documentation": "Class Of Warrant Or Right Exercised During Period" } } }, "auth_ref": [] }, "dbvt_ClassOfWarrantOrRightExpiredDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ClassOfWarrantOrRightExpiredDuringPeriod", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of warrants, expired during period (in shares)", "label": "Class Of Warrant Or Right Expired During Period", "documentation": "Class Of Warrant Or Right Expired During Period" } } }, "auth_ref": [] }, "dbvt_ClassOfWarrantOrRightForfeitedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ClassOfWarrantOrRightForfeitedDuringPeriod", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of warrants, forfeited during period (in shares)", "label": "Class Of Warrant Or Right Forfeited During Period", "documentation": "Class Of Warrant Or Right Forfeited During Period" } } }, "auth_ref": [] }, "dbvt_ClassOfWarrantOrRightGrantedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ClassOfWarrantOrRightGrantedDuringPeriod", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants, granted during period (in shares)", "label": "Class Of Warrant Or Right Granted During Period", "documentation": "Class Of Warrant Or Right Granted During Period" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, number of securities called by each warrant or right (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, number of securities called by warrants or rights (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r259" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of warrants outstanding, Beginning Balance (in shares)", "periodEndLabel": "Number of warrants outstanding, Ending Balance (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightUnissued", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, unissued (in shares)", "label": "Class of Warrant or Right, Unissued", "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights." } } }, "auth_ref": [] }, "dbvt_ClinicalProgramTrialPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ClinicalProgramTrialPeriod", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical program trial period", "label": "Clinical Program Trial Period", "documentation": "Clinical program trial period." } } }, "auth_ref": [] }, "dbvt_ClinicalStudyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ClinicalStudyExpense", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical studies", "label": "Clinical Study Expense", "documentation": "Clinical Study Expense" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r686" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r686" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r376" ] }, "dbvt_ComfortToddlersSafetyStudyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ComfortToddlersSafetyStudyMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Comfort Toddlers Safety Study", "label": "Comfort Toddlers Safety Study [Member]", "documentation": "Comfort toddlers safety study." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/Commitments" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r74", "r221", "r222", "r576", "r748", "r750" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited", "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Ordinary shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r626", "r627", "r628", "r630", "r631", "r632", "r633", "r733", "r734", "r736", "r765", "r815", "r818" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunauditedParenthetical", "http://www.dbv-technologies.com/role/ShareholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares par value (in Euro per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r54", "r515" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares oustanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r54", "r515", "r534", "r818", "r819" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, \u20ac0.10 par value; 102,858,868 and 102,847,501 shares authorized, and issued as at March 31, 2025 and December 31, 2024, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r54", "r443", "r619" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r691" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r690" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r692" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r689" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r15", "r118", "r120", "r126", "r436", "r451", "r452" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Country Region", "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial gains and losses on defined-benefit plans", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r268" ] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails_1": { "parentTag": "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrual", "weight": 1.0, "order": 2.0 }, "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Pension retirement obligations, beginning balance", "periodEndLabel": "Pension retirement obligations, ending balance", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r263" ] }, "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "DefinedBenefitPlanBenefitObligationAndLossContingencyAccrual", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Defined benefit plan, benefit obligation and loss contingency accrual, beginning balance", "periodEndLabel": "Defined benefit plan, benefit obligation and loss contingency accrual, ending balance", "label": "Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual", "documentation": "Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual" } } }, "auth_ref": [] }, "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrualForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "DefinedBenefitPlanBenefitObligationAndLossContingencyAccrualForeignCurrencyTranslationGainLoss", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Currency translation effect", "label": "Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual, Foreign Currency Translation Gain (Loss)", "documentation": "Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual, Foreign Currency Translation Gain (Loss)" } } }, "auth_ref": [] }, "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrualIncreaseInProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "DefinedBenefitPlanBenefitObligationAndLossContingencyAccrualIncreaseInProvision", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Increases in liabilities", "label": "Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual, Increase In Provision", "documentation": "Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual, Increase In Provision" } } }, "auth_ref": [] }, "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrualRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "DefinedBenefitPlanBenefitObligationAndLossContingencyAccrualRollForward", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual [Roll Forward]", "documentation": "Defined Benefit Plan, Benefit Obligation And Loss Contingency Accrual" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrualIncreaseInProvision", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases in liabilities", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation." } } }, "auth_ref": [ "r267" ] }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension retirement obligations", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrualForeignCurrencyTranslationGainLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Currency translation effect", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r269" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPayments" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payments", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r326", "r330", "r358", "r359", "r360", "r611" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r641" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r673" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r684" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Basic Net loss per share attributable to shareholders (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r127", "r137", "r138", "r139", "r140", "r141", "r142", "r147", "r149", "r152", "r153", "r154", "r158", "r372", "r375", "r389", "r390", "r437", "r453", "r584" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted Net loss per share attributable to shareholders (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r127", "r137", "r138", "r139", "r140", "r141", "r142", "r149", "r152", "r153", "r154", "r158", "r372", "r375", "r389", "r390", "r437", "r453", "r584" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShare" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r146", "r155", "r156", "r157" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r768" ] }, "dbvt_EmployeeRelatedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "EmployeeRelatedLiabilitiesMember", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee related liabilities", "label": "Employee Related Liabilities [Member]", "documentation": "Employee related liabilities." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails", "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payments [Line iteam]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "verboseLabel": "SO", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r638" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r638" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r638" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r723" ] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity number of employees", "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r638" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r638" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r638" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r678" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r719" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r719" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r719" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r100", "r121", "r122", "r123", "r132", "r133", "r134", "r136", "r141", "r143", "r145", "r160", "r198", "r199", "r214", "r260", "r366", "r367", "r369", "r370", "r371", "r373", "r374", "r375", "r381", "r382", "r383", "r384", "r385", "r386", "r388", "r400", "r402", "r403", "r404", "r405", "r406", "r408", "r410", "r422", "r450", "r477", "r478", "r479", "r493", "r558" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r688" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r646", "r656", "r666", "r698" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r643", "r653", "r663", "r695" ] }, "dbvt_EstimatedResearchTaxCreditForThePeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "EstimatedResearchTaxCreditForThePeriod", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated research tax credit for the period", "label": "Estimated Research Tax Credit For The Period", "documentation": "Estimated Research Tax Credit Ror The Period" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r694" ] }, "dbvt_ExpensesByFunctionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ExpensesByFunctionMember", "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses by function", "label": "Expenses by Function [Member]", "documentation": "Expenses by Function" } } }, "auth_ref": [] }, "dbvt_ExpensesByNatureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ExpensesByNatureMember", "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses by Nature", "label": "Expenses by Nature [Member]", "documentation": "Expenses by nature" } } }, "auth_ref": [] }, "dbvt_ExpensesForPensionCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ExpensesForPensionCommitments", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses for pension commitments", "label": "Expenses For Pension Commitments", "documentation": "Expenses For Pension Commitments" } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r392", "r393", "r394", "r395", "r396", "r397" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r392", "r393", "r394", "r395", "r396", "r397", "r398" ] }, "dbvt_FinanceIncomeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "FinanceIncomeExpenses", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial income (expense)", "label": "Finance Income Expenses", "documentation": "Financial (Expenses)." } } }, "auth_ref": [] }, "dbvt_FinancingDilutionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "FinancingDilutionPercentage", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing, dilution percentage", "label": "Financing, Dilution Percentage", "documentation": "Financing, Dilution Percentage" } } }, "auth_ref": [] }, "dbvt_FinancingMaximumPotentialDilutionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "FinancingMaximumPotentialDilutionPercentage", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing, maximum potential dilution percentage", "label": "Financing, Maximum Potential Dilution Percentage", "documentation": "Financing, Maximum Potential Dilution Percentage" } } }, "auth_ref": [] }, "dbvt_FirstPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "FirstPreFundedWarrantsMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First prefunded warrants", "label": "First Pre-Funded Warrants [Member]", "documentation": "First Pre-Funded Warrants" } } }, "auth_ref": [] }, "dbvt_ForeignCurrencyExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ForeignCurrencyExchangeRateChanges", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrualForeignCurrencyTranslationGainLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Currency translation effect", "label": "Foreign Currency Exchange Rate Changes", "documentation": "Foreign Currency Exchange Rate Changes" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r650", "r660", "r670", "r702" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r650", "r660", "r670", "r702" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r650", "r660", "r670", "r702" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r650", "r660", "r670", "r702" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r650", "r660", "r670", "r702" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r683" ] }, "dbvt_GainLossOnRestructuringOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "GainLossOnRestructuringOfLease", "crdr": "credit", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofRentExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net restructuring impact", "label": "Gain (Loss) on Restructuring Of Lease", "documentation": "Gain (Loss) on Restructuring Of Lease" } } }, "auth_ref": [] }, "us-gaap_GainLossOnTerminationOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnTerminationOfLease", "crdr": "credit", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofRentExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net termination impact", "label": "Gain (Loss) on Termination of Lease", "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term." } } }, "auth_ref": [ "r411" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails", "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "General and administrative expenses", "verboseLabel": "General & Administrative expenses", "terseLabel": "General & Administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r66", "r539" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "General & administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r66" ] }, "dbvt_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "GoingConcernPolicyTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Going Concern", "label": "Going Concern [Policy Text Block]", "documentation": "Going concern." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r64", "r86", "r90", "r438", "r448", "r586", "r591", "r738", "r740", "r741", "r742", "r743" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r215", "r217", "r218", "r393", "r397", "r398", "r474", "r476", "r543", "r579", "r613", "r786" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r217", "r218", "r393", "r397", "r398", "r474", "r476", "r543", "r579", "r613", "r786" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r92", "r98", "r144", "r145", "r159", "r175", "r189", "r364", "r365", "r368", "r454", "r612" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "(Decrease) increase in trade payables", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease (increase) in inventories and work in progress", "label": "Increase (Decrease) in Finished Goods and Work in Process Inventories", "documentation": "The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "dbvt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in operating lease liabilities and right of use assets", "label": "Increase Decrease In Operating Lease Liability And Right Of Use Asset", "documentation": "Increase decrease in operating lease liability and right of use asset." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r730" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "(Decrease) increase in other current and non-current liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dbvt_IncreaseDecreaseInTradeAccountsPayableNetOfForeignExchangeImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "IncreaseDecreaseInTradeAccountsPayableNetOfForeignExchangeImpact", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in trade accounts payable", "label": "Increase (Decrease) In Trade Accounts Payable, Net Of Foreign Exchange Impact", "documentation": "Increase (Decrease) In Trade Accounts Payable, Net Of Foreign Exchange Impact" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r650", "r660", "r670", "r694", "r702", "r706", "r714" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r712" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r642", "r718" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r642", "r718" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r642", "r718" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r212", "r746", "r747" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory write-downs", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r200" ] }, "dbvt_IssuanceOrSaleOfEquityMaximumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "IssuanceOrSaleOfEquityMaximumAmount", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance or sale of equity, maximum amount", "label": "Issuance Or Sale Of Equity, Maximum Amount", "documentation": "Issuance Or Sale Of Equity, Maximum Amount" } } }, "auth_ref": [] }, "dbvt_IssuanceOrSaleOfEquityPotentialAdditionalProceedsMaximumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "IssuanceOrSaleOfEquityPotentialAdditionalProceedsMaximumAmount", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance or sale of equity, maximum potential amount", "label": "Issuance Or Sale Of Equity, Potential Additional Proceeds, Maximum Amount", "documentation": "Issuance Or Sale Of Equity, Potential Additional Proceeds, Maximum Amount" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Rent expenses", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r770" ] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r415", "r421" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r415", "r421" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Operating Leases Future Minimum Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r771" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r419" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year 2", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r419" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year 3", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r419" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r771" ] }, "dbvt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearTwo", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Two", "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Two" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Effects of discounting", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r419" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/Leasecontracts" ], "lang": { "en-us": { "role": { "terseLabel": "Lease contracts", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r409" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r11", "r46", "r47", "r48", "r49", "r50", "r51", "r52", "r131", "r197", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r378", "r379", "r380", "r399", "r514", "r585", "r636", "r758", "r772", "r773" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Shareholder's equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r59", "r85", "r446", "r619", "r732", "r744", "r767" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and shareholders' equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r48", "r104", "r131", "r197", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r378", "r379", "r380", "r399", "r619", "r758", "r772", "r773" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r11", "r49", "r50", "r51", "r52", "r131", "r197", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r378", "r379", "r380", "r399", "r758", "r772", "r773" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Current liabilities", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "dbvt_LiabilityDefinedBenefitPlanAndLossContingencyCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "LiabilityDefinedBenefitPlanAndLossContingencyCurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrual", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Of which current", "label": "Liability, Defined Benefit Plan And Loss Contingency, Current", "documentation": "Liability, Defined Benefit Plan And Loss Contingency, Current" } } }, "auth_ref": [] }, "dbvt_LiabilityDefinedBenefitPlanAndLossContingencyNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "LiabilityDefinedBenefitPlanAndLossContingencyNoncurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrual", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Of which non-current", "label": "Liability, Defined Benefit Plan And Loss Contingency, Noncurrent", "documentation": "Liability, Defined Benefit Plan And Loss Contingency, Noncurrent" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r224", "r226", "r228", "r233", "r362", "r483", "r599", "r752", "r754" ] }, "us-gaap_LossContingencyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAbstract", "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency [Abstract]", "label": "Loss Contingency [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails_1": { "parentTag": "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrual", "weight": 1.0, "order": 1.0 }, "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contingencies, beginning balance", "periodEndLabel": "Contingencies, ending balance", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r224", "r725" ] }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValueCurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": "us-gaap_LossContingencyAccrualAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Of which current", "label": "Loss Contingency, Accrual, Current", "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r224" ] }, "us-gaap_LossContingencyAccrualCarryingValueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValueNoncurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": "us-gaap_LossContingencyAccrualAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Of which non-current", "label": "Loss Contingency, Accrual, Noncurrent", "documentation": "Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r224" ] }, "dbvt_LossContingencyAccrualLiabilitiesUsed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "LossContingencyAccrualLiabilitiesUsed", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Used liabilities", "label": "Loss Contingency Accrual, Liabilities Used", "documentation": "Loss Contingency Accrual, Liabilities Used" } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": "dbvt_DefinedBenefitPlanBenefitObligationAndLossContingencyAccrualIncreaseInProvision", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases in liabilities", "label": "Loss Contingency Accrual, Provision", "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } }, "auth_ref": [ "r751" ] }, "us-gaap_LossContingencyAccrualRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualRollForward", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other contingencies", "label": "Loss Contingency Accrual [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_LossContingencyDisclosures": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDisclosures", "presentation": [ "http://www.dbv-technologies.com/role/Contingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made." } } }, "auth_ref": [ "r223", "r224", "r225", "r227", "r229", "r230", "r231", "r232", "r362" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r224", "r226", "r228", "r233", "r362", "r483", "r599", "r752", "r754" ] }, "dbvt_ManufacturingSupplyAndQualityExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ManufacturingSupplyAndQualityExpense", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing & Supply and Quality", "label": "Manufacturing, Supply and Quality Expense", "documentation": "Manufacturing, Supply and Quality Expense" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r226", "r228", "r229", "r230", "r324", "r362", "r391", "r433", "r473", "r475", "r483", "r506", "r507", "r565", "r566", "r567", "r568", "r569", "r577", "r578", "r596", "r600", "r610", "r614", "r615", "r616", "r617", "r621", "r760", "r774", "r775", "r776", "r777", "r778", "r779" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r686" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r686" ] }, "dbvt_MedicalAffairsAndOtherMedicalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "MedicalAffairsAndOtherMedicalExpense", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Affairs & Other Medical", "label": "Medical Affairs And Other Medical Expense", "documentation": "Medical Affairs And Other Medical Expense" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r226", "r228", "r229", "r230", "r324", "r362", "r391", "r433", "r473", "r475", "r483", "r506", "r507", "r565", "r566", "r567", "r568", "r569", "r577", "r578", "r596", "r600", "r610", "r614", "r615", "r616", "r621", "r760", "r774", "r775", "r776", "r777", "r778", "r779" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r705" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r713" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r687" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows (used) / provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r128" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows (used) / provided by financing activities :", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r128" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows (used in) investing activities :", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flow (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r68", "r69", "r70" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 }, "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss for the period", "terseLabel": "Net (loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r65", "r70", "r87", "r102", "r116", "r119", "r123", "r131", "r135", "r137", "r138", "r139", "r140", "r141", "r144", "r145", "r151", "r197", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r372", "r375", "r390", "r399", "r449", "r536", "r556", "r557", "r634", "r758" ] }, "dbvt_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounting Pronouncements issued not yet adopted", "label": "New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]", "documentation": "New accounting pronouncements not yet adopted, policy." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Pronouncements Recently Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "No Trading Symbol Flag", "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r686" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r650", "r660", "r670", "r694", "r702" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r677" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r676" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r694" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r713" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r713" ] }, "dbvt_NonemployeewarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "NonemployeewarrantsMember", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-employee warrants", "label": "Nonemployeewarrants [Member]", "documentation": "Non-employee\u00a0warrants ." } } }, "auth_ref": [] }, "dbvt_NumberOfAdditionalCandidatesCoveredByTheStudy": { "xbrltype": "integerItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "NumberOfAdditionalCandidatesCoveredByTheStudy", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional candidates covered by the study", "label": "Number Of Additional Candidates Covered By The Study", "documentation": "Total number of additional candidates covered by the study." } } }, "auth_ref": [] }, "dbvt_NumberOfAdditionalSafetyStudy": { "xbrltype": "integerItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "NumberOfAdditionalSafetyStudy", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional safety study", "label": "Number Of Additional Safety Study", "documentation": "Number Of Additional Safety Study" } } }, "auth_ref": [] }, "dbvt_NumberOfLocalCountryRegulatoryHealthAuthorities": { "xbrltype": "integerItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "NumberOfLocalCountryRegulatoryHealthAuthorities", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of local country regulatory health authorities", "label": "Number Of Local Country Regulatory Health Authorities", "documentation": "Number Of Local Country Regulatory Health Authorities" } } }, "auth_ref": [] }, "dbvt_NumberOfMajorObjection": { "xbrltype": "integerItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "NumberOfMajorObjection", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of major objection", "label": "Number Of Major Objection", "documentation": "Number Of Major Objection" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r592", "r739" ] }, "dbvt_NumberOfPatches": { "xbrltype": "integerItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "NumberOfPatches", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patches", "label": "Number Of Patches", "documentation": "Number Of Patch" } } }, "auth_ref": [] }, "dbvt_NumberOfStudyComponent": { "xbrltype": "integerItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "NumberOfStudyComponent", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of study component", "label": "Number Of Study Component", "documentation": "Number Of Study Component" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails", "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails", "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total Operating expenses", "totalLabel": "Total personnel expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r90", "r586", "r738", "r740", "r741", "r742", "r743" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofRentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense / (income)", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r769" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r413" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited", "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term operating leases", "negatedLabel": "Less: current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r413" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited", "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating leases", "verboseLabel": "Long-term lease liabities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r413" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofSupplementalCashFlowInformationRelatedtoourOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows used in operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r414", "r416" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets related to operating leases", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r412" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r418", "r618" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r417", "r618" ] }, "dbvt_OtherAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "OtherAssetMember", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Asset [Member]", "documentation": "Other Asset [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited", "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "totalLabel": "Total", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r113", "r619" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r106" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation differences, net of taxes", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2", "r450" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r9", "r10", "r117", "r120", "r125", "r141", "r400", "r401", "r406", "r435", "r450", "r727", "r728" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains / (losses) on employee benefits, net of taxes", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax", "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r4", "r62", "r80", "r115" ] }, "dbvt_OtherContingenciesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "OtherContingenciesMember", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other contingencies", "label": "Other Contingencies [Member]", "documentation": "Other Contingencies" } } }, "auth_ref": [] }, "dbvt_OtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "OtherCurrentAssetsAbstract", "lang": { "en-us": { "role": { "label": "Other Current Assets [Abstract]", "documentation": "Other Current Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "dbvt_OtherDebtsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "OtherDebtsMember", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other debts", "label": "Other Debts [Member]", "documentation": "Other debts." } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r84", "r441", "r510", "r511", "r636", "r782", "r816" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited", "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r47", "r619" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r50" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other elements", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r70" ] }, "dbvt_OtherOperatingExpensesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "OtherOperatingExpensesTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses", "label": "Other Operating Expenses [Text Block]", "documentation": "Other operating expenses." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/OperatingincomeDetails": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OperatingincomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other operating income", "label": "Other Operating Income", "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r63" ] }, "us-gaap_OtherOperatingIncomeAndExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeAndExpenseTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/Operatingincome" ], "lang": { "en-us": { "role": { "terseLabel": "Operating income", "label": "Other Operating Income and Expense [Text Block]", "documentation": "The entire disclosure for other operating income and other operating expense items." } } }, "auth_ref": [ "r541" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r686" ] }, "dbvt_OtherReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "OtherReceivablesCurrent", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables, Current", "documentation": "Other receivables current." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r648", "r658", "r668", "r700" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r651", "r661", "r671", "r703" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r651", "r661", "r671", "r703" ] }, "dbvt_PFWBSPFWMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "PFWBSPFWMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PFW-BS-PFW", "label": "PFW-BS-PFW [Member]", "documentation": "PFW-BS-PFW" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r675" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "dbvt_PaymentsToAcquireNonCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "PaymentsToAcquireNonCurrentFinancialAssets", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in non-current financial assets", "label": "Payments to Acquire Non-Current Financial Assets", "documentation": "Payments to Acquire Non-Current Financial Assets" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in property, plant, and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r67" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r685" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r685" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofNonCurrentContingenciesandCurrentContingenciesDetails": { "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": "us-gaap_DefinedBenefitPlanBenefitObligation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails", "http://www.dbv-technologies.com/role/ContingenciesSummaryofNonCurrentContingenciesandCurrentContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current contingencies", "verboseLabel": "Of which current", "label": "Liability, Defined Benefit Plan, Current", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current." } } }, "auth_ref": [ "r47", "r261", "r262", "r283", "r602" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofNonCurrentContingenciesandCurrentContingenciesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofNonCurrentContingenciesandCurrentContingenciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total contingencies", "label": "Liability, Defined Benefit Plan", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r84", "r262", "r283", "r781" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryofNonCurrentContingenciesandCurrentContingenciesDetails": { "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails": { "parentTag": "us-gaap_DefinedBenefitPlanBenefitObligation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails", "http://www.dbv-technologies.com/role/ContingenciesSummaryofNonCurrentContingenciesandCurrentContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current contingencies", "verboseLabel": "Of which non-current", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r50", "r261", "r262", "r283", "r602" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r677" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r694" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r687" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r676" ] }, "dbvt_PercentageOfConfidenceInterval": { "xbrltype": "percentItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "PercentageOfConfidenceInterval", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of confidence interval", "label": "Percentage Of Confidence Interval", "documentation": "Percentage Of Confidence Interval" } } }, "auth_ref": [] }, "dbvt_PercentageOfDifferenceInResponseRates": { "xbrltype": "percentItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "PercentageOfDifferenceInResponseRates", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of difference in response rates", "label": "Percentage Of Difference In Response Rates", "documentation": "Percentage Of Difference In Response Rates" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r678" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r722" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r677" ] }, "us-gaap_PostemploymentRetirementBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PostemploymentRetirementBenefitsMember", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension retirement obligations", "label": "Postemployment Retirement Benefits [Member]", "documentation": "Special and contractual termination benefits provided in connection with termination of employment and payable upon retirement, but not payable from defined benefit plan. Excludes benefits payable upon termination from defined benefit pension and other postretirement plan, and postemployment benefits payable before retirement." } } }, "auth_ref": [] }, "dbvt_PrefundedPFWBSPFWMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "PrefundedPFWBSPFWMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prefunded PFW-BS-PFW", "label": "Prefunded PFW-BS-PFW [Member]", "documentation": "Prefunded PFW-BS-PFW" } } }, "auth_ref": [] }, "dbvt_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "PrefundedWarrantsMember", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prefunded warrants", "label": "Prefunded warrants [Member]", "documentation": "Prefunded warrants member" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r112", "r201", "r202", "r582" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other tax claims", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r583", "r597", "r745" ] }, "dbvt_PrivateInvestmentInPublicEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "PrivateInvestmentInPublicEquityMember", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private investment in Public Equity", "label": "Private Investment In Public Equity [Member]", "documentation": "Private Investment In Public Equity" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails", "http://www.dbv-technologies.com/role/TheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital increases, net of transaction costs", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r3", "r485" ] }, "dbvt_ProceedsFromPaymentForTreasuryStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ProceedsFromPaymentForTreasuryStock", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "label": "Proceeds From (Payment For) Treasury Stock", "documentation": "Proceeds from repayment of treasury stock" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails", "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r192", "r434", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r580", "r601", "r620", "r621", "r622", "r624", "r625", "r755", "r756", "r761", "r783", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails", "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r192", "r434", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r580", "r601", "r620", "r621", "r622", "r624", "r625", "r755", "r756", "r761", "r783", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814" ] }, "dbvt_ProgrammeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ProgrammeAxis", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Programme [Axis]", "label": "Programme [Axis]", "documentation": "Programme." } } }, "auth_ref": [] }, "dbvt_ProgrammeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ProgrammeDomain", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Programme [Domain]", "label": "Programme [Domain]", "documentation": "Programme." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r420" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant, and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r420", "r439", "r447", "r619" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r73", "r420" ] }, "dbvt_ProvisionForLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ProvisionForLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Current contingencies", "label": "Provision For Liabilities Current", "documentation": "Provision for liabilities current." } } }, "auth_ref": [] }, "dbvt_ProvisionForLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ProvisionForLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-current contingencies", "label": "Provision For Liabilities Noncurrent", "documentation": "Provision for liabilities noncurrent." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r675" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r675" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r226", "r228", "r229", "r230", "r284", "r324", "r353", "r354", "r355", "r362", "r391", "r431", "r432", "r433", "r473", "r475", "r483", "r506", "r507", "r565", "r566", "r567", "r568", "r569", "r577", "r578", "r596", "r600", "r610", "r614", "r615", "r616", "r617", "r621", "r628", "r749", "r760", "r766", "r775", "r776", "r777", "r778", "r779" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r226", "r228", "r229", "r230", "r284", "r324", "r353", "r354", "r355", "r362", "r391", "r431", "r432", "r433", "r473", "r475", "r483", "r506", "r507", "r565", "r566", "r567", "r568", "r569", "r577", "r578", "r596", "r600", "r610", "r614", "r615", "r616", "r617", "r621", "r628", "r749", "r760", "r766", "r775", "r776", "r777", "r778", "r779" ] }, "us-gaap_RealEstateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateMember", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsSummaryofOperatingLeasesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate", "label": "Real Estate [Member]", "documentation": "Property consisting of land, land improvement and buildings." } } }, "auth_ref": [ "r762" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r24", "r25" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r643", "r653", "r663", "r695" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/RelationshipswithRelatedParties" ], "lang": { "en-us": { "role": { "terseLabel": "Relationships with Related Parties", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r423", "r424", "r425", "r426", "r427", "r490", "r491", "r492", "r540", "r542", "r543", "r562", "r564" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 }, "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails", "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development expenses", "verboseLabel": "Research and Development expenses", "terseLabel": "Research & Innovation", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r363", "r579", "r591", "r780" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research & development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "dbvt_ResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ResearchTaxCredit", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit", "label": "Research Tax Credit", "documentation": "Research tax credit." } } }, "auth_ref": [] }, "dbvt_ResearchTaxCreditAdjustmentAndCurrencyTranslationEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ResearchTaxCreditAdjustmentAndCurrencyTranslationEffect", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "- Adjustment and currency translation effect", "label": "Research Tax Credit, Adjustment And Currency Translation Effect", "documentation": "Research tax credit adjustment and currency translation effect." } } }, "auth_ref": [] }, "dbvt_ResearchTaxCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ResearchTaxCreditCurrent", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails": { "parentTag": "dbvt_ResearchTaxCreditReceivable", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Of which - Current portion", "label": "Research Tax Credit, Current", "documentation": "Research tax credit current." } } }, "auth_ref": [] }, "dbvt_ResearchTaxCreditIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ResearchTaxCreditIncome", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/OperatingincomeDetails": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OperatingincomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit", "label": "Research Tax Credit Income", "documentation": "Research tax credit income." } } }, "auth_ref": [] }, "dbvt_ResearchTaxCreditNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ResearchTaxCreditNonCurrent", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails": { "parentTag": "dbvt_ResearchTaxCreditReceivable", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Of which - Non-current portion", "label": "Research Tax Credit, Non current", "documentation": "Research tax credit, non current." } } }, "auth_ref": [] }, "dbvt_ResearchTaxCreditOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ResearchTaxCreditOperatingIncome", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "+ Operating revenue", "label": "Research Tax Credit, Operating Income", "documentation": "Reverse tax credit operating revenue." } } }, "auth_ref": [] }, "dbvt_ResearchTaxCreditPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ResearchTaxCreditPaymentReceived", "crdr": "credit", "presentation": [ "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit, (Cr\u00e9dit d\u2019Imp\u00f4t Recherche) payment received", "label": "Research Tax Credit, Payment Received", "documentation": "Research tax credit payment received." } } }, "auth_ref": [] }, "dbvt_ResearchTaxCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ResearchTaxCreditReceivable", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Opening research tax credit receivable as of January\u00a01, 2025", "periodEndLabel": "Closing research tax credit receivable as of March 31, 2025", "label": "Research Tax Credit Receivable", "documentation": "Research tax credit receivable." } } }, "auth_ref": [] }, "dbvt_ResearchTaxCreditReceivableRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ResearchTaxCreditReceivableRollForward", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryofResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit Receivable [Roll Forward]", "label": "Research Tax Credit Receivable [Roll Forward]", "documentation": "Research Tax Credit Receivable" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r644", "r654", "r664", "r696" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r645", "r655", "r665", "r697" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r652", "r662", "r672", "r704" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "verboseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r56", "r79", "r445", "r480", "r482", "r489", "r516", "r619" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r100", "r132", "r133", "r134", "r136", "r141", "r143", "r145", "r198", "r199", "r214", "r366", "r367", "r369", "r370", "r371", "r373", "r374", "r375", "r381", "r383", "r384", "r386", "r388", "r408", "r410", "r477", "r479", "r493", "r818" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r261", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r325", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r261", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r325", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.dbv-technologies.com/role/OperatingincomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.dbv-technologies.com/role/OperatingincomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating income", "totalLabel": "Total", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r88", "r89", "r124", "r131", "r159", "r168", "r169", "r183", "r189", "r192", "r194", "r195", "r197", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r399", "r438", "r591", "r758" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r713" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r713" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "dbvt_ScheduleOfAllocationOfPersonnelExpensesByFunctionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ScheduleOfAllocationOfPersonnelExpensesByFunctionTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Allocation of Personnel Expenses By Function", "label": "Schedule of Allocation of Personnel Expenses By Function [Table Text Block]", "documentation": "Schedule of Allocation of Personnel Expenses By Function\u00a0[Table text block]" } } }, "auth_ref": [] }, "dbvt_ScheduleOfAllocationOfPersonnelExpensesByNatureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ScheduleOfAllocationOfPersonnelExpensesByNatureTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Allocation of Personnel Expenses By Nature", "label": "Schedule of Allocation of Personnel Expenses By Nature [Table Text Block]", "documentation": "Schedule of Allocation of Personnel Expenses By Nature[Table text block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Non-current Contingencies and Current Contingencies", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/CashandCashEquivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of breakdown of cash and cash equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r376" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryofMovementinContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r7", "r35", "r36", "r37", "r38" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails", "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of share-based payments expenses [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Share-Based Payments Expenses", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLossContingenciesByContingencyTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Movement in Provisions", "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]", "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date." } } }, "auth_ref": [ "r751", "r753", "r755", "r757" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of RSU Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r82" ] }, "dbvt_ScheduleOfOperatingIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ScheduleOfOperatingIncomeTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/OperatingincomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of operating income", "label": "Schedule of operating income [Table Text Block]", "documentation": "Schedule of operating income" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Current Asset", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r21", "r22", "r23" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r327", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersequityDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r26", "r27", "r28", "r29", "r30", "r31", "r75", "r77", "r78", "r79", "r108", "r109", "r110", "r161", "r244", "r245", "r246", "r248", "r251", "r256", "r258", "r485", "r486", "r487", "r488", "r600", "r724", "r731" ] }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "dbvt_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/LeasecontractsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Supplemental cash flow information related to our operating leases", "label": "Schedule Of Supplemental Cash Flow Information Related To Operating Leases [Table Text Block]", "documentation": "Schedule of Supplemental cash flow information related to operating leases [Table Text block]" } } }, "auth_ref": [] }, "dbvt_SecondPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "SecondPreFundedWarrantsMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second prefunded warrants", "label": "Second Pre-Funded Warrants [Member]", "documentation": "Second Pre-Funded Warrants" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r637" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r639" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r88", "r89", "r90", "r91", "r159", "r164", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r189", "r190", "r191", "r195", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r219", "r220", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r588", "r591", "r592", "r598", "r623", "r783", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/Reportablesegmentdisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable segment disclosure", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r91", "r159", "r163", "r164", "r165", "r166", "r167", "r179", "r181", "r182", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r195", "r587", "r589", "r590", "r591", "r593", "r594", "r595" ] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByFunctionDetails", "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Sales and marketing expenses", "verboseLabel": "Sales & Marketing expenses", "terseLabel": "Sales & Marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Sales & marketing", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r66" ] }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses related to share-based payments", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of RSU outstanding, Forfeited during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r347" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of RSU outstanding, Granted during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of RSU outstanding, Beginning Balance (in shares)", "periodEndLabel": "Number of RSU outstanding, Ending Balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r342", "r343" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of RSU outstanding, Released during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r346" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r327", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of RSU outstanding, Expired during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r81" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of stock option outstanding, Expired during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r341" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of stock options outstanding, Forfeited during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r340" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of stock options outstanding, Granted during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r338" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of stock options outstanding, Beginning Balance (in shares)", "periodEndLabel": "Number of stock options outstanding, Ending Balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r334", "r335" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dbvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsInstrumentsOutstandingRollForward", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Warrants Instruments, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Warrants Instruments, Outstanding [Roll Forward]", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Warrants Instruments, Outstanding" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofShareBasedPaymentsExpensesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356" ] }, "dbvt_ShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ShareCapitalMember", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Share Capital [Member]", "documentation": "Share Capital [Member]" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in dollars/euro per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "dbvt_SignificantEventsAndTransactionsOfThePeriodDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "SignificantEventsAndTransactionsOfThePeriodDisclosureTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Events and Transactions", "label": "Significant Events And Transactions Of The Period Disclosure [Text Block]", "documentation": "Significant events and transactions of the period disclsure." } } }, "auth_ref": [] }, "dbvt_SignificantEventsAndTransactionsOfThePeriodDisclsureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "SignificantEventsAndTransactionsOfThePeriodDisclsureAbstract", "lang": { "en-us": { "role": { "label": "Significant Events And Transactions of the Period Disclsure [Abstract]", "documentation": "Significant events and transactions of the period disclsure." } } }, "auth_ref": [] }, "dbvt_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "SocialSecurityContributions", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Social security contributions", "label": "Social Security Contributions", "documentation": "Social Security Contributions" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r88", "r89", "r90", "r91", "r101", "r159", "r164", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r189", "r190", "r191", "r195", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r216", "r219", "r220", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r588", "r591", "r592", "r598", "r623", "r783", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage", "http://www.dbv-technologies.com/role/TheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r99", "r108", "r109", "r110", "r131", "r149", "r150", "r152", "r154", "r161", "r162", "r197", "r234", "r236", "r237", "r238", "r241", "r242", "r244", "r245", "r248", "r251", "r258", "r399", "r485", "r486", "r487", "r488", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r505", "r515", "r537", "r558", "r570", "r571", "r572", "r573", "r574", "r724", "r731", "r737" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r54", "r57", "r58", "r100", "r121", "r122", "r123", "r132", "r133", "r134", "r136", "r141", "r143", "r145", "r160", "r198", "r199", "r214", "r260", "r366", "r367", "r369", "r370", "r371", "r373", "r374", "r375", "r381", "r382", "r383", "r384", "r385", "r386", "r388", "r400", "r402", "r403", "r404", "r405", "r406", "r408", "r410", "r422", "r450", "r477", "r478", "r479", "r493", "r558" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r132", "r133", "r134", "r160", "r410", "r434", "r484", "r505", "r508", "r509", "r510", "r511", "r512", "r513", "r515", "r518", "r519", "r520", "r521", "r522", "r524", "r525", "r526", "r527", "r529", "r530", "r531", "r532", "r533", "r535", "r538", "r539", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r558", "r629" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r132", "r133", "r134", "r160", "r196", "r410", "r434", "r484", "r505", "r508", "r509", "r510", "r511", "r512", "r513", "r515", "r518", "r519", "r520", "r521", "r522", "r524", "r525", "r526", "r527", "r529", "r530", "r531", "r532", "r533", "r535", "r538", "r539", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r558", "r629" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r647", "r657", "r667", "r699" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of ordinary shares (in shares)", "terseLabel": "Stock issued during period (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r53", "r54", "r79", "r485", "r558", "r571" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryofBSASORSUactvityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of stock option outstanding, Exercised during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r53", "r54", "r79", "r339" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of ordinary shares", "terseLabel": "Issuance of ordinary shares", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r53", "r54", "r79", "r493", "r558", "r571", "r635" ] }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "crdr": "credit", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement." } } }, "auth_ref": [ "r9", "r32", "r53", "r54", "r79" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited", "http://www.dbv-technologies.com/role/ShareholdersequityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Shareholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Share capital", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r54", "r57", "r58", "r72", "r517", "r534", "r559", "r560", "r619", "r636", "r732", "r744", "r767", "r818" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity :", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/Shareholdersequity" ], "lang": { "en-us": { "role": { "verboseLabel": "Shareholders' equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r76", "r130", "r243", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r260", "r387", "r561", "r563", "r575" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r407", "r429" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails", "http://www.dbv-technologies.com/role/TheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r407", "r429" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r407", "r429" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails", "http://www.dbv-technologies.com/role/TheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r407", "r429" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriodDetails", "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails", "http://www.dbv-technologies.com/role/TheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r407", "r429" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/EventsaftertheCloseofthePeriod" ], "lang": { "en-us": { "role": { "terseLabel": "Events after the Close of the Period", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r428", "r430" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee [Line Items]", "label": "Subsidiary or Equity Method Investee [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfTaxCreditCarryforwardsTextBlock", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Research Tax Credit", "label": "Summary of Tax Credit Carryforwards [Table Text Block]", "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances." } } }, "auth_ref": [ "r764" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r693" ] }, "dbvt_TaxCreditCarryforwardAmountBeforeCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "TaxCreditCarryforwardAmountBeforeCurrencyTranslation", "crdr": "debit", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforward amount before currency translation", "label": "Tax Credit Carryforward Amount Before Currency Translation", "documentation": "Tax Credit Carryforward Amount Before Currency Translation" } } }, "auth_ref": [] }, "dbvt_TaxLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "TaxLiabilitiesMember", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesandOtherLiabilitiesSummaryofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax liabilities", "label": "Tax Liabilities [Member]", "documentation": "Tax liabilities." } } }, "auth_ref": [] }, "dbvt_TotalNumberOfCandidatesCoveredByTheStudy": { "xbrltype": "integerItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "TotalNumberOfCandidatesCoveredByTheStudy", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total number of candidates covered by the study", "label": "Total Number Of Candidates Covered By The Study", "documentation": "Total Number Of Candidates Covered By The Study" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r685" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r692" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r712" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r714" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r715" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r716" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r716" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r714" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r714" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r717" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r715" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r32" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r32" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofFinancialPositionunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, 230,513 and 266,868 ordinary shares as of March 31, 2025 and December 31, 2024, respectively, at cost", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r32", "r33", "r57" ] }, "dbvt_TypeOfArrangement1Axis": { "xbrltype": "stringItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "TypeOfArrangement1Axis", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type Of Arrangement1 [Axis]", "label": "Type Of Arrangement1 [Axis]", "documentation": "Type Of Arrangement1" } } }, "auth_ref": [] }, "dbvt_TypeOfArrangement1Domain": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "TypeOfArrangement1Domain", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type Of Arrangement1 [Domain]", "label": "Type Of Arrangement1 [Domain]", "documentation": "Type Of Arrangement1 [Domain]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r711" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r18", "r19", "r20", "r94", "r95", "r96", "r97" ] }, "dbvt_ViaskinPeanutSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ViaskinPeanutSegmentMember", "presentation": [ "http://www.dbv-technologies.com/role/ReportablesegmentdisclosureScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Viaskin Peanut Segment", "label": "Viaskin Peanut Segment [Member]", "documentation": "Viaskin Peanut Segment" } } }, "auth_ref": [] }, "dbvt_ViaskintmClinicalProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "ViaskintmClinicalProgramMember", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsClinicalProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Viaskintm Clinical Program", "label": "Viaskintm Clinical Program [Member]", "documentation": "Viaskintm Clinical Program" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r681" ] }, "dbvt_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.dbv-technologies.com/role/OperatingExpensesSummaryofAllocationofPersonnelExpensesByNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wages and salaries", "label": "Wages And Salaries", "documentation": "Wages And Salaries" } } }, "auth_ref": [] }, "dbvt_WarrantSharesToWarrantsRatio": { "xbrltype": "decimalItemType", "nsuri": "http://www.dbv-technologies.com/20250331", "localname": "WarrantSharesToWarrantsRatio", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsandTransactionsFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ratio of ABSA warrant shares to ABSA warrants", "label": "Warrant Shares To Warrants, Ratio", "documentation": "Warrant Shares To Warrants, Ratio" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding used in computing per share amounts (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r148", "r154" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding used in computing per share amounts (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r147", "r154" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r679" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450-20/tableOfContent" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450-30/tableOfContent" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r724": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r725": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 81 0001613780-25-000011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001613780-25-000011-xbrl.zip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end XML 82 dbvt-20250331_htm.xml IDEA: XBRL DOCUMENT 0001613780 2025-01-01 2025-03-31 0001613780 dei:AdrMember 2025-01-01 2025-03-31 0001613780 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001613780 2025-04-30 0001613780 2025-03-31 0001613780 2024-12-31 0001613780 2024-01-01 2024-03-31 0001613780 2023-12-31 0001613780 2024-03-31 0001613780 us-gaap:CommonStockMember 2023-12-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001613780 us-gaap:TreasuryStockCommonMember 2023-12-31 0001613780 us-gaap:RetainedEarningsMember 2023-12-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001613780 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0001613780 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001613780 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001613780 us-gaap:CommonStockMember 2024-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001613780 us-gaap:TreasuryStockCommonMember 2024-03-31 0001613780 us-gaap:RetainedEarningsMember 2024-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0001613780 us-gaap:CommonStockMember 2024-12-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001613780 us-gaap:TreasuryStockCommonMember 2024-12-31 0001613780 us-gaap:RetainedEarningsMember 2024-12-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0001613780 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2025-01-01 2025-03-31 0001613780 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001613780 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001613780 us-gaap:CommonStockMember 2025-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001613780 us-gaap:TreasuryStockCommonMember 2025-03-31 0001613780 us-gaap:RetainedEarningsMember 2025-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2025-03-31 0001613780 dbvt:PrivateInvestmentInPublicEquityMember 2022-01-01 2022-12-31 0001613780 us-gaap:SubsequentEventMember 2025-04-07 2025-04-07 0001613780 dbvt:ViaskintmClinicalProgramMember 2021-03-01 2021-03-31 0001613780 dbvt:ComfortToddlersSafetyStudyMember dbvt:ViaskintmClinicalProgramMember 2023-07-31 2023-07-31 0001613780 dbvt:ComfortToddlersSafetyStudyMember dbvt:ViaskintmClinicalProgramMember 2024-10-22 2024-10-22 0001613780 srt:MinimumMember dbvt:ComfortToddlersSafetyStudyMember dbvt:ViaskintmClinicalProgramMember 2024-10-22 2024-10-22 0001613780 srt:MaximumMember dbvt:ComfortToddlersSafetyStudyMember dbvt:ViaskintmClinicalProgramMember 2024-10-22 2024-10-22 0001613780 dbvt:ViaskintmClinicalProgramMember 2021-08-02 0001613780 dbvt:ViaskintmClinicalProgramMember 2024-10-22 2024-10-22 0001613780 2024-12-11 0001613780 srt:MinimumMember 2024-12-11 0001613780 2025-03-27 0001613780 srt:MinimumMember 2025-03-27 0001613780 dbvt:ABSAWarrantsMember 2025-03-27 0001613780 dbvt:ABSAWarrantsMember us-gaap:SubsequentEventMember 2025-04-07 2025-04-07 0001613780 dbvt:ABSAWarrantsMember us-gaap:SubsequentEventMember 2025-04-07 0001613780 srt:MaximumMember dbvt:ABSAWarrantsMember us-gaap:SubsequentEventMember 2025-04-07 0001613780 dbvt:PFWBSPFWMember us-gaap:SubsequentEventMember 2025-04-07 2025-04-07 0001613780 dbvt:PFWBSPFWMember us-gaap:SubsequentEventMember 2025-04-07 0001613780 dbvt:PrefundedPFWBSPFWMember us-gaap:SubsequentEventMember 2025-04-07 0001613780 dbvt:FirstPreFundedWarrantsMember us-gaap:SubsequentEventMember 2025-04-07 0001613780 dbvt:BSWarrantsMember us-gaap:SubsequentEventMember 2025-04-07 0001613780 dbvt:SecondPreFundedWarrantsMember us-gaap:SubsequentEventMember 2025-04-07 0001613780 srt:MaximumMember dbvt:FirstPreFundedWarrantsMember us-gaap:SubsequentEventMember 2025-04-07 2025-04-07 0001613780 srt:MaximumMember dbvt:SecondPreFundedWarrantsMember us-gaap:SubsequentEventMember 2025-04-07 2025-04-07 0001613780 us-gaap:RealEstateMember 2025-03-31 0001613780 dbvt:OtherAssetMember 2025-03-31 0001613780 us-gaap:RealEstateMember 2024-12-31 0001613780 dbvt:OtherAssetMember 2024-12-31 0001613780 dbvt:EmployeeRelatedLiabilitiesMember 2025-03-31 0001613780 dbvt:EmployeeRelatedLiabilitiesMember 2024-12-31 0001613780 dbvt:TaxLiabilitiesMember 2025-03-31 0001613780 dbvt:TaxLiabilitiesMember 2024-12-31 0001613780 dbvt:OtherDebtsMember 2025-03-31 0001613780 dbvt:OtherDebtsMember 2024-12-31 0001613780 dbvt:ShareCapitalMember 2025-03-31 0001613780 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001613780 dbvt:BSAWarrantsMember 2024-12-31 0001613780 us-gaap:EmployeeStockOptionMember 2024-12-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001613780 dbvt:BSAWarrantsMember 2025-01-01 2025-03-31 0001613780 dbvt:BSAWarrantsMember 2025-03-31 0001613780 us-gaap:EmployeeStockOptionMember 2025-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2025-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2025-01-01 2025-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2025-01-01 2025-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2024-12-31 0001613780 dbvt:OtherContingenciesMember 2024-12-31 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2025-01-01 2025-03-31 0001613780 dbvt:OtherContingenciesMember 2025-01-01 2025-03-31 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2025-03-31 0001613780 dbvt:OtherContingenciesMember 2025-03-31 0001613780 dbvt:ExpensesByFunctionMember 2025-01-01 2025-03-31 0001613780 dbvt:ExpensesByFunctionMember 2024-01-01 2024-03-31 0001613780 dbvt:ExpensesByNatureMember 2025-01-01 2025-03-31 0001613780 dbvt:ExpensesByNatureMember 2024-01-01 2024-03-31 0001613780 dbvt:NonemployeewarrantsMember 2025-01-01 2025-03-31 0001613780 dbvt:NonemployeewarrantsMember 2024-01-01 2024-03-31 0001613780 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001613780 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001613780 dbvt:PrefundedWarrantsMember 2025-01-01 2025-03-31 0001613780 dbvt:PrefundedWarrantsMember 2024-01-01 2024-03-31 0001613780 us-gaap:SubsequentEventMember 2025-04-15 2025-04-15 0001613780 dbvt:ViaskinPeanutSegmentMember 2025-01-01 2025-03-31 0001613780 dbvt:ViaskinPeanutSegmentMember 2024-01-01 2024-03-31 shares iso4217:USD iso4217:EUR shares iso4217:USD shares iso4217:EUR dbvt:study dbvt:candidate dbvt:objection dbvt:regulatory dbvt:patch pure dbvt:employee dbvt:segment 0001613780 --12-31 2025 Q1 false 10-Q true 2025-03-31 false 001-36697 DBV TECHNOLOGIES S.A. I0 FR 107 Av. de la République 92320 Châtillon +33 1 55 42 78 78 American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share DBVT NASDAQ Ordinary shares, nominal value €0.10 per share* true NASDAQ Yes Yes Non-accelerated Filer true false false 136948872 12962000 32456000 16186000 11932000 29148000 44388000 10813000 11306000 5613000 5502000 29000 40000 4960000 4423000 21414000 21271000 50562000 65658000 34146000 22032000 709000 654000 82000 122000 5447000 8328000 40384000 31136000 6525000 6297000 780000 838000 7305000 7135000 47688000 38271000 0.1 0.1 102858868 102858868 102847501 102847501 11652000 11651000 317313000 315613000 230513 266868 1263000 1309000 -313454000 -286375000 1036000 905000 -12411000 -13097000 2873000 27387000 50562000 65658000 753000 1407000 21483000 21403000 262000 758000 5626000 7804000 27370000 29964000 -26618000 -28558000 -461000 1261000 -27079000 -27297000 0 48000 -27079000 -27345000 686000 -3026000 132000 -59000 -26261000 -30429000 -0.26 -0.26 -0.28 -0.28 102617429 102617429 96176057 96176057 -27079000 -27345000 952000 53000 1702000 1958000 4286000 1289000 -465000 8000 4286000 1289000 3662000 835000 10943000 -4805000 -3104000 -3765000 -115000 -56000 -19668000 -34692000 10000 1335000 366000 797000 -375000 -2132000 45000 -62000 45000 -62000 504000 -2957000 -19494000 -39842000 32456000 141367000 12962000 101525000 96431770 10972000 377468000 -1263000 -238862000 742000 -8871000 140187000 -27345000 -27345000 -59000 -3026000 -3084000 2599 0 -62000 -62000 1958000 1958000 96434369 10972000 379426000 -1325000 -266207000 683000 -11897000 111654000 102847501 11651000 315613000 -1309000 -286375000 905000 -13097000 27387000 -27079000 -27079000 132000 686000 817000 11367 1000 -1000 0 46000 46000 1702000 1702000 102858868 11652000 317313000 -1263000 -313454000 1036000 -12411000 2873000 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 1: The Company</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies” or the “Company”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy (“EPIT”), a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. </span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">U.S. dollars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on April 11, 2025 (the “ Annual Report”). The condensed consolidated statement of financial position as of December 31, 2024 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2024.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2025, or any other future period.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On an on-going basis, management evaluates its estimates, primarily those related to: (1) research tax credits, (2) assumptions used in the valuation of right of use assets—operating lease, (3) impairment of right-of-use assets related to leases and property, plant and equipment, (4) recoverability of the Company’s net deferred tax assets and related valuation allowance, (5) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, 6) estimate of contingencies and provisions, and (7) estimate of employee benefits obligations. </span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Going Concern </span></div><div style="margin-bottom:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">These Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. </span></div><div style="margin-bottom:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations since inception. The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.</span></div><div style="margin-bottom:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Since its inception, the Company has primarily funded its operations through equity financings, as well as public assistance and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research Tax Credit.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Prior to 2022, the Company underwent restructuring efforts, scaled down certain clinical programs, and engaged with regulatory authorities to advance Viaskin Peanut’s approval process in the United States and European Union. In 2022, the Company secured a private placement financing of $194 million and lifted a partial clinical hold from the FDA on its VITESSE Phase 3 clinical study.</span></div><div style="margin-bottom:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On April 7, 2025, the Company received gross proceeds of $125.5 million (€116.3 million) from the issuance of the ABSA and PFW-BS-PFW, as described in Note 15. With the receipt of the aforementioned proceeds, and based on its current operations, plans, and assumptions examined by the Board of Directors (“Board”) on March 23, 2025, the Company estimates that its cash and cash equivalents are sufficient to fund its operations into June 2026.</span></div><div style="margin-bottom:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Given the Company’s historical operating losses and reliance on external financings, the Company may still seek additional capital for future needs through a combination of public or private equity or debt financings, collaborations, licensing agreements, and other funding options. While recent financing events have improved the Company’s financial position, access to additional capital in the future remains subject to market conditions and investor interest.</span></div><div style="margin-bottom:4pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Accounting Pronouncements Recently Adopted</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There have been no recently issued accounting standards adopted during the period which had a material impact on the Company’s financial statements. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that are expected to have a material impact on our results of operations, financial condition, or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Accounting Pronouncements issued not yet adopted</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740 — Improvements to Income Tax Disclosures which enhances the transparency and usefulness of income tax disclosures. This amendment requires disclosure of disaggregated information about the Company’s effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. For SEC filers, this ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income Topic 220 — Expense Disaggregation Disclosures. The guidance requires disclosure of additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. For SEC filers, this ASU is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this ASU 2024-03 will have on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption.</span></div> <div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">U.S. dollars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on April 11, 2025 (the “ Annual Report”). The condensed consolidated statement of financial position as of December 31, 2024 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2024.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2025, or any other future period.</span></div> <div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates. </span></div>On an on-going basis, management evaluates its estimates, primarily those related to: (1) research tax credits, (2) assumptions used in the valuation of right of use assets—operating lease, (3) impairment of right-of-use assets related to leases and property, plant and equipment, (4) recoverability of the Company’s net deferred tax assets and related valuation allowance, (5) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, 6) estimate of contingencies and provisions, and (7) estimate of employee benefits obligations. <div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Going Concern </span></div><div style="margin-bottom:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">These Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. </span></div><div style="margin-bottom:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations since inception. The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.</span></div><div style="margin-bottom:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Since its inception, the Company has primarily funded its operations through equity financings, as well as public assistance and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research Tax Credit.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Prior to 2022, the Company underwent restructuring efforts, scaled down certain clinical programs, and engaged with regulatory authorities to advance Viaskin Peanut’s approval process in the United States and European Union. In 2022, the Company secured a private placement financing of $194 million and lifted a partial clinical hold from the FDA on its VITESSE Phase 3 clinical study.</span></div><div style="margin-bottom:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On April 7, 2025, the Company received gross proceeds of $125.5 million (€116.3 million) from the issuance of the ABSA and PFW-BS-PFW, as described in Note 15. With the receipt of the aforementioned proceeds, and based on its current operations, plans, and assumptions examined by the Board of Directors (“Board”) on March 23, 2025, the Company estimates that its cash and cash equivalents are sufficient to fund its operations into June 2026.</span></div><div style="margin-bottom:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Given the Company’s historical operating losses and reliance on external financings, the Company may still seek additional capital for future needs through a combination of public or private equity or debt financings, collaborations, licensing agreements, and other funding options. While recent financing events have improved the Company’s financial position, access to additional capital in the future remains subject to market conditions and investor interest.</span></div> 194000000 125500000 116300000 <div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Accounting Pronouncements Recently Adopted</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There have been no recently issued accounting standards adopted during the period which had a material impact on the Company’s financial statements. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that are expected to have a material impact on our results of operations, financial condition, or cash flows.</span></div> <div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Accounting Pronouncements issued not yet adopted</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740 — Improvements to Income Tax Disclosures which enhances the transparency and usefulness of income tax disclosures. This amendment requires disclosure of disaggregated information about the Company’s effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. For SEC filers, this ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income Topic 220 — Expense Disaggregation Disclosures. The guidance requires disclosure of additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. For SEC filers, this ASU is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this ASU 2024-03 will have on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption.</span></div> <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 2: Significant Events and Transactions</span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Clinical Programs</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">United States Regulatory History and Current Status</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In August 2019, we announced the submission of a BLA to the FDA for Viaskin Peanut for the treatment of peanut allergy in children four to </span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> years of age.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In August 2020, the Company received a Complete Response Letter (“CRL”) in which the FDA indicated it could not approve the Viaskin Peanut BLA in its then-current form. The FDA did not raise any safety concerns related to Viaskin Peanut.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In January 2021, the Company received written responses from the FDA to questions provided in the Type A meeting request that the Company submitted in October 2020 following receipt of the CRL. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In March 2021, the Company commenced CHAMP (Comparison of adHesion Among Modified Patches), a Phase 1 trial in healthy adult volunteers. . In May 2021, the Company submitted a proposed protocol to the FDA for STAMP (Safety, Tolerability, and Adhesion of Modified Patches)a 6-month safety and adhesion study which was to be conducted concurrently with DBV’s allergen uptake comparison studies (i.e., ‘EQUAL in Adults’, EQUAL). On October 14, 2021, in an Advice/Information Request letter, the FDA requested the Company conduct a stepwise, or sequential, approach to the modified Viaskin patch development program by conducting EQUAL first and submitting the data for FDA review and feedback prior to starting the STAMP study.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In December 2021, the Company decided not to pursue the sequential approach requested by the FDA and instead announced its plan to initiate a pivotal Phase 3 placebo-controlled efficacy trial for a modified Viaskin Peanut patch (mVP) in children in the intended patient population. Following written exchanges with the FDA, the FDA confirmed it was aligned with the Company’s strategy. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On September 7, 2022, the Company announced the initiation of VITESSE, a Phase 3 pivotal study of the mVP in children ages </span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> years with peanut allergy. On September 21, 2022, the Company announced it received from FDA a partial clinical hold letter related to certain design elements of VITESSE. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December 23, 2022, the Company announced that the FDA lifted the partial clinical hold The Company announced on September 23, 2024, that subject screening was completed in the third quarter of 2024. Topline results are anticipated in the fourth quarter of 2025.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2022, the Company announced positive topline results from Part B of EPITOPE. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On April 19, 2023, the Company outlined the regulatory pathway for Viaskin Peanut in children </span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> – </span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> years old after the FDA confirmed in written responses to the Company’s Pre-BLA meeting request that the Company’s EPITOPE phase 3 study met the pre-specified criteria for success for the primary endpoint and did not request an additional efficacy study in this age group. The FDA required additional safety data to augment the safety data collected from EPITOPE in support of a BLA.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On July 31, 2023, the Company announced receipt of feedback from FDA on two supplemental safety studies, COMFORT Children and COMFORT Toddlers. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On November 9, 2023, the Company submitted the protocol for its COMFORT Toddlers supplemental safety study in </span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> – </span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> years-old to FDA. The Company received comments and queries to the protocol from the FDA on March 11, 2024. On July 30, 2024, the Company announced that it and the FDA had been engaged in ongoing dialogue since May 2023 on the COMFORT Toddlers supplemental safety study in </span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> – </span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> years-old with a peanut allergy. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company also announced on November 9, 2023, 2-year results from the ongoing phase 3 open-label extension to the EPITOPE trial, EPOPEX, of Viaskin Peanut in toddlers.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On October 22, 2024, the Company announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV had agreed to guidance provided by the FDA on a potential pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old. FDA confirmed that the Company has met Accelerated Approval qualifying criterion 1 and 2. Regarding criterion 3, FDA has provided guidance and suggestion regarding the intermediate clinical endpoint, which the Company agreed to in informal discussions with the FDA. The Company formalized the Accelerated Approval guidance provided by FDA via submission of a meeting request and confirmed the general elements of the two study components: the COMFORT Toddlers safety study, to be completed before BLA submission, and the confirmatory effectiveness study, including </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the third Accelerated Approval criterion regarding the intermediate clinical endpoint. The Company expects that the confirmatory study will be initiated by the time of BLA submission and would run in parallel to commercialization in the United States, if Viaskin Peanut is approved.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company announced further that it has aligned with FDA on a wear time collection methodology in COMFORT Toddlers intended to generate sufficient data to support a BLA submission. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. The company anticipates enrolling approximately 300 – 350 subjects on active treatment into the safety study, which would bring the total Viaskin Peanut patch safety database in toddlers to approximately 600 subjects, consistent with prior FDA guidance. With this path forward, the BLA submission for Viaskin Peanut patch in 1 – 3 years-old under the Accelerated Approval program is anticipated to be supported by:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Positive efficacy and safety data from DBV’s previously completed EPITOPE Phase 3 Study; and</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional safety data generated in COMFORT Toddlers supplemental safety study to be initiated in the second quarter of 2025. </span></div><div><span><br/></span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December 11, 2024, the Company announced that it reached alignment with FDA on the Accelerated Approval pathway for Viaskin Peanut patch in toddlers 1 – 3 years-old and on key study design elements for the COMFORT Toddlers study, including study size and wear time collection methodology and analysis. The Company announced further that FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1-3 years-old and that the Company and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch, will include a double-blind, placebo-controlled food challenge (DBPCFC), will use the same statistical criteria for success (i.e., lower bound of the 95% CI &gt; 15%) as used in the EPITOPE, and will need to be initiated at the time that the BLA is submitted.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company submitted the protocol for its COMFORT Children supplemental safety study in ages </span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-through-</span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-years-old to the FDA on November 29, 2023. On March 24, 2025, the Company announced that in a Written Responses Only to the Company’s Type D IND meeting request the FDA agreed with the Company’s proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in </span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span><span style="color:#e6007e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-year-olds will be sufficient to support a BLA filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required and the Company will not conduct the study. The Company will utilize the safety data from the VITESSE participants randomized to active treatment as well as placebo-crossover participants in the VITESSE Open Label Extension (OLE). Accordingly, the Company plans to submit a BLA in the first half of 2026 and anticipates potentially accelerating the product launch by approximately one year, subject to FDA approval.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Viaskin Peanut —European Union Regulatory History and Current Status </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In November 2020, we announced that our Marketing Authorization Application, or MAA, for Viaskin Peanut, submitted under the name “Abylqis®”, had been validated by the European Medicines Agency, or EMA. The validation of the MAA confirmed that the submission was sufficiently complete to begin the formal review process for Viaskin Peanut to treat peanut allergies in children ages four to 11 years. Following the MAA validation, the EMA’s Committee for Medicinal Products for Human Use, or CHMP, reviews the application and provides a recommendation to the European Commission, on whether to grant a marketing authorization. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On August 2, 2021, we announced we had received from the EMA the Day 180 list of outstanding issues, which is an established part of the prescribed EMA review process. The EMA identified one Major Objection remained at Day 180n questioning the limitations of the data, for example, the clinical relevance and effect size supported by a single pivotal study.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December 17, 2021, we announced we had withdrawn the MAA for Viaskin Peanut, submitted under the name “Abylqis”, and formally notified the EMA of our decision. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On October 22, 2024, the Company announced it received scientific advice from EMA on an indication for ages 1 – 7 years-old in Europe regarding the components of a MAA for the Viaskin Peanut patch. Previous advice obtained from two local country regulatory health authorities indicated a potential path for a 1 – 7 year-old registration with one patch, the modified patch. The EMA recently confirmed through scientific advice that the completed EPITOPE study in 1 – 3 years-old, and a positive VITESSE study in 4 – 7 years-old, could constitute an MAA submission for a 1 – 7 years-old indication for peanut allergy patients using the modified patch, along with a new safety study in toddlers ages 1 – 3 years-old with the modified patch. Timing for the initiation of this new safety study to satisfy the important EU market is currently being planned.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company intends to resubmit the MAA when that data set is available.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Viaskin Peanut for Children Ages 1 – 3</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2020, the Company announced that in Part A of the EPITOPE phase 3 clinical study subject in both treatment arms showed consistent treatment effects after 12 months of therapy, as assessed by a double-blind placebo-controlled food challenge and biomarker results. Part A subjects were not included in Part B and the efficacy analyses from Part A were not statistically powered to demonstrate superiority of either dose versus placebo.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2022, the Company announced positive topline results from Part B of EPITOPE.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On April 19, 2023, the Company outlined the regulatory pathway for Viaskin Peanut in children 1 – 3 years old after the FDA confirmed in written responses to the Company’s Pre-BLA meeting request that the Company’s EPITOPE phase 3 study met the pre-specified criteria for success for the primary endpoint and did not request any additional efficacy study in this age group. The FDA requires additional safety data to augment the safety data collected from EPITOPE in support of a BLA. This new safety study will also generate patch adhesion data and will include updated instructions for use.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On May 10, 2023, the New England Journal of Medicine (“NEJM”) published results from the EPITOPE phase 3 clinical study that demonstrated EPIT with Viaskin Peanut was statistically superior to placebo in desensitizing children to peanut exposure by increasing the peanut dose that triggers allergic symptoms. As stated in an accompanying editorial piece, these data are seen as “very good news” for toddlers with peanut allergy. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In November 2023, the Company announced the interim analyses from the first year of the open-label extension of EPITOPE, called EPOPEX, which showed improvement between months 12 and 24 of treatment with Viaskin Peanut across all efficacy parameters. These data were presented at the annual American College of Allergy, Asthma and Immunology (ACAAI) in November 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">On November 9, 2023, the Company submitted the protocol for its COMFORT Toddlers supplemental safety study in 1 – 3 years-old to FDA. The Company received comments and queries to the protocol from the FDA on March 11, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On October 22, 2024, the Company announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV agreed to guidance provided by the FDA on a potential pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FDA confirmed that the Company has met Accelerated Approval qualifying criteria 1 and 2. Regarding criterion 3, FDA has provided guidance and suggestion regarding the intermediate clinical endpoint, which the Company has agreed to in informal discussions with the FDA. The Company formalized the Accelerated Approval guidance provided by FDA via submission of a meeting request and confirmed the general elements of the two study components: the COMFORT Toddlers safety study, to be completed before BLA submission, and the confirmatory effectiveness study, including the third Accelerated Approval criterion regarding the intermediate clinical endpoint. The Company expects that the confirmatory study will be initiated by the time of BLA submission and would run in parallel to commercialization in the United States, if Viaskin Peanut is approved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company announced further that it has aligned with FDA on a wear time collection methodology in COMFORT Toddlers that provides a practical approach for subjects and families, is intended to generate sufficient data to support a BLA submission, and places wear time into an acceptable clinical hierarchy relative to other study endpoints. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. The company anticipates enrolling approximately 300 – 350 subjects on active treatment into the safety study, which would bring the total Viaskin Peanut patch safety database in toddlers to approximately 600 subjects, consistent with prior FDA guidance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With this path forward, the BLA submission for Viaskin Peanut patch in 1 – 3 years-old under the Accelerated Approval program is anticipated to be supported by:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Positive efficacy and safety data from DBV’s previously completed EPITOPE Phase 3 Study; and</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional safety data generated in COMFORT Toddlers supplemental safety study to be initiated in the second quarter of 2025.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December 11, 2024, the Company announced that it reached alignment with FDA on the Accelerated Approval pathway for Viaskin Peanut patch in toddlers 1-3 years-old and on key study design elements for the COMFORT Toddlers study, including study size and wear time collection methodology and analysis. The Company announced further that FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1-3 years-old and that the Company and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch, will include a double-blind, placebo-controlled food challenge (DBPCFC), will use the same statistical criteria for success (i.e., lower bound of the 95% CI &gt; 15%) as used in the EPITOPE, and will need to be initiated at the time that the BLA is submitted.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Viaskin Peanut for Children Ages 4 – 7</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On September 7, 2022, the Company announced the initiation of VITESSE, a Phase 3 pivotal study of the mVP in children ages 4-7 years with peanut allergy. The Company defined initiation as the submission of the trial protocol to selected study sites for subsequent Institutional Review Board (IRB)/Ethics Committee (EC) approval.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">On September 21, 2022, the Company announced it received from the FDA a partial clinical hold letter related to certain design elements of VITESSE. The Company announced on December 23, 2022 that the FDA lifted the partial clinical hold.The Company announced on September 23, 2024 that subject screening was completed in the third quarter of 2024. Topline results are anticipated in the fourth quarter of 2025.</span></div><div style="margin-bottom:4pt"><span><br/></span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In July 2023, the Company received Type C Meeting Written Responses from the FDA regarding key study design elements for COMFORT Children. Subsequently, in October 2023, the Company received feedback from the FDA addressing the remaining protocol design elements for COMFORT Children. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company submitted the protocol for its COMFORT Children supplemental safety study in 4--7-years-old to the FDA on November 29, 2023.On March 24, 2025, the Company announced that in a Written Responses Only to the Company’s Type D IND meeting request the FDA agreed with the Company’s proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4 – 7-year-olds will be sufficient to support a BLA filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required and the Company will not conduct the study. The Company will utilize the safety data from the VITESSE participants randomized to active treatment as well as placebo-crossover participants in the VITESSE Open Label Extension (OLE). Accordingly, the Company plans to submit a BLA in the first half of 2026 and anticipates potentially accelerating the product launch by approximately one year, subject to FDA approval.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Financing</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On March 27, 2025, the Company announced a financing of up to $306.9 million (€284.5 million), to advance the Viaskin Peanut Patch through BLA submission and U.S. commercial launch, if approved. The financing includes gross proceeds of $125.5 million (€116.3 million) received on April 7, 2025, and up to $181.4 million (€168.2 million) in potential additional gross proceeds that may be received if all the warrants are exercised, subject to satisfaction of specified conditions. The VITESSE Phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of some of the warrants. The ABSA Warrants (defined below) will be exercisable from their respective date of issue until the earlier of (i) April 7, 2027 and (ii) 30 days following the publication by the Company of a press release announcing that the ongoing VITESSE trial of Viaskin Peanut in children 4-7 years old met the primary endpoint defined in the VITESSE study protocol, it being specified that (i) the primary measure of treatment effect will be the difference in response rates at Month 12 between active and placebo treatment groups, (ii) the primary analysis will be based on a 2-sided confidence interval (“CI”) for the difference in response rates, and (iii) the primary analysis must be positive according to the success criterion (lower bound of the 2-sided 95% CI of the difference in response rates ≥ 15%) (the “ABSA Warrant Exercise Period”). The exercise of one (1) ABSA Warrant will give the holder the right to subscribe to one point seventy-five (1.75) ABSA Warrant Shares at a price of €1.5939 per ABSA Warrant.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The financing resulted in an immediate dilution of 22.4% and a maximal dilution of up to 73.7% of existing shareholders (on a non-diluted basis) if all the warrants in the Offering are exercised in full.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The financing consists of:</span></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-indent:-9.92pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.12pt">a share capital increase without preferential subscription rights reserved to categories of persons satisfying determined characteristics pursuant to the 24th resolution of the general meeting of shareholders of May 16, 2024 (the "2024 General Meeting") completed on April 7, 2025 for an amount of €38 million, consisting of the issuance of (i) 34,090,004 new shares at a par value of €0.10 (the "New Shares") each with warrants of the Company attached (the "ABSA Warrants", and together with the New Shares, the "ABSA") at a subscription price of €1.1136 per ABSA and (ii) up to 59,657,507 additional new shares, if all the ABSA Warrants attached to the New Shares are exercised (the "ABSA Warrant Shares"); and</span></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-indent:-9.92pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.12pt">the issue through an offering reserved to categories of persons satisfying determined characteristics of 71,005,656 units (the “PFW-BS-PFW”) completed on April 7, 2025 for an amount of €79 million at a subscription price of €1.1136 per PFW-BS-PFW (of which €1.1036 will have been </span></div><div style="margin-bottom:4pt;padding-left:9.92pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">prefunded on the issue date), each PFW-BS-PFW consisting of one pre-funded warrant to subscribe for one share of the Company (the "First Pre-Funded Warrants") and one warrant (the "BS Warrants") to subscribe to one second pre-funded warrants (the "Second Pre-Funded Warrants"), each of which entitles the holder to subscribe for 1.75 shares of the Company (the "Second PFW Shares"), allowing to issue up to 71,005,656 additional new shares if all the First Pre-Funded Warrants are exercised (the "First PFW Shares") and up to 124,259,898 additional new shares if all the Second Pre-Funded Warrants are exercised (the "Second PFW Shares", together with the ABSA Warrant Shares and the First Pre-Funded Warrant Shares, the "Warrant Shares", and together with the New Shares, the "Offered Shares"),</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(together, the "Offering").</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The net proceeds from the issue of the ABSA and the PFW-BS-PFW, together with existing cash and cash equivalents, will be mainly used by the Company in the following order of priority (i) for working capital and general corporate purposes, (ii) to finance the continued development of the Viaskin Peanut program, (iii) to finance the preparation and submission of a potential BLA and, (iv) to finance the readiness of a launch of Viaskin Peanut in the U.S., if approved.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The ordinary shares, including the ordinary shares issuable upon exercise of the warrants from the Offering, have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the ordinary shares, including the ordinary shares underlying the warrants issued as part of the Offering.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Taking into account the net proceeds of $125.5 million (€116.3 million) received on April 7, 2025 from the issuance of the ABSA and the PFW-BS-PFW and based on its current operations, plans and assumptions, the Company estimates that it has sufficient balance of cash &amp; cash equivalents to fund its operations into June 2026.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Legal Proceedings</span></div>From time to time, the Company may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. The Company is not currently subject to any material legal proceedings. P6M 2 2 300 350 600 1 2 1 2 300 350 600 0.95 0.15 306900000 284500000 125500000 116300000 181400000 168200000 0.95 0.15 1.75 1.5939 0.224 0.737 38000000 34090004 0.10 1.1136 59657507 71005656 79000000 1.1136 1.1036 1 1 1 1 1.75 71005656 124259898 125500000 116300000 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 3: Cash and Cash Equivalents</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following tables summarize the cash and cash equivalents as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:65.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash </span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,962 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32,456 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total cash and cash equivalents as reported in the statements of financial position</span></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12,962</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">32,456</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following tables summarize the cash and cash equivalents as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:65.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash </span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,962 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32,456 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total cash and cash equivalents as reported in the statements of financial position</span></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12,962</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">32,456</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 12962000 32456000 0 0 12962000 32456000 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 4: Other Current Assets</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other current assets consisted of the following:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:65.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,917 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,980 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other tax claims</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,015 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,452 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,875 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,541 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,380 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,959 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">Research tax credit</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The variance in Research Tax Credit is presented as follows:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:82.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount in thousands of US dollars</span></div></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Opening research tax credit receivable as of January 1, 2025</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+ Operating revenue </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">753 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">- Adjustment and currency translation effect</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">184 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Closing research tax credit receivable as of March 31, 2025</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,917</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Of which - Non-current portion</span></td><td colspan="2" style="border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">— </span></td><td style="border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Of which - Current portion</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4,917 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Before currency translation effect, the balance in research tax credit as of March 31, 2025, consisted of $4.0 million research tax credit for the previous fiscal year filed with the tax authorities. The estimated research tax credit for the first three months of the 2025 fiscal year amounts to $0.8 million.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The other tax claims are primarily related to the VAT as well as the reimbursement of VAT that has been requested. Prepaid expenses are comprised primarily of insurance expenses, as well as legal and scientific consulting fees.</span></div> <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other current assets consisted of the following:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:65.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,917 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,980 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other tax claims</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,015 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,452 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,875 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,541 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,380 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,959 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4917000 3980000 6015000 4452000 3875000 1541000 1380000 1959000 16186000 11932000 <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The variance in Research Tax Credit is presented as follows:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:82.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount in thousands of US dollars</span></div></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Opening research tax credit receivable as of January 1, 2025</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+ Operating revenue </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">753 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">- Adjustment and currency translation effect</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">184 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Closing research tax credit receivable as of March 31, 2025</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,917</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Of which - Non-current portion</span></td><td colspan="2" style="border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">— </span></td><td style="border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Of which - Current portion</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4,917 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3980000 753000 184000 4917000 0 4917000 4000000.0 800000 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 5: Lease contracts</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company’s operating leases’ right of use as of March 31, 2025 and December 31, 2024, are as follows:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:20.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.063%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Real Estate</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Real Estate</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current portion</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,015 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">76 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,091 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">810 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">836 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year 2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">56 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,315 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,222 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,228 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year 3</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,267 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,274 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,230 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,237 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,990 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,997 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,127 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,677</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">49</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,437</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Effects of discounting</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,430)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,463)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,486)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,234</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(643)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(709)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(648)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(654)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Long-term lease liabities</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.92pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.04</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.02</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.06 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.09 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.02 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.02 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company recognizes rent expense, calculated as the remaining cost of the lease allocated over the remaining lease term on a straight-line basis. Rent expense presented in the consolidated statement of operations and comprehensive loss was:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:65.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.163%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease expense / (income)</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">288 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">586 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net termination impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net restructuring impact</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases is as follows for the period March 31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:65.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.163%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating cash flows used in operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">501 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company’s operating leases’ right of use as of March 31, 2025 and December 31, 2024, are as follows:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:20.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.063%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Real Estate</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Real Estate</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current portion</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,015 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">76 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,091 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">810 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">836 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year 2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">56 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,315 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,222 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,228 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year 3</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,267 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,274 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,230 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,237 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,990 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,997 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,127 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,677</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">49</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,437</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Effects of discounting</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,430)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,463)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,486)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,234</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(643)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(709)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(648)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(654)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Long-term lease liabities</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.92pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.04</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.02</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.06 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.09 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.02 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.02 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td></tr></table></div> 1015000 76000 1091000 810000 26000 836000 1259000 56000 1315000 1222000 7000 1228000 1267000 7000 1274000 1230000 7000 1237000 4990000 7000 4997000 5127000 9000 5136000 8531000 146000 8677000 8388000 49000 8437000 1430000 13000 1443000 1463000 23000 1486000 7101000 133000 7234000 6925000 26000 6951000 643000 66000 709000 648000 6000 654000 6459000 66000 6525000 6278000 20000 6297000 P7Y4M2D P0Y14D P7Y5M26D P0Y7D 0.0506 0.0009 0.0502 0.0002 <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company recognizes rent expense, calculated as the remaining cost of the lease allocated over the remaining lease term on a straight-line basis. Rent expense presented in the consolidated statement of operations and comprehensive loss was:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:65.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.163%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease expense / (income)</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">288 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">586 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net termination impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net restructuring impact</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 288000 586000 -49000 1000 7000 <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases is as follows for the period March 31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:65.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.163%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating cash flows used in operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">501 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 96000 501000 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 6: Trade Payables and Other Liabilities</span></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">6.1 Trade Payables</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade payables increased by $12.1 million as of March 31, 2025, compared to December 31, 2024.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each fiscal period presented.</span></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">6.2 Other Liabilities</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following tables summarize the other liabilities as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.617%"><tr><td style="width:1.0%"></td><td style="width:34.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.798%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr style="height:30pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other non-current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other non-current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee related liabilities</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,844 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,844 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,294 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,294 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax liabilities</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">332 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">332 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">188 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">188 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other debts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">272 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">272 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Employee related liabilities include short-term debt to employees including social welfare, tax agency obligations and bonus provision. The variance versus year end is due to bonus accruals.</span></div> 12100000 <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following tables summarize the other liabilities as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.617%"><tr><td style="width:1.0%"></td><td style="width:34.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.798%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr style="height:30pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other non-current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other non-current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee related liabilities</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,844 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,844 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,294 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,294 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax liabilities</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">332 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">332 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">188 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">188 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other debts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">272 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">272 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4844000 0 4844000 7294000 0 7294000 332000 0 332000 188000 0 188000 272000 0 272000 846000 0 846000 5447000 0 5447000 8328000 0 8328000 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 7: Shareholders’ equity</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The share capital as of March 31, 2025 is set at the sum of €10,285,887 ($11,652 thousand converted at historical rates). It is divided into102,858,868 fully authorized, subscribed and paid-up ordinary shares with a par value of €0.10.</span></div> 10285887 11652000 102858868 0.10 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 8: Share-Based Payments</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Board of Directors has been authorized at the General Meeting of the Shareholders to grant restricted stock units (“RSU”), stock options plan (“SO”), and non-employee warrants (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Bons de Souscription d’Actions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> or “BSA”).</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, the Company granted neither stock options nor restricted stock units to employees. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 12 to the consolidated financial statements included in the Annual Report.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in Number of BSA/SO/RSU:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:47.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.164%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of outstanding </span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SO</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RSUs</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of December 31, 2024</span></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">244,693</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,444,803</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,813,366</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.92pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted during the period    </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt 2px 10.92pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited during the period    </span></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,725)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(36,350)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.92pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercised/released during the period    </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20,467)</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt 2px 10.92pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expired during the period    </span></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of March 31, 2025</span></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">244,693</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,441,078</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,756,549</span></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based payments expense reflected in the condensed consolidated statements of operations is as follows:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.260%"><tr><td style="width:1.0%"></td><td style="width:31.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.629%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.389%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research &amp; development</span></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SO</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(382)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(513)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">RSU</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(199)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(256)</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales &amp; marketing</span></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SO</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(23)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">RSU</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General &amp; administrative</span></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SO</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(997)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,030)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">RSU</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(105)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(126)</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total share-based compensation (expense)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,701)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,958)</span></td></tr></table></div> 0 0 <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in Number of BSA/SO/RSU:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.769%"><tr><td style="width:1.0%"></td><td style="width:47.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.164%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of outstanding </span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SO</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RSUs</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of December 31, 2024</span></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">244,693</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,444,803</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,813,366</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.92pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted during the period    </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt 2px 10.92pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited during the period    </span></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,725)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(36,350)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.92pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercised/released during the period    </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20,467)</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt 2px 10.92pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expired during the period    </span></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of March 31, 2025</span></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">244,693</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,441,078</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,756,549</span></td></tr></table></div> 244693 10444803 2813366 0 0 0 0 3725 36350 0 0 20467 0 0 0 244693 10441078 2756549 <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based payments expense reflected in the condensed consolidated statements of operations is as follows:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.260%"><tr><td style="width:1.0%"></td><td style="width:31.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.629%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.389%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research &amp; development</span></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SO</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(382)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(513)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">RSU</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(199)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(256)</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales &amp; marketing</span></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SO</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(23)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">RSU</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General &amp; administrative</span></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SO</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(997)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,030)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">RSU</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(105)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(126)</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total share-based compensation (expense)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,701)</span></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,958)</span></td></tr></table></div> 382000 513000 199000 256000 12000 23000 6000 9000 997000 1030000 105000 126000 1701000 1958000 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 9: Contingencies</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following tables summarize the contingencies as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.466%"><tr><td style="width:1.0%"></td><td style="width:65.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current contingencies</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">122 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current contingencies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">780 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">838 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total contingencies</span></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">861</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The changes in contingencies are as follows:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.393%"><tr><td style="width:1.0%"></td><td style="width:36.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.072%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pension retirement obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other contingencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">At January 1, 2025</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Increases in liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Used liabilities</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(63)</span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(63)</span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reversals of unused liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial gains and losses on defined-benefit plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Currency translation effect</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">41 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">At March 31, 2025</span></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">861</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Of which current </span></td><td colspan="2" style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Of which non-current </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">780 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">780 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company does not hold any plan assets related to long-term employee benefit for any of the periods presented. There have been no significant changes in assumptions for the estimation of the retirement commitments from those disclosed in Note 13 to the consolidated financial statements included in the Annual Report. <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following tables summarize the contingencies as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.466%"><tr><td style="width:1.0%"></td><td style="width:65.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current contingencies</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">122 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current contingencies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">780 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">838 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total contingencies</span></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">861</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 82000 122000 780000 838000 861000 961000 <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The changes in contingencies are as follows:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.393%"><tr><td style="width:1.0%"></td><td style="width:36.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.072%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pension retirement obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other contingencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">At January 1, 2025</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Increases in liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Used liabilities</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(63)</span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(63)</span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reversals of unused liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial gains and losses on defined-benefit plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Currency translation effect</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">41 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">At March 31, 2025</span></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">861</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Of which current </span></td><td colspan="2" style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">— </span></td><td style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#c9e8fb;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Of which non-current </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">780 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">780 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 838000 122000 961000 34000 21000 55000 63000 63000 132000 132000 -39000 -1000 -41000 780000 82000 861000 0 82000 82000 780000 0 780000 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 10: Operating income</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table summarizes the operating income during the three and nine months ended March 31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.198%"><tr><td style="width:1.0%"></td><td style="width:47.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.786%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">753 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,407 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other operating income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The decrease in Research tax credit was primarily due to the fact that a greater proportion of studies activities were carried out in North America and were therefore not eligible to the French Research tax credit.</span></div> <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table summarizes the operating income during the three and nine months ended March 31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.198%"><tr><td style="width:1.0%"></td><td style="width:47.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.786%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">753 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,407 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other operating income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#c9e8fb;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 753000 1407000 0 0 753000 1407000 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 11: Operating Expenses</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company had an average of 106 employees during the three months ended March 31, 2025, in comparison with an average of 105 employees during the three months ended March 31, 2024. The increase is mainly due to hiring to support development activities and quality activities.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table summarizes the allocation of personnel expenses by function during the three months ended March 31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.198%"><tr><td style="width:1.0%"></td><td style="width:47.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.786%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and Development expenses</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,630 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,048 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales &amp; Marketing expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General &amp; Administrative expenses</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,996 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,236 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> Total personnel expenses</span></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table summarizes the allocation of personnel expenses by nature during the three months ended March 31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.502%"><tr><td style="width:1.0%"></td><td style="width:48.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.438%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Wages and salaries</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,677 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,144 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Social security contributions </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,370 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,207 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expenses for pension commitments</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">309 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,702 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,958 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> Total</span></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The decrease in personnel expenses is primarily due to lower bonuses paid in 2025 compared to last year.</span></div> 106 105 <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table summarizes the allocation of personnel expenses by function during the three months ended March 31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.198%"><tr><td style="width:1.0%"></td><td style="width:47.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.786%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and Development expenses</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,630 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,048 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales &amp; Marketing expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General &amp; Administrative expenses</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,996 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,236 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> Total personnel expenses</span></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 4630000 5048000 155000 334000 2996000 3236000 7782000 8618000 <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table summarizes the allocation of personnel expenses by nature during the three months ended March 31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.502%"><tr><td style="width:1.0%"></td><td style="width:48.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.438%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Wages and salaries</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,677 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,144 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Social security contributions </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,370 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,207 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expenses for pension commitments</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">309 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,702 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,958 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> Total</span></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 4677000 5144000 1370000 1207000 34000 309000 1702000 1958000 7782000 8618000 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 12: Commitments</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There were no significant changes in other commitments from those disclosed in Note 17 to the consolidated financial statements included in the  Annual Report.</span></div> <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 13: Relationships with Related Parties</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There were no new significant related-party transactions during the period nor any changes in the nature of the transactions from those described in Note 18 to the consolidated financial statements included in the Annual Report.</span></div> <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 14: Loss Per Share</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Basic loss per share is calculated by dividing the net loss attributable to the shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. As the Company was in a loss position for each of the three-month periods ended March 31, 2025 and 2024, the diluted loss per share is equal to basic loss per share because the effects of potentially dilutive shares were anti-dilutive as a result of the Company’s net loss.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three months period ended March 31, 2025 and 2024 indicated in number of potential shares:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.047%"><tr><td style="width:1.0%"></td><td style="width:47.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.844%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-employee warrants </span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">244,693 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">244,693 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,492,903 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,388,016 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,087,872 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,064,035 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prefunded warrants</span></td><td colspan="2" style="border-bottom:2pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">22,266,331 </span></td><td style="border-bottom:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,276,331 </span></td><td style="border-bottom:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three months period ended March 31, 2025 and 2024 indicated in number of potential shares:</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.047%"><tr><td style="width:1.0%"></td><td style="width:47.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.844%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-employee warrants </span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">244,693 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">244,693 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,492,903 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,388,016 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,087,872 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,064,035 </span></td><td style="background-color:#c9e8fb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prefunded warrants</span></td><td colspan="2" style="border-bottom:2pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">22,266,331 </span></td><td style="border-bottom:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,276,331 </span></td><td style="border-bottom:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 244693 244693 10492903 7388016 3087872 2064035 22266331 28276331 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 15: Events after the Close of the Period</span></div><div style="margin-bottom:4pt"><span><br/></span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On March 27, 2025, the company announced a financing of up to $306.9 million (€284.5 million), to advance Viaskin® Peanut Patch through biologics license application submission and U.S. commercial launch, if approved. The financing includes gross proceeds of $125.5 million (€116.3 million) received on April 7, 2025 and up to $181.4 million (€168.2 million) in potential additional gross proceeds that may be received if all the warrants are exercised, subject to satisfaction of specified conditions. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On April 15, 2025, the Company received the 2024 Research Tax Credit (Crédit d’Impôt Recherche) in the amount of $4.0M in cash.</span></div> 306900000 284500000 125500000 116300000 181400000 168200000 4000000.0 <div style="margin-bottom:10pt;margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Note 16: Reportable segment disclosure </span></div><div style="margin-bottom:4pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.047%"><tr><td style="width:1.0%"></td><td style="width:47.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.844%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Clinical studies</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,802 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,173 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BLA &amp; Regulatory</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,385 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,480 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Medical Affairs &amp; Other Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research &amp; Innovation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Manufacturing &amp; Supply and Quality</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,594 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,896 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales &amp; Marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">262 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">758 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General &amp; Administrative </span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,626 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,804 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total expenses</span></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">27,371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">29,965</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">The Company operates and is managed as one operating segment driving expenses for the development of Viaskin Peanut. The Company’s R&amp;D organization is primarily responsible for the development and registration efforts of Viaskin Peanut. The Company’s technical operations group is responsible for the development of manufacturing processes, supplying clinical drug product. The Company is also supported by corporate staff functions.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company’s Chief Executive Officer as the CODM manages and allocates resources to the operations of the total company by assessing the overall level of resources available and how to best allocate them to support the Company’s long-term company-wide strategic goals. In making this decision, the CODM uses consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The CODM's analysis includes a comparison to budgeted results. Segment assets provided to the CODM are consistent with those reported on the Consolidated Statement of Financial Position with particular emphasis on the Company's available liquidity including cash, cash equivalents.</span></div> <div style="margin-bottom:8pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.047%"><tr><td style="width:1.0%"></td><td style="width:47.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.844%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#c9e8fb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Clinical studies</span></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,802 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c9e8fb;padding:0 1pt"></td><td colspan="2" style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,173 </span></td><td style="background-color:#c9e8fb;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BLA &amp; Regulatory</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,385 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,480 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Medical Affairs &amp; Other Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research &amp; Innovation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Manufacturing &amp; Supply and Quality</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,594 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,896 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales &amp; Marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">262 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">758 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General &amp; Administrative </span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,626 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,804 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total expenses</span></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">27,371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">29,965</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6802000 8173000 1385000 1480000 1958000 2664000 744000 190000 10594000 8896000 262000 758000 5626000 7804000 27371000 29965000 1 false false false false